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Abstract 
 
The mature lymphatic vasculature consists of two distinct vessel types, lymphatic 
capillaries and collecting lymphatic vessels, which have distinct functions in the uptake 
and transport of lymph respectively.  However, despite the functional importance of 
these two vessel types, much remains unknown about the processes involved in 
remodelling the initially uniform lymphatic plexus into a functional hierarchy of mature 
vessels, and particularly the role of smooth muscle cells and the extracellular matrix in 
this process and in the subsequent function of collecting lymphatic vessels.  Here we 
have identified Reelin, an extracellular matrix protein whose previous characterisation 
has remained largely confined to the central nervous system, as required for correct 
development and function of collecting lymphatic vessels.  In the absence of Reelin, 
collecting vessels are enlarged, with a reduction in smooth muscle cell coverage and a 
concomitant failure to down-regulate expression of the capillary marker, LYVE-1.  
Unexpectedly, the canonical Reelin receptors ApoER2 and VLDLR were dispensable 
for normal lymphatic development, suggesting the involvement of alternative 
receptor(s).  We have also uncovered a previously un-described mechanism for 
activation of Reelin signalling via interactions between smooth muscle cells and 
lymphatic endothelial cells, and have shown that the latter increase expression of the 
smooth muscle cell recruitment factor, MCP1, upon stimulation by Reelin.  This work 
highlights the largely unexplored importance of the extracellular matrix for correct 
lymphatic development and function, emphasises the importance of interactions 
between the lymphatic endothelium and surrounding smooth muscle cells in 
propagating vessel development and emphasises the hitherto unrecognised importance 
of smooth muscle cells for lymphatic vessel morphogenesis and function. 
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Chapter 1. Introduction 
 
1.1 Functions and associated pathology of the lymphatic 
vasculature 
 
1.1.1 Discovery of the lymphatic system 
 
The lymphatic system is a network of vessels and organs that grows alongside the blood 
vasculature and is found in all vascularised tissue, except the central nervous system 
and bone marrow (Figure 1.1).  The term ‘lymphaticus’, derived from the latin meaning 
‘distracted and confused’ was first used to refer to the lymphatic system in the 17th 
Century, and was an apt description of the understanding of lymphatic biology to date. 
The ancient Greeks first described structures filled with colourless fluid, which 
Hippocrates termed ‘white blood’, but they were unsure what they were describing, so it 
wasn’t until Gasparo Aselli observed white fluid-filled vessels, which he called ‘lacteis 
venis’ or ‘milky veins’, in the mesentery of a well-fed dog in 1622 that the lymphatic 
system was truly discovered.  His mistaken belief that lymphatic fluid flowed into the 
liver where it was converted to blood was not corrected until Jean Pecquet described the 
entry of the thoracic duct into the veins in 1651 and gave the first correct description of 
the route of lymphatic fluid into the blood.  In 1653, Olaus Rudbeck and Thomas 
Bartholin independently described the presence of lymphatic vessels throughout the 
body and hypothesised their involvement in movement of fluid filtered from the blood.  
It was then nearly another hundred years before William Hunter and his students 
proposed that the lymphatic vessels acted as absorbing vessels throughout the body 
(Witte et al., 1997, Skobe and Detmar, 2000).  
The first true insight into the fine structure of lymphatic vessels came from von 
Recklinghausen in 1862, who discovered that lymphatic vessel walls comprised a single 
Chapter 1. Introduction 
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layer of endothelial cells, whose borders stained black with silver nitrate.  He was thus 
able to disprove the prevailing hypothesis that lymph moved into the blood vessels via 
fine tubular structures and instead proposed that interstitial fluid flowed into ‘open-
ended’ lymphatic capillaries.  The major breakthrough in understanding lymph 
formation and lymphatic flow arose from Earnest Starling in 1896, whose experiments 
showed that lymph formed from the blood by filtration and that ‘transcapillary 
exchange’ depended on the balance of blood capillary and tissue hydrostatic pressure.  
Starling also made the key observation that oedema was the result of imbalanced lymph 
formation and absorption (Skobe and Detmar, 2000, Witte et al., 1997).  An interesting 
new insight into regulation of tissue fluid volume and lymphatic function suggests that 
it is not only the difference in volume, but also in tonicity (ratio of Na+ and K+ to water) 
of interstitial fluid that affects homeostasis (Machnik et al., 2009).  Furthermore, 
macrophages play a key role in this system, by releasing the lymphatic chemokine 
VEGF-C to act as an osmoprotective protein, maintaining interstitial volume via 
increased lymphangiogenesis (Machnik et al., 2009). 
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Figure 1.1 The human lymphatic system.   
The lymphatic system is a network of vessels and organs that grows into all 
vascularised tissue, except the central nervous system and bone marrow.  Image 
purchased from www.123rf.com. 
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1.1.2 Maintenance of tissue homeostasis 
 
Maintenance of the body’s tissue fluid balance is an extremely important function of the 
lymphatic vasculature.  Blood pressure causes water, proteins and other 
macromolecules to escape from the blood capillaries.  Over the course of a day, 50% of 
the circulating protein leaks from the capillaries and cannot be directly reabsorbed 
(Skobe and Detmar, 2000).  The major function of the lymphatic vasculature is to 
collect this interstitial fluid, part of which is also taken up by post-capillary venules, and 
return it to the blood vasculature via lympho-venous connections, the main example of 
which is between the thoracic duct and the junction between the left subclavian and 
internal jugular veins.  This is the drainage route of lymph from the left side of the 
body, abdomen and lower limbs.  The right lymphatic trunk returns lymph from the 
right upper arm, thorax and head to the right subclavian vein (Tammela and Alitalo, 
2010).  Additional lympho-venous connections occur in the renal, hepatic and adrenal 
veins as well as other peripheral locations (Alitalo et al., 2005).  Estimates of total post-
nodal lymph flow have reached as high as 4 litres/day in humans, which is increased to 
around 8 litres when the volume of fluid absorbed by lymph node microvessels is also 
taken into account (Levick and Michel, 2010).  This huge fluid turnover is critical for 
maintenance of plasma volume and to avoid an increase in tissue pressure.  Moreover, 
efficient drainage of interstitial fluid ensures adequate cell nutrition by minimising 
distances between cells and capillaries (Skobe and Detmar, 2000).   
Interestingly, it seems likely that the major function of the lymphatic vasculature can 
also be a driving force for its formation.  A sophisticated tail skin wound model, in 
which the dermis is removed to arrest lymphatic flow and collagen is injected under a 
silicon sleeve to act as a bridge for interstitial flow, revealed that directional movement 
of interstitial fluid precedes lymphangiogenesis and that newly forming lymphatic 
vessels grow in the direction of flow (Boardman and Swartz, 2003).  Furthermore, 
arresting flow by allowing interstitial fluid to circumvent the wound area prevented 
lymphangiogenesis, suggesting that flow is in fact necessary for lymphatic vessel 
formation, at least in adult skin (Rutkowski et al., 2006). 
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1.1.3 Immune surveillance 
 
Dendritic cells (DCs) act as the ‘sentinels’ of the immune system.  They reside in 
peripheral tissues and upon encountering foreign antigens, traffic back to the lymph 
nodes via lymphatic vessels, where they are optimally positioned to encounter naïve or 
memory T cells and thus activate a specific immune response (Randolph et al., 2005).  
For a long time, DC entry and passage through the lymphatic vessels was viewed as a 
passive process, where the lymphatic vasculature was simply a conduit through which 
dendritic cells travelled.  While the presence of erythrocytes and a large number of 
neutrophils in the afferent lymph following contact elicitation (an inflammatory 
immune reaction at the site of a second (or subsequent) contact with a sensitizing 
antigen) suggests that some non-specific or passive uptake into the lymphatic vessels 
can occur, an increasing body of research has revealed an active role for the lymphatic 
endothelium in interacting with DCs and mediating their entry into the lymphatic 
capillaries (Randolph et al., 2005, Jurisic and Detmar, 2009). 
The discovery that the chemokine receptor CCR7 is required both in homeostatic and 
inflammatory conditions for DC entrance to lymphatic vessels was a first indication that 
DC entry into afferent lymph was not a passive process, consistent with the observation 
that CCL21, a ligand for CCR7, is expressed in the lymphatic endothelium (Ohl et al., 
2004).  Shear stress is also an important regulator of DC transmigration, as high 
transmural flow increased LEC expression of CCL21 as well as the leukocyte adhesion 
molecules ICAM-1 and E-selectin both in vitro and in vivo, thus enhancing DC 
transmigration.  In lymphoedema conditions, when flow is greatly decreased, LEC 
expression of CCL21 (and therefore DC transmigration) is also diminished (Miteva et 
al., 2010).  
Pflicke and colleagues demonstrated through sophisticated explant culture and 
microscopy techniques that the basement membrane (BM) of the lymphatic capillaries 
was discontinuous and organised into pre-formed ‘portals’ through which DCs migrated 
in an integrin-independent manner.  These portals were still present in CCR7-/- mice, 
even though DC were incapable of migrating through, indicating that it is not the DC, 
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but the lymphatic endothelium itself that mediates organisation of the BM in such a way 
as to allow transmigration of immune cells (Pflicke and Sixt, 2009).  Studies of Plexin-
A1-/- mice and transplant of wild type DCs into Sema3A-/- mice elicited two more 
molecules indispensable for DC entrance to the lymphatics, and suggested a mechanism 
by which the lymphatic endothelium actively participates in DC transmigration.  LEC-
derived Sema 3A interacts with its receptor Plexin-A1, which is expressed on the rear 
side of the dendritic cell.  This promotes acto-myosin contraction by phosphorylation of 
the myosin light chain, and allows the DC to squeeze through the narrow gap in the 
lymphatic BM and between the LEC to enter the afferent lymph (Takamatsu et al., 
2010). 
 
1.1.4 Dietary fat absorption 
 
Since Aselli discovered the lymphatic vessels in the mesentery of a well-fed dog in the 
17th Century, lymphatic function in absorption of dietary fat has been documented.  
Enterocytes in the small intestine assemble lipid-rich, water-soluble complexes called 
chylomicrons, which are absorbed by lacteals (intestinal lymphatics) and constitute up 
to 15% of lymph volume after ingestion of a fat-containing meal (Jurisic and Detmar, 
2009, Wang and Oliver, 2010).  There is evidence suggesting a link between lymphatic 
function and fat absorption/deposition, for example the transformation of chronic 
oedema following breast cancer surgery from accumulation of lymph fluid to excess 
deposition of subcutaneous adipose tissue (Brorson et al., 2006) and decreased 
lymphatic function in patients suffering from lipidema (reviewed in (Wang and Oliver, 
2010)).  However, the role of the lymphatic vasculature in fat metabolism is not yet well 
understood.   
The homeobox transcription factor Prox1 is an essential regulator of lymphatic 
development, and, as will be discussed in more detail below, its loss is incompatible 
with life (Wigle and Oliver, 1999).  In 2005, Harvey and colleagues showed that 
surviving Prox1+/- mice developed adult-onset obesity, despite no changes in exercise or 
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eating habits (Harvey et al., 2005).  However, Prox1+/- mice did display abnormal 
patterning and function of lymphatic vessels, especially in the mesentery, and the 
severity of lymphatic abnormalities correlated with the degree of obesity.  The authors 
also went on to show that culturing pre-adipocytes with chyle from the thoracic cavity 
of Prox1+/- newborns increased adipogenesis, thereby suggesting a mechanism by 
which lymph leaking from malfunctioning lymphatic vessels could promote local 
adipogenesis and eventually result in obesity (Harvey et al., 2005).   
Interestingly, a recent study demonstrated that hypocholesterolemia, resulting from 
ApoE deficiency, causes destruction of previously functioning lymphatic vessels (Lim 
et al., 2009).  This suggests that the link between lymphatic function and fat metabolism 
is not linear, and leads to the possible conclusion of an increasingly devastating 
feedback loop in which hypercholesterolemia can cause lymphatic vessel malfunction, 
and in turn lymph leakage from damaged lymphatic vessels can increase adipogenesis.  
Further research into the mechanisms of fat absorption into lymphatic vessels and 
whether lymphatic defects can cause any human obesity syndromes is required to help 
us further understand the role of the lymphatics in metabolism of dietary fat (Jurisic and 
Detmar, 2009, Wang and Oliver, 2010). 
A summary of lymphatic function is given in Figure 1.2 
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Figure 1.2 Function of the lymphatic vasculature.   
Fluid is extravasated from the blood vasculature due to high pressure and accumulates 
in the interstitium.  From here, it enters the lymphatic capillaries through the over-
lapping cell-junctions of the blind-ended lymphatic capillaries, along with proteins and 
other macromolecules, antigen presenting cells and cancer cells undergoing metastasis. 
 
1.1.5 Lymphoedema 
 
Failures in lymphatic development or function can result in lymphoedema, which 
although rarely life-threatening, is disfiguring and disabling and can lead to social or 
psychological disorders.  Lymphoedema results from an imbalance in lymph formation 
and absorption and is characterised by swelling of the limbs, tissue fibrosis, 
accumulation of subcutaneous fat and increased susceptibility to infection (Wang and 
Oliver, 2010, Jurisic and Detmar, 2009, Rockson, 2001).  Lymphoedema can either be 
inherited (primary lymphoedema) or caused by traumas due to surgery, infection or 
radiation therapy (secondary lymphoedema) (Alitalo et al., 2005).  Although some 
headway has been made in pre-clinical studies of curative therapies (Karkkainen et al., 
2001, Tammela et al., 2007), as yet available treatments still aim to manage the 
symptoms, rather than solve the problem, for example, by manual drainage, massage, 
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compression garments, liposuction and dietary modification (Rockson, 2001, Wang and 
Oliver, 2010, Brorson et al., 2006). 
 
1.1.5.1 Primary Lymphoedema 
 
Primary, or congenital, lymphoedema is a heterogeneous disease that is often seen in 
conjunction with other problems, as one symptom of a more complex syndrome.  
Mutations responsible for congenital lymphoedema in a number of human diseases have 
been identified, and mouse models of these mutations have been essential to understand 
its underlying causes.  However, since many of the genes involved are also important 
for lymphatic development, these will be discussed in more detail below and this 
section will concentrate on human disease. 
Heterozygous mutations in the tyrosine kinase domain of VEGFR3 have been found in a 
number of families with Milroy’s disease, in which functional failure and, probably to a 
lesser extent, hypoplasia of the lymphatic capillaries leads to lymphoedema (Mellor et 
al., 2010), (Karkkainen et al., 2000), (reviewed in (Wang and Oliver, 2010, Alitalo et 
al., 2005)). 
Mutations in FOXC2 have also been linked to human lymphatic disease; in this case 
lymphoedema-distichiasis (LD), which is characterised by a double row of eyelashes 
(distichiasis) and bilateral lower limb lymphoedema (Fang et al., 2000). Interestingly, 
skin biopsies of human LD patients revealed that while there was abnormal SMC 
recruitment to lymphatic capillaries in the skin of the swollen oedematous feet, the 
vessels of the unaffected forearms remained normal (Petrova et al., 2004).  Furthermore, 
a recent study of lymphatic function in LD patients with a FOXC2 mutation revealed 
that lymphatic function in the swollen foot was dependant on gravity, suggesting that a 
genetic predisposition to lymphatic abnormality might have an anatomical trigger 
(Mellor et al., 2011).  
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Other lymphoedema syndromes that have been linked to specific mutations include 
Hypotrichosis-lymphoedema-telengiectasia (HLTS), a rare disease linked to mutations 
in the transcription factor SOX18 (Irrthum et al., 2003) and Hennekam syndrome, 
which is characterised by mental retardation, limb lymphoedema, intestinal 
lymphangiectasias and facial abnormalities and is caused by mutations in CCBE1, 
which encodes Collagen and Calcium-Binding EGF-domain-1, a secreted protein 
essential for lymphatic development in zebrafish (Alders et al., 2009), (Hogan et al., 
2009).  Finally, mutations in GJC2, which encodes the gap junction protein Connexin 
47 have recently been found in several families with inherited lymphoedema.  This may 
be due to disrupted lymphatic flow, resulting from gap junction abnormalities (Ferrell et 
al., 2010). 
 
1.1.5.2 Secondary Lymphoedema 
 
The leading cause of secondary lymphoedema in the developing world is filariasis, 
more commonly known as elephantiasis.  This is a parasitic infection of the lymphatic 
vessels by Wuchereria bancrofti or Brugia malayi worms, transmitted by mosquito bites 
(Alitalo et al., 2005).  An inflammatory reaction that triggers production of VEGF, 
VEGF-C and VEGF-D leads to hyperplasia and severe damage to the lymphatic 
vasculature.  This leads to chronic lymphoedema of the lower limbs or genitalia 
(reviewed in (Wang and Oliver, 2010, Rockson, 2001)).  In industrialised nations, the 
leading cause of secondary lymphoedema is damage to lymphatic vessels and removal 
of lymph nodes after breast cancer surgery or radiation therapy.  It has been estimated 
that around 20% of women develop the condition after breast cancer surgery (Jurisic 
and Detmar, 2009, Wang and Oliver, 2010).  While some success has been reported in 
long-term management of post-operative lymphoedema with liposuction (Brorson et al., 
2006), treatments aiming to repair the damaged lymphatic vasculature are still a long 
way from the clinic.  Promising pre-clinical data however, suggests that a solution may 
be on the horizon.  Application of VEGF-C after lymph node removal promoted the 
development of new, functional lymphatic vessels in mice, which lead to a 
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corresponding reduction in oedema.  Furthermore, VEGF-C aided the incorporation of 
transplanted lymph nodes into the existing vasculature, which again improved 
lymphatic drainage (Tammela et al., 2007).   
Increasing understanding of the underlying causes of congenital lymphoedema and 
forays into novel treatment strategies means that we can hopefully look forward to the 
development of curative, rather than management, treatment strategies for 
lymphoedema in the future. 
 
1.1.6 Inflammation 
 
The role of the lymphatic system in immune surveillance has been discussed above, but 
the consequences of inflammation-induced lymphangiogenesis are mixed.  During 
inflammation, inflammatory cells and macrophages express VEGF-C, which promotes 
lymphangiogenesis (Baluk et al., 2005, Kerjaschki et al., 2004).  Furthermore, a number 
of studies have also shown evidence for incorporation of LEC progenitors, believed to 
be macrophages or other bone-marrow derived cells, into lymphatic vessels under 
inflammatory or tumour conditions and that these cells are capable of stimulating de 
novo lymphangiogenesis.   
Maruyama and colleagues demonstrated direct incorporation of cells co-expressing the 
macrophage marker CD11b with lymphatic endothelial markers Prox1 and LYVE-1 in 
the walls of newly generated lymphatic vessels in the inflamed corneal stroma.  These 
vessels were not continuous with the limbal lymphatic vessels, suggesting that innate 
immune cells contributed to pathological lymphvasculogenesis, rather than 
incorporating into sprouts growing from existing vessels.  Furthermore, macrophage 
depletion by application of clodronate liposomes prevented CD11b+ macrophage 
infiltration and lymphangiogenesis in the stroma, providing compelling evidence for the 
importance of these cells in pathological lymphangiogenesis (Maruyama et al., 2005).  
Furthermore, in studies of renal transplant rejection, 4.5% of Prox1+ LECs, which 
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accounted for 12.9% of the lymphatic vessels in female-donor kidney transplants, were 
found to derive from male recipient LEC progenitors (Kerjaschki et al., 2006).  Recent 
work has aimed to more completely characterise the phenotype of bone marrow derived 
LEC progenitors and assess their role in lymphangiogenesis.  Lee and colleagues 
demonstrated that culturing bone marrow derived cells with lymphangiogenic cytokines 
lead to up-regulation of LEC markers including Prox1, LYVE-1, Podoplanin, VEGFR-3 
and Foxc2, while still expressing the macrophage marker CD11b (Lee et al., 2010).  
Over time in culture, these cells lost hematopoietic identity, but maintained expression 
of LEC markers, and furthermore could contribute to lymphatic neovascularisation in 
vivo under pathological conditions, thus providing important evidence for the 
involvement of bone marrow derived cells in pathological lymphangiogenesis (Lee et 
al., 2010).  However, it is important to note that bone marrow derived cells do not 
contribute to lymphangiogenesis in all pathological conditions.  For example, studies of 
tumour-induced lymphangiogenesis found that new vessels sprouted from the 
preexisting lymphatic endothelium with no contribution from bone marrow derived 
cells (He et al., 2004). 
Increased lymphangiogenesis during infection promotes removal of fluid, chemokines 
and leukocytes from the site of inflammation, the importance of which was 
demonstrated by blocking VEGF-C signalling using soluble VEGFR-3-IgG during 
Mycoplasma pulmonis infection, which resulted in accumulation of fluid and leukocytes 
and mucosal oedema (Baluk et al., 2005).  However, increased lymphangiogenesis also 
promotes immune cell trafficking to the lymph nodes and may support the formation of 
an inflammatory loop, for example CCL21 on new lymphatic vessels attracts CCR7-
positive dendritic cells, which may promote the inflammatory reaction that leads to 
renal transplant rejection (Kerjaschki et al., 2004, Jurisic and Detmar, 2009).  Increased 
lymphatic vessel density is also a feature of inflammatory bowel disease (Rahier et al., 
2011), but whether this is protective or pathological is unclear.  While increased 
lymphatic vessels clear cytokines and immune cells and may act to ‘balance’ increased 
inflammatory angiogenesis, increased lymphatic remodelling or obstruction causes a 
build-up of cytokines and immune cells and can recapitulate the symptoms of 
inflammatory bowel disease (reviewed in (Alexander et al., 2010)).  Likewise, treatment 
of a mouse model of psoriasis with a VEGFR-3 tyrosine kinase inhibitor resolved 
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inflammation by reducing the number of inflammation associated blood and lymphatic 
vessels, suggesting that again in this situation, lymphangiogenesis is pathological, rather 
than protective (Halin et al., 2008). 
 
1.1.7 Metastasis 
 
The lymphatic vessels provide a crucial route for tumour cell metastasis.  Once tumour 
cells reach the lymph node, they can disseminate to distal sites in the body and become 
secondary tumours, the prognosis for which is often poor.  There is still some question 
as to the mechanism, or purpose, of lymph node metastasis.  The lymph node could be 
‘trapping’ the tumour cells, leading to a lag phase in dissemination, or the presence of 
tumour cells in the lymph node could simply be evidence of metastatic potential; 
tumour cells are found in the lymph nodes while in transit around the body.  
Alternatively, the lymph nodes could be a site for tumour cell amplification, promoting 
their metastatic spread (Tammela and Alitalo, 2010).  Regardless, the extent of lymph 
node metastasis is an important determinant for the staging and prognosis of most 
human malignancies, and in some cases determines or guides treatment options (Tobler 
and Detmar, 2006).   
Over-expression of VEGF-C in breast cancer cells increases intratumoural 
lymphangiogenesis, and the presence of tumour cells within these lymphatic vessels 
suggests functionality (Skobe et al., 2001), however there is suggestion that 
intratumoural lymphatic vessels may collapse under the high pressure inside the tumour, 
so may not be useful for enhanced metastasis (Alitalo et al., 2005).  Despite this, Skobe 
and colleagues found increased lymph node and lung metastases in VEGF-C over-
expressing tumours and in the case of lung metastasis, saw strong positive correlation 
between the density of lymphatic vessels within the tumour, and the lung area covered 
by metastases (Skobe et al., 2001).  Similarly, crossing a mouse line that over-expresses 
VEGF-C in β cells of the endocrine pancreas with mice that develop non-
lymphangiogenic, non-metastatic tumours in the same tissue, induced the onset of both 
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lymphangiogenesis and metastasis, strongly indicating a causal relationship between 
VEGF-C, lymphangiogenesis and lymph node metastasis (Mandriota et al., 2001). 
Increased tumour associated lymphangiogenesis has also been observed in mice that 
over-express VEGF-C in the skin (Hirakawa et al., 2007).  VEGF-C expressing tumours 
developed enhanced lymphatic vessel networks in the lymph nodes even prior to 
metastasis, suggesting that the tumour can regulate lymphangiogenesis at a distance, 
thus paving the way for further tumour cell dissemination. In support of this hypothesis, 
increased lung and distant lymph node metastasis were observed in mice over-
expressing VEGF-C in the skin  (Hirakawa et al., 2007).  Indeed, VEGF-C and VEGF-
D expression can be considered useful prognostic indicators, as clinical data suggests 
that their expression in a number of tumour types is highly correlated with 
lymphangiogenesis and lymph node metastasis (Feng et al., 2010, Liu et al., 2008).  
Furthermore, blocking VEGF-C/VEGF-D signalling by inhibiting VEGFR-3 can 
prevent increased lymphangiogenesis and also lymph node metastasis in several 
different tumour models (He et al., 2002, Karpanen et al., 2001, Zhang et al., 2010a, 
Yang et al., 2011, Padera et al., 2008). 
Other studies suggest that the correlation between tumour-expressed VEGF-C and 
lymphatic metastasis is unlikely to be solely due to increased lymphangiogenesis.  
Using high resolution imaging, Tammela and colleagues observed that VEGF-C 
induced lymphatic sprouting resulted in ‘leaky’ lymphatic vessels that had intercellular 
gaps in the endothelial monolayer, which could potentially facilitate tumour cell 
invasion (Tammela et al., 2007).  More recently, a series of 3-dimensional cell culture 
assays demonstrated that VEGF-C over-expression in tumour cells increased their 
chemoattraction to LEC (Issa et al., 2009).  This occurred predominantly via VEGFR-3 
dependant up-regulation of CCL21 in LEC, which attracted tumour cells to the 
lymphatic vessels via its receptor, CCR7.  Additionally, autocrine VEGF-C-stimulated 
VEGFR-3 phosphorylation in tumour cells resulted in increased proteolytic activity and 
motility through a 3 dimensional matrix, demonstrating increased tumour cell 
invasiveness (Issa et al., 2009).  Notably, while LEC-derived CCL21 promotes tumour 
cell chemotaxis towards lymphatic vessels, interstitial flow also synergistically 
enhances tumour cell chemotaxis towards the lymphatic endothelium via autocrine 
CCL7/CCL21 signalling (Shields et al., 2007).  Furthermore, the mode of tumour cell 
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migration may influence its metastatic spread, for example single cell migration is 
required for blood-borne metastasis and requires TGFβ signalling, while in the absence 
of TGFβ tumour cells migrate collectively, in which state they are more likely to spread 
via the lymphatic vasculature (Giampieri et al., 2009). 
 
1.2 Development of the lymphatic vasculature 
 
Most evidence to date supports the model of mammalian lymphatic development first 
proposed by Florence Sabin in the early 20th Century.  By making detailed anatomical 
observations after ink injection into pig embryos, she proposed that the lymphatic 
vasculature sprouted from the cardinal veins (Sabin, 1902).  An alternative theory 
proposed a few years later, following analysis of domestic cat embryos, suggested that 
the jugular lymphatic sacs arise after the venous network is ‘surrounded’ in some places 
by a ‘secondary capillary network’ and so the lymphatic endothelial cells in fact derive 
from mesenchymal precursors (Huntington and McClure, 1910). These studies formed 
the basis of the debate that has existed ever since, as to whether mesodermal progenitors 
contribute to mammalian developmental lymphangiogenesis.  
The development of sophisticated genetic tools has enabled lineage-tracing studies, 
which have aimed to resolve this controversy. Expressing Cre recombinase under the 
control of Prox1, which is expressed only in lymphatic endothelial cells, or Tie2, which 
at the stages examined is expressed only in blood vascular endothelial cells, revealed 
Prox1-positive prospective LEC in the cardinal vein at E9.5.  These cells subsequently 
sprouted from the vein to form the lymph sacs, and from there the entire lymphatic 
vasculature.  Normal lymph sacs in Runx1 deficient mice, which lack haematopoietic 
precursors, lead to the conclusion that murine lymphatics are solely venous derived and 
include no contribution from haematopoietic-derived cells (Srinivasan et al., 2007).  
Nevertheless, the ability of bone marrow derived cells to incorporate into growing 
lymphatic vessels under pathological conditions in adults, as discussed above, has 
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contributed to the controversy surrounding the origins of the lymphatic vasculature.  
Furthermore, grafting quail somites into chick embryos and analysing the lymphatic 
vasculature using a quail-specific antibody, indicates that the somitic mesoderm of the 
avian wing bud can differentiate into lymphatic endothelium (Wilting et al., 2000).  In 
addition, Prox1+ lymphangioblasts, which share a common origin with angioblasts, have 
been identified in Xenopus tadpoles (Ny et al., 2005), (reviewed in (Karpanen et al., 
2006b, Makinen et al., 2007)).  However, a contribution of mesenchymal progenitors to 
the lymphatic endothelium has yet to be identified during normal lymphatic 
development in mammals and recent lineage-tracing experiments suggest that cells of 
the myeloid lineage do not transdifferentiate into embryonic LECs and furthermore, are 
not a significant source of lymphangiogenic cytokines in embryonic skin, contrary to 
the situation in adult pathological lymphangiogenesis (Gordon et al., 2010). 
In summary, the current model of lymphatic development favours the view that 
lymphatic endothelial specification occurs in a polarised fashion on one side of the 
cardinal veins at E9.5-10.5 in mouse and embryonic weeks 6-7 in humans (Tammela 
and Alitalo, 2010).  LEC bud from the veins and form the lymph sacs, after which the 
lymphatic and blood vasculatures separate; only maintaining connections in defined 
locations for the purpose of returning lymph to venous circulation.  Lymphatic vessels 
sprout from the lymph sacs to form a primary lymphatic plexus, which then undergoes 
extensive remodelling in late embryonic and early postnatal stages to give rise to the 
mature lymphatic vasculature, consisting of distinct collecting vessels and capillaries 
(Schulte-Merker et al., 2011, Tammela and Alitalo, 2010, Jurisic and Detmar, 2009, 
Makinen et al., 2007, Karpanen et al., 2006b) (Figure 1.3).  The molecular regulation of 
this carefully orchestrated differentiation process is discussed in more detail below.  
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Figure 1.3 Development of the lymphatic system.   
Current model of lymphatic development in mice, and the genes involved in regulating 
each step.  Adapted from (Karpanen and Makinen, 2006) 
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1.2.1 Lymphatic specification 
 
In mice, a number of genes have been identified whose expression marks the onset of 
lymphatic differentiation, and in many cases, the proteins they encode are essential for 
lymphatic development. 
LYVE-1 was initially identified by its structural homology to CD44 in the Hyaluronan 
(HA) binding domain (Banerji et al., 1999), and starts to be expressed in the venous 
endothelium just prior to Prox1, making it one of the earliest markers of prospective 
lymphatic endothelial cells (Alitalo et al., 2005).  However, despite extensive analysis 
of both physiological and pathological conditions in Lyve1 null mice, no phenotype 
could be identified.  Therefore, despite its early expression in the prospective lymphatic 
endothelium - and throughout lymphatic development - until its final down-regulation 
in mature lymphatic collecting vessels, the function of LYVE-1 is yet to be discovered 
(Gale et al., 2007, Huang et al., 2006). 
The homeobox transcription factor Prox1 has been identified as a master regulator of 
lymphatic identity, since its over-expression in BEC can to some extent re-programme 
them to a lymphatic phenotype; suppressing expression of around 40% blood vascular 
endothelial markers, while up-regulating expression of 19% lymphatic specific genes 
(Petrova et al., 2002).  Sox18 binds to specific sites in the Prox1 promoter and directly 
activates Prox1 expression (Francois et al., 2008).  Consistent with this, Sox18 is first 
detected in EC of the cardinal vein at E9, just prior to Prox1 expression, and continues 
to be expressed in LEC until E13.5, at which stage it is expressed in almost all cells of 
the lymph sac.  Its expression subsequently subsides and Sox18 is not found in dermal 
or mesenteric LEC, or in lymphatic vessels in adult tissues, suggesting that it is not 
required for maintenance of LEC identity after specification (Francois et al., 2008).   
Ragged mice have a naturally occurring mutation in Sox18 and homozygous mouse 
mutants do not initiate lymphatic differentiation, dying at around E14.5 with gross 
subcutaneous oedema, thus demonstrating the importance of Sox18 function for 
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lymphatic development.  Mice heterozygous for Sox18 mutations show defects in 
lymphatic patterning, which is suspected to contribute to the oedema shown in both 
Sox18-/- mice and HLTS (Francois et al., 2008). 
Prox1 expression is first detected at E9.5 in lymphatic endothelial fated cells on one 
side of the cardinal veins (Wigle and Oliver, 1999), and its expression is maintained in 
LEC throughout development, although levels of Prox1 are reduced in the collecting 
lymphatic vessels except in the luminal valves (Norrmen et al., 2009).  Prox1 is 
essential for lymphatic development.  In Prox1-/- embryos, LEC are initially specified, 
but fail to bud from the veins and no lymph sacs or lymphatic capillary networks form.  
These mice display gross subcutaneous oedema at E14.5 and die between E14.5 and 
E15 (Wigle and Oliver, 1999).  Prox1 haploinsufficient pups also die, with chyle in the 
mesentery, at or around birth in all but one genetic background.  Surviving Prox1+/- 
mice have disorganised and leaky lymphatic vessels, again demonstrating the 
importance of Prox1 for normal lymphatic development (Harvey et al., 2005).  
Although the importance of Prox1 for lymphatic development is now well understood, 
it is also important for development of other tissues, for example the central nervous 
system and the heart, as evidenced by growth retardation and structural disorganisation 
of the heart in both Prox1 null and cardiac-specific mutant embryos (Risebro et al., 
2009). 
The transcription factor Coup-TFII has also been recently identified as important for 
LEC specification.  Coup-TFII deletion at different stages of early lymphatic 
development revealed that it is required for both specification and maintenance of early 
LEC identity (up to E13.5) (Lin et al., 2010).  However, deletion at E14.5 or E15.5 had 
no effect, suggesting that after this stage Coup-TFII is no longer required for 
maintenance of LEC fate (Srinivasan et al., 2010).  Consistent with a similar role in 
specifying, but not maintaining, LEC fate to that of Sox18, Coup-TFII may also be able 
to directly bind to, and activate, Prox1 (Srinivasan et al., 2010).  Interestingly, while 
Coup-TFII does not appear to function in quiescent adult lymphatic vessels, inactivation 
in a tumour model lead to a decrease in tumour lymphatic vessels, suggesting a role for 
Coup-TFII in neo-lymphangiogenesis (Lin et al., 2010). 
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1.2.2 Lymphatic Sprouting 
 
In the blood vasculature, sprouting angiogenesis involves the growth of new vessels 
from pre-existing ones.  Angiogenic stimuli activate endothelial cells in the pre-existing 
vessel, which then secrete proteases to degrade the basement membrane, allowing the 
EC to migrate and proliferate into the extracellular matrix (Eilken and Adams, 2010).  
According to the current dogma, during lymphatic development the newly specified 
LEC must first sprout from the cardinal vein to form the lymph sacs and then from the 
lymph sacs to form the rest of the lymphatic vasculature.  However, less is known about 
the regulation of this process in lymphatic than blood vasculature, although it seems that 
some important differences may exist, for example BEC migrate in tandem, while LEC 
can migrate as single cells and then assemble together into new vessels (Rutkowski et 
al., 2006). 
One major signalling pathway known to be essential for lymphatic sprouting is VEGF-
C/VEGFR-3.  VEGFR-3 is expressed from about E8.5 in the mouse embryo, where it is 
initially expressed in all endothelial cells.  However, upon initiation of lymphatic 
specification around E10.5, its expression becomes restricted to LEC (Kaipainen et al., 
1995). VEGF-C is expressed in mesenchyme neighbouring the VEGFR-3+ jugular veins 
from which the lymphatic endothelial cells sprout.  In the absence of Vegfc, LEC are 
initially specified (as visualised by Prox1 expression) in the jugular vein, but fail to 
sprout, resulting in absence of the lymph sacs and subsequently the later lymphatic 
vessels (Karkkainen et al., 2004). Unlike Vegfc-/- mice, Vegfc happloinsufficient animals 
survived embryogenesis, but newborn pups transiently accumulated chyle in the 
abdomen, and even adult mice displayed lymphoedema and hypoplastic, dysfunctional 
lymphatic vessels, thus emphasising the importance of VEGF-C for lymphatic 
development (Karkkainen et al., 2004).  
An early role for VEGFR-3 in blood vessel remodelling means that Vegfr3-/- mice die at 
E9.5 before the onset of lymphatic development (Dumont et al., 1998).  However, Chy 
mice, which have a heterozygous targeted mutation in the tyrosine kinase domain of 
Vegfr3 have defective or absent lymphatic vessels, accumulate chyle in the abdomen 
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and develop lymphoedema (Karkkainen et al., 2001), demonstrating the importance of 
VEGFR-3 for normal lymphatic development.  
VEGFR-3 stimulation protects cultured LEC from starvation-induced apoptosis and 
promotes cell survival, growth and migration in vitro, via activation of p42/p44 MAPK 
and Akt phosphorylation (Makinen et al., 2001b).  The in vivo importance of these 
functions was demonstrated by blocking VEGF-C/VEGFR-3 signalling using a VEGF-
C/D trap: a soluble form of VEGFR-3 that competes with the membrane-bound receptor 
for VEGF-C/D ligand binding.  Expressing this construct from E14.5 in the basal 
epidermis not only prevents foetal lymphangiogenesis, but also causes regression, via 
apoptosis, of lymphatic capillaries that had already formed in deeper tissues.  
Interestingly, these mice are still healthy and viable and regressed vessels grow back by 
about 3 weeks after birth (Makinen et al., 2001a).  Blocking VEGFR-3 signalling in 
postnatal mice prevented lymphatic vessel regeneration in a tail skin model of adult 
lymphangiogenesis, but had no effect on existing vessels, which still functioned 
normally (Pytowski et al., 2005).  Together, these results suggest that the requirement 
for VEGF-C/VEGFR-3 signalling for the spouting and survival of new lymphatic 
vessels is not constant (Karpanen et al., 2006b).   
There is some functional redundancy between the two known VEGFR-3 ligands, 
VEGF-C and VEGF-D, because over-expression of VEGF-D rescues lymphatic 
hypoplasia in Vegfc+/- mice (Haiko et al., 2008), and could also induce a weak LEC 
migratory response in explant assays (Karkkainen et al., 2004).  However, Vegfc-/- mice 
have no lymphatic vessels, suggesting that physiological levels of VEGF-D cannot 
substitute for the requirement for VEGF-C during lymphatic development and normal 
lymphatic vasculature in Vegfd-/- mice indicates that VEGF-C is sufficient for lymphatic 
vessel growth (Haiko et al., 2008).   
Surprisingly, Vegfc-/-;Vegfd-/- mice do not phenocopy Vegfr3-/- mice.  The lymphatic 
defects are as severe as those seen in Vegfc-/- mice alone, but the double mutants 
appeared as wild-type at E11.5, with normal blood vasculature, while Vegfr3-/- embryos 
had already died by this stage (Haiko et al., 2008).  These data suggested that there may 
be ligand independent functions of VEGFR-3 in blood vascular development and 
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concordant with this hypothesis, disrupting the ligand-binding domain of VEGFR-3 
lead to disrupted lymphangiogenesis, but allowed normal blood vessel development 
(Zhang et al., 2010b).  Interestingly, the lymph sacs still formed normally in these mice, 
although lymphatic vessels subsequently failed to sprout.  This suggests that VEGFR-3 
can also function in a ligand-independent manner in this context (Zhang et al., 2010b).  
However, this is in direct contradiction with the lack of lymph sacs in Vegfc-/- mice 
(Karkkainen et al., 2004). 
The axon guidance receptor Neuropilin-2 (Nrp2) is a co-receptor for VEGFR-3 
(Karpanen et al., 2006a).  It is initially expressed in veins and lymphatic vessels, but 
becomes restricted to the lymphatics after about E13 (Yuan et al., 2002).  Mice deficient 
for Nrp2 develop normal collecting vessels, but although lymphatic capillaries develop 
postnatally, they appear to be absent or reduced between E13-P3 (Yuan et al., 2002).  
Both VEGF-C and VEGF-D bind to Nrp-2, which is internalised with VEGFR-3 upon 
VEGF-C/D stimulation.  Co-immunoprecipitation experiments revealed an interaction 
between VEGFR-3 and Nrp2, and Nrp2 internalisation upon ligand binding is 
dependant on VEGFR-3 (Karpanen et al., 2006a).  Nrp2 does not have intrinsic 
enzymatic signalling ability, but Nrp2 cooperation with VEGFR-3 may aid LEC sensing 
of growth factor gradients and maximise their response to VEGF-C (Tammela and 
Alitalo, 2010).  In line with this hypothesis, Nrp2 blocking antibodies inhibited LEC tip 
cell sprouting in vivo, in a VEGFR-3 dependant manner, resulting in decreased 
lymphatic vessel branching in the tail and sprouting in the intestinal lymphatics.  
However, only the induction of sprouting was affected; Nrp2 blockade had no effect on 
sprout elongation (Xu et al., 2010). 
 
1.2.3 Separation from the blood vasculature 
 
Separation of the primary lymphatic plexus from the blood vasculature is essential for 
normal lymphatic function.  According to the current model of lympho-venous 
separation, Podoplanin, on the surface of lymphatic endothelial cells, activates platelets 
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circulating in the blood via its receptor CLEC-2.  CLEC-2 signalling, via the 
haematopoietic signalling proteins Syk, SLP-76 and PLC-γ2, leads to platelet activation 
and aggregation at the junctions between blood and lymphatic vasculature, thus ‘sealing 
off’ the junction and mediating their separation (Schulte-Merker et al., 2011). 
Much of this signalling pathway was identified by analysis of mice deficient in one or 
more of the components.  Pdpn-/- mice displayed tortuous, blood filled lymphatic 
vessels, where abnormal connections between the two vascular systems could be 
identified by intra-venous injection of dye or FITC-dextran and visualisation of the dye 
in lymphatic vessels (Uhrin et al., 2010, Bertozzi et al., 2010).  Pdpn-/- mice failed to 
aggregate platelets at the separation site of the lymph sac and cardinal vein, suggesting 
the involvement of haematopoietic cells (Uhrin et al., 2010).  This was further 
confirmed by deletion of Meis1 (which results in ablation of megakaryocytes/platelets 
and deficiencies in haematopoietic stem cells) and specific deletion of megakaryocytes, 
which caused a failure of lymphatic-blood separation (Carramolino et al., 2010).  
Furthermore, a podoplanin fusion protein was found to bind wild type, but not Clec2-/- 
platelets, suggesting that CLEC-2 is the podoplanin receptor on platelets (Bertozzi et 
al., 2010).   
This was further confirmed by studies of Clec2-/- mice.  CLEC-2 (C-type lectin-like 
receptor 2) is specifically expressed on the surface of platelets and megakaryocytes and 
mice deficient for this protein display disorganised and dysfunctional lymphatic vessels, 
oedema and blood-filled lymphatics (Suzuki-Inoue et al., 2010, Bertozzi et al., 2010).  
Furthermore, CLEC-2 signals through Syk and SLP-76 (Suzuki-Inoue et al., 2006), 
suggesting that activation of CLEC-2 on the surface of platelets may lead to lymphatic 
and blood vascular separation via Syk and SLP-76.  This was consistent with previous 
observations that mice deficient in Slp76 or Syk displayed abnormal connections 
between the blood and lymphatic vasculatures, resulting in blood in the lymphatic 
vessels and chyle in the mesenteric blood vessels of these mice (Abtahian et al., 2003). 
Transplanting Slp76-/- bone marrow into irradiated wild type mice was sufficient to 
induce mixing of the blood and lymphatic vasculature, as was platelet specific deletion 
of Slp76, demonstrating that SLP-76 is required in hematopoietic cells to regulate 
lympho-venous seperation (Abtahian et al., 2003, Bertozzi et al., 2010). 
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1.2.4 Lymphatic Remodelling 
 
Several genes have been specifically implicated in the later stages of lymphatic 
development, such as specification of capillary vs. collecting vessel identity, or 
formation of luminal valves, and these will be discussed in more detail below. 
 
1.2.4.1 Foxc2 
 
The forkhead transcription factor Foxc2 is an essential regulator of lymphatic 
remodelling and maturation of the primary lymphatic plexus.  However, consistent with 
its low expression in LEC prior to E15.5, it does not appear to be important for early 
lymphatic development (Petrova et al., 2004, Norrmen et al., 2009). 
In the mesentery, Foxc2 is transiently up-regulated in all LECs at E15.5, before 
becoming restricted to sites of luminal valve formation in the mature collecting 
lymphatic vessels (Norrmen et al., 2009).  Consistent with this expression pattern, 
Foxc2-/- mice fail to develop luminal valves, which results in abnormal outflow of 
FITC-Dextran from collecting vessels.  Additionally, dermal capillaries of Foxc2-/- mice 
have irregular sized, dilated lumens, deposit ectopic Collagen IV and display abnormal 
investment of SMC, where there should usually be none.  Concomitantly, Foxc2-/- 
capillaries have increased expression of the SMC recruitment factors PDGFB and 
Endoglin (Petrova et al., 2004).  Transient up-regulation of Foxc2 at E15.5 is followed 
by down-regulation of Prox1, VEGFR3 and LYVE-1 in maturing collecting lymphatic 
vessels, although Prox1 and VEGFR3 continue to be expressed in the luminal valves 
(Norrmen et al., 2009).  These capillary markers fail to down-regulate in Foxc2-/- mice, 
suggesting that Foxc2 is essential for regulating the maturation of the primary lymphatic 
plexus into collecting vessels and capillaries, as well as for initiating the development of 
luminal valves and restricting SMC recruitment to lymphatic capillaries (Norrmen et al., 
2009) (Petrova et al., 2004).   
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Aberrant SMC recruitment to dermal capillaries in Foxc2-/- mice may be linked to 
failure to arrest VEGFR-3 signalling in these mice, which leads to a corresponding 
increase in Ang2 expression (Norrmen et al., 2009).  Ang2 is required for proper 
lymphatic development and its loss results in impaired SMC migration to the collecting 
lymphatic vessels (Gale et al., 2002).  Conversely, ectopic Ang2 expression in Foxc2-/- 
capillaries may result in atypical SMC coverage. 
Interestingly, a number of Foxc2 binding sites in primary LECs are also enriched with 
nuclear factor of activated T cells (NFAT) binding sites.  Inhibition of NFATc-1 with 
cyclosporin A results in a similar phenotype to Foxc2 deficiency, which is enhanced 
when NFATc-1 is inhibited in Foxc2+/- mice.  This suggests that Foxc2 may co-operate 
with NFATc-1 to mediate the regulation of capillary vs. collecting vessel identity 
(Norrmen et al., 2009). 
 
1.2.4.2 Connexins 
 
A recent study has identified a role for Connexin 37 (Cx37) and Connexin 43 (Cx43) in 
lymphatic valve development.  Mice lacking either one of these proteins show a 
reduction in the number of lymphatic valves formed, although this is more extreme in 
the case of Cx43-/- than Cx37-/-.  However, loss of both proteins results in a complete 
absence of lymphatic valves (Kanady et al., 2011).  This appears to be a valve-specific 
defect, rather than a general failure of collecting vessel specification as expression of 
other lymphatic markers was normal in Cx37-/-;Cx43-/- mice.  Foxc2 may be at least 
partly responsible for regulating connexin-mediated valve formation, since Cx37 
expression was reduced in Foxc2-/- mice, although expression of Cx43 was unaffected 
(Kanady et al., 2011).  Cx47 was also localised to the luminal valves (Kanady et al., 
2011), which is especially interesting given the recent data demonstrating that mutations 
in GJC2, which encodes Connexin 47, cause primary lympoedema (Ferrell et al., 2010). 
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1.2.4.3 EphrinB2 
 
Eph receptor tyrosine kinases and their binding partners Ephrins are involved in 
repulsive axon guidance in the nervous system, but are also essential for embryonic 
angiogenesis.  Ephrins are divided into EphrinAs that are attached to the cell surface by 
a glycosylphosphatidylinisotol anchor or EphrinBs, which possess a transmembrane 
domain. Ephrins are capable of both ligand-like activity, via activation of their 
associated Eph receptors (forward signalling) and receptor-like signal transduction 
activity (reverse signalling) (Adams and Eichmann, 2010).  In the case of EphrinBs, 
reverse signalling involves recruitment of adaptor proteins to phosphotyrosine residues 
in the cytoplasmic domain or to a PDZ binding motif. Expression of EphrinB2 in 
arteries and EphB4 in veins suggests a role for EphB4/EphrinB2 in cell sorting or vessel 
segregation, but this has yet to be definitively proved (Adams and Eichmann, 2010).  
Due to embryonic lethality, Efnb2 null mutants cannot be used to examine the role of 
this protein in the mature vasculature, but a recent endothelial cell specific Efnb2 
deletion (Efnb2iΔEC) demonstrated that its loss resulted in reduction of endothelial cell 
proliferation, tip cell number and complexity of the endothelial network in the postnatal 
retina (Wang et al., 2010).  Interestingly, a cell autonomous requirement for EphrinB2 
in vascular SMC and pericytes has also been identified.  Efnb2-/- pericytes display 
spreading defects and fail to form focal adhesions, resulting in disassociation from 
small-diameter blood vessels (Foo et al., 2006).   
Surprisingly, neither the intracellular tyrosine residues, nor the PDZ binding domain of 
EphrinB2 are required for embryonic blood vessel remodelling (Makinen et al., 2005).  
However, the lymphatic vasculature was severely disturbed upon disruption of the PDZ 
binding domain, thus revealing a previously unknown requirement for EphrinB2 reverse 
signalling via the PDZ binding domain for collecting lymphatic vessel maturation 
(Makinen et al., 2005). 
In contrast to the blood vasculature, within the lymphatic vessels, EphrinB2 expression 
is confined to the lymphatic endothelium and is not expressed in lymphatic SMC.  
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However it is expressed only in the endothelium of the collecting lymphatic vessels, not 
the capillaries, and when the EphrinB2 PDZ binding domain is mutated (referred to as 
Efnb2ΔVΔV), the distinction between these two vessel types is lost (Makinen et al., 
2005).  Although initial formation of the capillary plexus occurs normally, there is 
failure in sprout extension and the entire network is hyperplastic.  Collecting lymphatic 
vessels fail to down-regulate LYVE-1 or form luminal valves, while there is ectopic 
SMC recruitment to the capillaries.  The lack of luminal valves and failure of capillary 
remodelling resulted in FITC-Dextran reflux, indicating loss of functionality in the 
lymphatic vessels of Efnb2ΔVΔV mice (Makinen et al., 2005).  
Interestingly, recent work has linked EphrinB2 signalling to the VEGF-C/VEGFR-3 
pathway (Wang et al., 2010).  Stimulation of LEC with soluble EphrinB2-Fc or EphB4-
Fc fusion proteins resulted in VEGFR-3 internalisation, even in the absence of VEGF-
C.  However, downstream signalling components were not activated, implying that 
EphrinB2/EphB4 could not replace VEGF-C.  Intraperitoneal (IP) injection of VEGF-C 
in mice caused VEGFR-3 internalisation and accumulation in the perinuclear regions of 
mesenteric LEC in wild type, but not Efnb2iΔEC or Efnb2ΔV/ΔV mice, suggesting that 
EphrinB2 is also a regulator of VEGFR-3 internalisation and signalling in vivo (Wang 
et al., 2010).  
 
1.2.4.4 Angiopoietin/Tie signalling 
 
Tie1 and Tie2 receptor tyrosine kinases are expressed mainly in endothelial and 
haematopoietic cells, while the Tie2 ligands Angiopoietin-1 (Ang1) and Angiopoietin-2 
(Ang2) are expressed variably.  Ang2 is expressed in almost all endothelial cells, while 
Ang1 is expressed in SMC, pericytes, fibroblasts and other non-vascular normal and 
tumour cells (Augustin et al., 2009).  Ang1 and Ang2 share a binding site on Tie2, but 
while Ang1 is a Tie2 agonist, Ang2 is a context-dependant antagonist of Tie2 signalling 
(Augustin et al., 2009).  Tie1 and Tie2 are crucial for embryonic blood vascular 
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remodelling and stabilisation and are also involved in regulation of lymphatic 
development. Tie1 has an early role in lymphatic development; Tie1-/- mice develop 
oedema and show abnormal lymph sac patterning at E12.5, which defects precede blood 
vascular deficiencies (D'Amico et al., 2010).  In contrast, Ang2 has a later role in 
stabilisation of the mature lymphatic vasculature and SMC recruitment to collecting 
lymphatic vessels.  One report of Ang2-/- mice observed that instead of single, straight 
collecting lymphatic vessels with a regular, but discontinuous coverage of SMC in wild 
type mesenteries, Ang2-/- mice showed disorganised vessel networks, surrounded by 
clusters of poorly organised and dissociated SMCs, suggesting that Ang2 might 
normally induce SMC recruitment to the vessel (Gale et al., 2002).  However, in a 
different genetic background, the lymphatic defects were slightly different.  In this case, 
collecting lymphatic vessels failed to specify correctly.  Very few lymphatic valves 
formed, but those that did appeared normal and SMC were recruited prematurely to the 
collecting vessels and ectopically to the lymphatic capillaries (Dellinger et al., 2008).  
Interestingly, while unable to rescue the blood vascular phenotype of Ang2-/- mice, over-
expression of Ang1 under the control of the Ang2 promoter was able to fully rescue the 
lymphatic phenotype (Gale et al., 2002) (Dellinger et al., 2008).  Also, Ang1 over-
expression by injection into the mouse ear causes VEGFR-3 dependent lymphatic 
capillary sprouting and hyperplasia (Tammela et al., 2005), both of which suggest that 
the requirement for Angiopoietins in the mature lymphatic vasculature may be rather a 
requirement for Tie2 activation.  
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1.3 Structure of the mature lymphatic vasculature 
 
The mature lymphatic vasculature consists of two different vessel types: lymphatic 
capillaries and collecting vessels.  These are structurally and molecularly distinct, 
particularly suiting them to their individual functions (Figure 1.4 A-B). 
 
1.3.1  Lymphatic capillaries 
 
Lymphatic capillaries are highly permeable, blind-ended structures, with thin walls, 
wide lumens and a discontinuous basement membrane.  Oak-leaf shaped capillary 
endothelial cells are anchored at the sides and base by VE-cadherin ‘button’ junctions 
(Baluk et al., 2007), while the free tips of the cells interdigitate with and loosely overlap 
their neighbours, forming ‘flap junctions’ through which dendritic cells and interstitial 
fluid can pass (Tammela and Alitalo, 2010, Schulte-Merker et al., 2011)(Figure 1.4 A).  
Sprouting capillaries have ‘zipper’ junctions, as are found in the collecting lymphatic 
vessels, which indicates that button junctions are a feature of mature and quiescent 
capillary endothelium.  However, it is interesting to note that both button and zipper 
junctions have the same protein composition, indicating that specialised junctions form 
by reorganisation of tight junction proteins, rather than by changes in protein expression 
(Baluk et al., 2007).  
Capillary endothelial cells are anchored to the extracellular matrix by anchoring 
filaments, which are primarily composed of Emilin-1 and fibrillin (Danussi et al., 2008).  
An increase in interstitial pressure due to fluid accumulation or movements in the 
surrounding tissue that put strain on the extracellular matrix causes extension of the 
anchoring filaments and opening of the capillaries.  This leads to an increase in luminal 
volume and a transient pressure decrease inside the vessel causing an influx of fluid.  As 
the capillary fills, the overlapping junctions close and the pressure returns to normal, 
Chapter 1. Introduction 
 44 
preventing leakage of lymph back into the interstitium (Tammela and Alitalo, 2010, 
Randolph et al., 2005).  Capillary fluid uptake is also sensitive to transmural flow.  
Increased flow causes disorganisation of VE-cadherin and PECAM-1 in the LEC 
junctions, increased permeability to Dextran and expression of Aquasporin-2, a 
component of channels controlling water flux (Miteva et al., 2010). 
 
1.3.2 Lymphatic collecting vessels 
 
Following absorption from the capillaries, fluid drains first into pre-collecting vessels, 
which share features of both capillary and collecting vessels.  For example, the cells are 
oak-leaf shaped and continue to express LYVE-1 as in the capillaries, but they develop 
luminal valves and acquire a very sparse coverage of SMC, reminiscent of the 
collecting vessels (Schulte-Merker et al., 2011, Randolph et al., 2005).  
Endothelial cells of the collecting lymphatic vessels are spindle shaped and tightly 
linked by continuous ‘zipper’ junctions.  Together with a more extensive basement 
membrane and SMC coverage, this prevents fluid leakage from the vessel (Figure 1.4 
B).  Collecting vessels are organised into a series of lymphangions, which are separated 
by luminal valves. The intrinsic pumping action of the lymphatic system is a unique 
requirement of the lymphatic vasculature, because unlike the blood vasculature the 
lymphatic system does not have the heart; a central pump to regulate blood flow.  
Lymph propulsion occurs via both intrinsic pumping action due to lymphatic smooth 
muscle cell contractions and by passive pressure changes caused by contractions of 
surrounding skeletal muscle or arterial pulsations.  The lymphangions contract 
sequentially as high pressure on the ‘upstream’ side of the valve forces it open, while 
reverse flow closes the valve, thus preventing lymph backflow, as will be discussed in 
more detail in section 1.4.5 (Randolph et al., 2005, Tammela and Alitalo, 2010, Schulte-
Merker et al., 2011).   Interestingly, a recent study has identified the capacity for solute 
exchange from the collecting lymphatic vessels, challenging the current belief that 
lymphatic vessels absorb fluid without ever leaking it back into the interstitium   
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(Scallan and Huxley, 2010).  This work demonstrated that solute does move from the 
vessel lumen into the interstitium, thus increasing the protein concentration of lymph in 
prenodal collecting lymphatic vessels; an observation that has important implications 
for lymphatic function and maintenance of tissue fluid balance (Scallan and Huxley, 
2010). 
 
 
Figure 1.4 Organisation of the mature lymphatic vasculature.   
Details of the structural organisation of (A) lymphatic capillaries and (B) lymphatic 
collecting vessels 
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1.4 Smooth muscle cells in blood vascular and lymphatic 
function 
 
1.4.1 Pericytes and Smooth Muscle Cells 
 
The majority of our understanding of the importance of smooth muscle cells and 
pericytes, commonly referred to as mural cells (MC), comes from studies of the blood 
vascular system.  The distinction between smooth muscle cells and pericytes is fluid and 
often hazy.  Attempts have been made to distinguish the two cell types by marker gene 
expression, for example αSMA is commonly used to identify SMC, while Desmin, 
NG2 and RGS5 are often used to distinguish pericytes.  However none of these markers 
are exclusive to pericytes and their expression is dynamic; they may all be expressed in 
both pericytes and smooth muscle cells in different tissues, developmental stages and 
species. For example, αSMA does not identify pericytes in the mouse retina, but does in 
the chicken (Gerhardt and Betsholtz, 2003, Armulik et al., 2005).  Another way to 
differentiate between the two cell types is by defining them based on contacts with 
endothelial cells and the extracellular matrix.  By this definition, pericytes contact 
endothelial cells directly through holes in their shared basement membrane, while SMC 
are separated from the endothelium by the basement membrane (Gerhardt and 
Betsholtz, 2003).  However, this distinction also fails during developmental and even 
postnatal angiogenesis, when the basement membrane is not yet complete.  For this 
reason, the distinctions between pericytes and smooth muscle cells are unclear and it 
seems probable that rather than representing two distinct cell types, they instead 
represent two ends of a continuum from the same lineage, where the larger blood 
vessels are surrounded by αSMA positive SMC, capillaries are covered with a pericyte 
layer and intermediate vessels may be covered by cells that take on the characteristics of 
both.  In accord with this is the ability of pericytes to differentiate into SMC and vice 
versa (Armulik et al., 2005). 
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The density of pericyte coverage and pericyte morphology varies between different 
organs and may reflect specialised functions of different vascular beds, for example 
pericyte coverage is high in the legs and lower torso in humans, where increased blood 
pressure is necessary to pump blood against gravitational force (Armulik et al., 2005, 
Bergers and Song, 2005, Gerhardt and Betsholtz, 2003). 
 
1.4.2 Vascular SMC / Pericyte ontogeny 
 
Vascular smooth muscle cells (vSMC) and pericytes have a complex ontogeny that has 
not yet been fully resolved.  Most evidence suggests multiple origins for vSMC and 
pericytes, including transdifferentiation from mesenchymal progenitors (Hirschi et al., 
1998, Hellstrom et al., 1999), and derivation from neural crest cells (Etchevers et al., 
2001).  It is also unclear whether vSMC and pericytes derive from the same, or different 
origins.  However, work in quail-chick chimeras demonstrated that cranial neural crest 
cells could derive into αSMA-expressing pericytes in capillaries and vSMC in arteries, 
and furthermore that much of the vasculature of the face and jaw contained cells that 
had derived from quail cranial neural crest (Etchevers et al., 2001).  Together with the 
phenotypic plasticity of SMC and pericytes, this suggests that they share a common 
origin (Armulik et al., 2005).  However, SMC in different vascular beds have been 
demonstrated to derive from distinct origins.  Apart from neural crest and mesenchymal 
cells previously mentioned, somites, the proepicardium and the secondary heart field 
have all been implicated as sources of SMC progenitors and incredibly, the aorta has 
been shown to have SMC from different origins along its length, for example the neural 
crest, somites and mesoepithelium (Majesky, 2007).  SMC progenitors, termed 
‘mesoangioblsts’ capable of differentiating into skeletal or smooth muscle cells or 
fibroblasts, also reside in the arterial wall and are postulated to be able to differentiate 
into SMC during vessel remodelling or repair (Majesky, 2007, Majesky et al., 2011).  
However, despite the large volume of research involved in characterising vascular SMC 
ontogeny, the molecular regulation of SMC differentiation has not yet been fully 
elucidated and what it is that controls the fate determination of such an ontologically 
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diverse range of progenitors to finally express the same proteins and function in a 
similar manner are unclear (Majesky et al., 2011).  
 
1.4.3 Vascular SMC / Pericyte recruitment to the endothelium 
 
1.4.3.1 PDGFB/PDGFRβ 
 
Paracrine signalling between PDGF-B, expressed in angiogenic sprouts and PDGFR-β 
in developing pericytes is crucial for proper pericyte recruitment to newly formed blood 
vessels.  Mice deficient for PDGF-B die embryonically, due to haemorrhage and 
oedema caused by lack of pericytes (Lindahl et al., 1997).  The same phenotype is seen 
in mice lacking PDGFR-β, which also show decreased vSMC coverage of the large 
arteries, although this is more severe in superficial than deeper vessels (Hellstrom et al., 
1999).  Pdgfbret/ret mice have a mutation in the C terminal retention motif that allows 
PDGF-B binding to proteoglycans in the extracellular matrix, which results in impaired 
pericyte recruitment in many vascularised tissues (Abramsson et al., 2003).  Tumours 
transplanted into these mice have reduced pericyte coverage and weaker pericyte 
adhesion to the vessel wall than those in wild-type mice.  Applying exogenous PDGF-B 
by injecting tumour cells that over-express it, rescued the density of pericytes recruited 
to the vessel, but not their attachment, demonstrating that PDGF-B must be retained 
close to the endothelial surface for proper integration of pericytes into the vessel wall 
(Abramsson et al., 2003).   Numerous other studies have confirmed the importance of 
PDGF-B/PDGFR-β signalling for pericyte migration and proliferation both in vitro and 
in vivo, by demonstrating enhanced SMC migration and proliferation after PDGF-BB 
stimulation, or by preventing pericyte recruitment by blocking PDGF-B/PDGFR-β 
signalling (Benjamin et al., 1998, Stratman et al., 2010, Fuxe et al., 2011). 
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1.4.3.2 Ang1/Tie2 
 
Mice lacking either Tie2 or Ang1 show very similar embryonic lethal phenotypes, 
including failure of vascular remodelling and pericyte recruitment, suggesting a role for 
this signalling pathway in this process.  This hypothesis is consistent with the generally 
held view that Tie2 is expressed in the endothelium, while Ang1 is expressed initially in 
mesenchymal tissues surrounding the vessels, and is later restricted to SMC/pericytes 
(Sato et al., 1995, Suri et al., 1996, Augustin et al., 2009).  However, recent data is 
contradicting these conclusions and is likely to reopen the debate over the function of 
Angiopoietin/Tie signalling in the vasculature.  A study of cultured retinal pericytes 
identified Tie2 expression in these cells and showed that Ang1 acts directly on pericytes 
to promote survival and migration (Cai et al., 2008), while recently published work 
using a conditional Ang1 knock-out mouse showed that either global or cardiac specific 
Ang1 deletion gives the same phenotype as previously reported, except that pericyte 
recruitment is completely unaffected.  Pericyte coverage continues to be normal at any 
stage of Ang1 deletion despite severe vascular defects that occur when deletion occurs 
prior to E13.5, arguing against any role for Ang1 in pericyte recruitment (Jeansson et 
al., 2011).  It is possible that the vascular deficiencies observed in the original Ang1-/- 
are secondary to cardiac failure and therefore pericyte loss could result from endothelial 
cell death (Gaengel et al., 2009).  However, this is not consistent with normal pericyte 
recruitment even when Ang1 is deleted very early in the conditional mutant, leaving the 
reason for the discrepancies between these results unclear. 
To add to the confusion over Ang1 involvement in pericyte recruitment, in human 
venous malformation a mutation causes constitutive activation of Tie2, and smooth 
muscle cell coverage is uneven or absent on certain veins (reviewed in (Gaengel et al., 
2009)).  Likewise, over-expression of Ang1 is known to cause a reduction in the 
number of pericytes, while also reducing vessel leakage in inflammatory conditions 
(Fuxe et al., 2011).  This may be consistent with the findings of Jeansson et al, who 
reported no phenotype in normal, quiescent vasculature of Ang1 deficient mice, if 
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deletion occurred after E13.5, but enhanced angiogenesis and fibrosis during wound 
healing in Ang1 deficient mice (Jeansson et al., 2011).   
Overall, it seems that Ang1 is necessary for proper cardiac and vascular development, 
but its role in pericyte recruitment remains unclear.  In the adult vasculature, it is 
possible that Ang1/Tie2 signalling is not functional, except in pathological conditions 
such as wound healing or inflammation, where it may constrain angiogenesis and 
promote vessel stability.  The complex functions of Ang1 in the vasculature may rely on 
a fine balance between Ang1-mediated Tie2 activation, and Ang2-mediated antagonism. 
 
1.4.4 vSMC / Pericyte function 
 
The contractile behaviour of vSMC and pericytes has been widely documented (eg 
(Bastin and Heximer, 2011, Rucker et al., 2000)), and allows performance of one of the 
major functions of vascular smooth muscle; regulating vessel tone and blood flow by 
calcium dependant tonic contractions.  Briefly, Myosin Light Chain Kinase (MLCK) is 
activated upon Ca2+ binding to calmodulin.  MLCK then phosphorylates Regulatory 
Myosin Light Chain (RMLC), which leads to activation of Myosin ATPase and 
interaction between Myosin and Actin that then initiates smooth muscle contractions 
(Bastin and Heximer, 2011, Muthuchamy and Zawieja, 2008).  When Ca2+ is reduced, 
inactivation of MLCK leads to Myosin Light Chain Phosphatase (MLCP) mediated 
dephosphorylation of RMLC that then deactivates ATPase and the smooth muscle 
relaxes (Muthuchamy and Zawieja, 2008).  However, this is only one function of 
vSMC/Pericytes.  In large blood vessels, the thick coating of vSMC also provides 
structural support (Gerhardt and Betsholtz, 2003), and a further essential role for 
pericytes in maintaining vessel stability by either limiting endothelial cell proliferation 
or depositing extracellular matrix (or both) is discussed in more detail below.  
Deletion of Pdgfb or Pdgfrβ resulted in a 25% increase in capillary diameter, although 
this was highly variable and irregular along the vessel length, in contrast to the wild-
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type state (Hellstrom et al., 2001).  This corresponded to a 60% increase in the number 
of EC nuclei, despite a shortening of junction length (ie vessels were dilated, but the 
endothelial cells were densely packed), and a lack of pericytes from E11.5 onwards, 
indicating that pericytes regulate vessel stability, at least in part, by limiting endothelial 
cell proliferation.  There was also a reduction in the junction proteins VE-cadherin and 
Occludin at E18.5 in Pdgfb-/- and Pdgfrβ-/- mice, suggesting that pericytes may also 
regulate junctional, and therefore vessel, stability (Hellstrom et al., 2001).  However, 
since VE-cadherin and Occludin levels are normal at E12.5, despite there already being 
a lack of pericytes at this stage, this defect may be secondary to the earlier endothelial 
abnormalities.  Recently, it has been shown that reducing pericyte recruitment to 
endothelial tubes by blocking PDGF-B/PDGFR-β or HB-EGF/EGFR signalling by 
soluble receptor trap, ligand blocking antibodies, or siRNA knockdown of the receptors 
in SMC, results in increased endothelial tube diameter, although in this case not due to 
increased proliferation, and a decrease in basement membrane deposition (Stratman et 
al., 2010).  This suggests that, as previously hypothesised, pericyte regulation of 
vascular stability is also in part due to basement membrane deposition (von Tell et al., 
2006). However, it is surprising that given the apparent importance of pericytes for 
vascular stability, pericyte loss of up to 90% can be tolerated (Enge et al., 2002). 
Pericyte regulation of vascular stability is also important in pathological conditions. 
Pdgfbret/ret mice survive to adulthood despite impaired pericyte recruitment and 
attachment to the vessels.  However, the vasculature of tumours grown in Pdgfbret/ret 
mice is unstable, with a greater vessel diameter (Abramsson et al., 2003).  A recent 
study demonstrated that pericyte ablation decreased vessel stability and increased vessel 
remodelling in conditions of sustained inflammation, but not in uninfected controls.  
This perhaps suggests that pericytes are required to regulate vessel stability in actively 
remodelling vessels, such as occurs in development or chronic inflammation, but not in 
the quiescent, adult vasculature (Fuxe et al., 2011).  However, the potential for 
increased vessel deterioration following PDGF-B blockade beyond the 7 day duration 
of the study cannot be ruled out, as vessel stability at later timepoints was not examined.  
Some research suggests that pericytes can maintain vessel integrity even in conditions 
such as hyperoxia, which is detrimental to the vasculature and leads to vessel regression 
in immature vessels that are not yet fully protected by pericyte coverage (Benjamin et 
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al., 1998).  This is supported by work in 3D collagen matrices, which showed that 
addition of 20-30% pericytes relative to endothelial cells into the culture completely 
inhibited Matrix Metalloproteinase-1 (MMP)-1 and MMP-10 mediated vessel 
regression by delivering Tissue Inhibitor of Metalloproteinase -3 (TIMP)-3, whose 
expression by pericytes is strongly up-regulated upon EC-Pericyte co-culture (Saunders 
et al., 2006).  However, other work suggests that the presence of pericytes is not enough 
on its own to protect vessels from regression.  Treatment of tumours with VEGF-
targeting angiogenesis inhibitors lead to a decrease in pericyte marker expression and 
basement membrane immunoreactivity in tumour vessels.  Despite this reduction being 
only half as extensive as the reduction in endothelial cell marker expression, it 
demonstrated that vessel regression occurred even in vessels associated with pericytes 
(Inai et al., 2004), so the suggestion that pericytes act as a protective mechanism and 
marker of vessel maturity remains controversial.  However, the discrepancy between 
these two results may be resolved by consideration of pericyte organisation around the 
vessels investigated.  While pericyte association with the endothelium in the mature 
vasculature is close, with the SMC wrapping around the endothelial cells of larger 
vessels and tightly associated with the endothelium even in small-calibre blood vessels, 
pericyte investiture of tumour vessels is much looser, perhaps rendering pericytes a less 
effective protection against regression in this situation (Inai et al., 2004, von Tell et al., 
2006). 
 
1.4.5 Lymphatic smooth muscle 
 
Despite major advances in understanding of vascular smooth muscle, our knowledge of 
lymphatic smooth muscle is limited, for example it is not known whether lymphatic 
smooth muscle derives from the same lineage as vascular smooth muscle.  While one 
study has suggested that lymphatic smooth muscle is of mesenchymal origin (Ohtani 
and Ohtani, 2001), nothing else is known of its ontogeny and differences in protein 
expression profiles and contractile functions of lymphatic and blood vascular smooth 
muscle may cast doubt on the shared lineage hypothesis.  On the other hand, blood 
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vessels display specialised functions in different organs that are subjected to different 
metabolic demands (Gerhardt and Betsholtz, 2003), and it is possible that 
vSMC/pericyte function varies accordingly, which may be consistent with the 
‘continuum’ of perictye phenotypes observed in the blood vasculature.  Therefore, the 
same may be true of lymphatic smooth muscle, and functional specialisation may occur 
in situ.  Consistent with this is the observation that, like blood vascular smooth muscle, 
there are differences in the SMC density around lymphatic vessels in different tissues, 
which have different contractile properties.  This is reflected in a change of contractile 
protein expression, for example between smooth muscle cells from mesenteric 
lymphatics and the thoracic duct (Muthuchamy et al., 2003). 
The poor survival of mice mutant in the pathways responsible for vascular SMC/ 
pericyte recruitment to blood vessels means that these mice often die before any 
potential role in lymphatic smooth muscle recruitment can be determined.  However, as 
discussed previously, we know that Ang2 acts as a Tie2 agonist in the lymphatic 
system, contrary to the case in the blood vasculature and Ang2-/- mice display lymphatic 
defects suggestive of a role in SMC organisation (Gale et al., 2002) (Dellinger et al., 
2008).  We can also infer by over-expression of PDGF-B in the mesenchyme and 
resulting SMC dissociation from the lymphatic vessels (Tammela et al., 2007), and up-
regulation of PDGF-B expression in capillaries of Foxc2-/- mice that recruit ectopic 
SMC (Petrova et al., 2004) that lymphatic endothelial/smooth muscle cells are 
responsive to PDGF-B/PDGFR-β signalling.  However, a lack of mouse mutants with 
specific defects in lymphatic smooth muscle means that in general we have less 
opportunity to study this process in lymphatic than blood vascular development. 
The major difference between blood vascular and lymphatic smooth muscle is in their 
contractile functions.  As is reflected by their contractile protein expression profiles 
(Muthuchamy et al., 2003), lymphatic smooth muscle is capable of both slow, tonic 
contractions to control flow resistance, such as is seen in blood vessels, and also brisk, 
phasic contractions more reminiscent of cardiac muscle (von der Weid and Zawieja, 
2004, Muthuchamy and Zawieja, 2008, Zawieja, 2009). 
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In steady state conditions, prevailing pressure gradients usually act against the passive 
flow of lymph through the system; therefore energy must be provided to allow the 
central transport of lymph against a hydrostatic pressure gradient.  Energy comes from 
either intrinsic, or extrinsic lymph pumps.  Extrinsic pumps combine all the forces 
outside the lymphatics, for example respiration, skeletal muscle contraction and 
heartbeat that can compress the lymphatics and move fluid centrally (Muthuchamy and 
Zawieja, 2008).  This mechanism is thought to be particularly important in heart, 
skeletal muscle, thorax and gut wall lymphatics, which are exposed to strong external 
forces, while most other lymphatic networks rely on the intrinsic pump (Zawieja, 2009).  
This is supported by experimental evidence demonstrating a difference between the 
intrinsic pumping capability of lymphatic vessels from different tissues, for example a 
comparison of the lymphatic pump in mesenteric, cervical, femoral and thoracic duct 
lymphatics revealed that mesenteric lymphatics had the most and the thoracic duct the 
least effective intrinsic pumps (Gashev et al., 2004).  This is almost certainly due to 
anatomical location and the greater exposure of the thoracic duct to extrinsic pumping 
forces generated by respiration and heartbeat and therefore reduced requirement for 
intrinsic pumping activity. 
In the absence of the heart, which pumps blood through the vascular system, or ‘lymph 
hearts’ that pump lymph in lower vertebrates, each lymphangion in the mammalian 
lymphatics must be capable of acting as an intrinsic pump.  This relies on strong, co-
ordinated phasic contractions of lymphatic smooth muscle, which result in rapid 
decrease of lymphatic diameter, increase in local lymph pressure, closure of the 
upstream valve, opening of the downstream valve and ejection of lymph downstream 
(Muthuchamy and Zawieja, 2008, Zawieja, 2009) (Figure 1.5).  Phasic lymphatic 
contractions are initiated by action potentials generated by pacemaker cells in the 
muscle wall.  These cells are capable of generating a rhythm even when the vessels are 
empty, and while their exact nature is yet to be defined, they have been identified by 
their electron dense nature and expression of c-Kit and vimentin, which are widely used 
as markers of pacemaker cells in the gastrointestinal tract, just underneath the muscle 
layer in the sheep lymphatic vessel wall (McCloskey et al., 2002).  Earlier studies in 
guinea pig mesenteric lymphatics suggested that the mechanism of pacemaking activity 
might be related to calcium-dependant spontaneous transient depolarisations (STDs).  
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These transient depolarisations precede and underlie action potentials, and are 
correlated with the pumping activity of the lymphangion; increasing lymphatic pumping 
increases STD activity and vice versa, supporting the hypothesis that STDs of sufficient 
amplitude may give rise to action potentials and therefore muscle contractions (Van 
Helden, 1993, von der Weid and Zawieja, 2004).  
 
 
Figure 1.5 The lymphatic pump.   
Collecting lymphatic vessels are organised into lymphangions, separated by luminal 
valves.  Direction of flow is indicated with an arrow.  Pressure from SMC contractions 
or extrinsic forces, causes the lymphangion to contract, rapidly narrowing its diameter 
and opening the downstream luminal valve.  Lymph then fills the downstream 
lymphangion, whose contraction propels the lymph further through the vessel.  Closure 
of the upstream luminal valve prevents backflow of lymph. 
 
Physical factors such as transmural pressure (stretch) and flow (shear) exert strong 
effects on the lymphatic pump.  Initial increases in transmural pressure led to increased 
pump activity, but further pressure increases then caused a decrease in lymphatic 
pumping (Gashev et al., 2004).  As expected, optimal pump function occurred at 
different pressures for lymphatics from different tissues; the mesenteric lymphatic pump 
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functioned optimally at a higher transmural pressure than thoracic duct, cervical or 
femoral lymphatics, indicating that these lymphatic vessels are better able to withstand 
high pressure and pressure changes, since significant pumping activity could still be 
maintained at high transmural pressures (Gashev et al., 2004).  
Increasing flow, while transmural pressure remained constant, caused an immediate 
decrease in lymphatic pump activity in all tissues.  This was measured by increased 
systolic lymphatic diameter, a corresponding decrease in the amplitude of contractions, 
reduced contraction frequency, ejection fraction (the proportion of lymph released from 
the lymphangion during each contraction) and fractional pump flow (a measure of 
overall pump activity taking into account all the above parameters) (Gashev et al., 2004, 
Gashev et al., 2002).  Sophisticated high speed video microscopy and mathematical 
techniques to measure fluid velocity (by lymphocyte tracking), volume flow rate, wall 
shear stress, and retrograde flow developed later, confirmed the physiological relevance 
of the transmural pressure and flow rates imposed during these studies (Dixon et al., 
2006).  Therefore, decreased phasic smooth muscle contractions when flow increased 
was not simply an artifact caused by imposing physiologically abnormal pressure 
gradients on the vessel.   
This phenomenon can be explained by the unique requirement of the lymphatic vessels 
to function as both pump and conduit.  Usually, inlet pressure is lower than outlet 
pressure and lymph movement requires active pumping.  However, in cases when the 
pressure is reversed and inlet pressure exceeds outlet pressure, the lymphatic vessel 
must switch from pump to conduit.  In this case, the pressure gradient itself becomes the 
main source of energy to drive lymph, which then flows in a passive manner through 
the vessel and flow can even be reduced, or inhibited, by muscle contraction (Quick et 
al., 2009).  This pressure reversal can occur in a number of situations.  Particularly in 
humans, elevating limbs above the level of the great veins can cause a reversal of the 
pressure gradient, as can oedema if it causes a rise in interstitial pressure, for example 
when due to venous hypertension.  Finally, external compression of an upstream 
lymphangion may cause a transient increase in inlet pressure that could lead to a switch 
from pump to conduit behaviour (Quick et al., 2009, Quick et al., 2007).  
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There is evidence that flow induced inhibition of lymphatic pumping may be regulated 
by nitric oxide (NO), as this effect could be recapitulated by addition of NO in the 
absence of flow, and abolished even in the presence of flow by NO synthase inhibition 
(Gashev et al., 2002).  This perhaps gives some insight into a mechanism by which the 
lymphatic vessel may switch from pump to conduit:  when flow imposes a positive 
pressure gradient, the lymphatic endothelium is stimulated to release NO, which acts on 
the lymphatic smooth muscle to reduce contractions and allow the passive flow of 
lymph.   
 
1.5 The extracellular matrix and vascular basement membrane 
 
The extracellular matrix (ECM) is a complex meshwork of proteins and sugars, which 
surrounds and supports cells, tissues, and organs providing a protective and structural 
scaffold.  Different organs and tissues express distinct ECM components, which partly 
helps them to perform their individual functions (Cox and Erler, 2011).  One such 
specialised extracellular matrix is the basement membrane.  This was originally 
identified by electron microscopy as an acellular, sheet-like structure, about 50-100 nm 
thick, which is always associated with cells (Sasaki et al., 2004, Kalluri, 2003).  
Similarly to the case with SMC and pericytes, far more is known about the composition, 
structure and function of blood vascular than lymphatic basement membranes. 
 
1.5.1 Vascular basement membrane function 
 
Vascular basement membranes consist predominantly of Collagen IV, Fibronectin, 
Nidogen/Entactin, Laminin and heparan sulfate proteoglycans (HSPGs) and the 
importance and distinct functions of individual matrix components can be assessed by 
studies of mouse knock-out models (reviewed in (Aszodi et al., 2006)).   
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For example, loss of Laminin β1 or γ1 leads to early embryonic lethality and the failure 
to assemble any basement membrane, while Lama1-/- mice survive slightly longer, due 
to partial compensation from Laminin-α5, which is expressed in many of the same 
tissues.  However, this rescue is incomplete, and Laminin-α1 deficient mice still die by 
E7.5 (Miner et al., 2004).  Collagen IV and Perlecan deficient mice assemble basement 
membranes, but these are weaker and prone to rupture in areas of mechanical stress, 
indicating that Collagen IV and Perlecan are necessary to maintain basement membrane 
integrity (Poschl et al., 2004, Costell et al., 1999).  The phenotype of Col4a1/2-/- mice is 
the more severe of the two and while the blood vasculature develops and recruits 
pericytes in the absence of Collagen IV, there are spatial irregularities and the 
capillaries are dilated, suggesting that Collagen IV is required for the proper 
organisation of local capillary networks and demonstrating the importance of an intact 
basement membrane for vascular stability (Poschl et al., 2004).  This is confirmed by 
studies of other vascular basement membrane components.  Embryonic lethality of 
Laminin-α5 deficient mice is probably attributable in part to defects in placental 
vascularisation. Although there is BM associated with the endothelium of these 
embryos, it is discontinuous and of variable width. The vessels themselves display 
increased diameters and reduced branching compared to controls, thus reducing the 
surface area available for gas and nutrient exchange and indicating that Laminin-α5 has 
an essential role in development of the placental vasculature (Miner et al., 1998).  
Laminin α4 is another laminin isoform widely distributed in vascular basement 
membranes and Lama4 deletion leads to disorganisation and collapse of microvessels, 
both embryonically and in the adult, due to deficient formation and stability of capillary 
basement membranes (Thyboll et al., 2002).  Contrary to the case of laminin isoforms, 
where blood vessels can still form in their absence, although their stability may be 
compromised (Davis and Senger, 2008), deletion of Fibronectin results in loss, or 
severe deformity of the dorsal aorta and the embryonic vasculature is severely deficient 
(George et al., 1993). 
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1.5.2 Regulation of cell behaviour by the vascular basement membrane 
 
It is well established that the vascular basement membrane is vitally important for 
providing structural support and stability to the vessels.  However, it is also involved in 
regulating cell behaviour, such as migration, differentiation, survival and proliferation 
and can mediate efficient communication between endothelial cells, without the need 
for direct cell-cell contact (reviewed in (Davis and Senger, 2005, Aszodi et al., 
2006)(Kruegel and Miosge, 2010).  
One important way in which the vascular basement membrane regulates cellular 
behaviour is by binding to and influencing growth factor signalling.  VEGF is a 
powerful pro-angiogenic growth factor that promotes endothelial cell migration and 
proliferation.  It is alternatively spliced to give rise to 4 different isoforms, which bind 
variously to Heparan Sulfate Proteoglycans (HSPGs) in the ECM.  The longest forms of 
VEGF, VEGF206 and VEGF189 are almost entirely matrix-bound, while the shortest 
form, VEGF121 is always soluble.  VEGF165 behaves in an intermediate manner: 50-70% 
VEGF165 can be released from the matrix upon heparin treatment (Houck et al., 1992).  
Matrix-bound VEGF can be released by proteolytic processing by either the serine 
protease Plasmin, or by MMPs 3, 7, 9 and 19 (Houck et al., 1992, Lee et al., 2005).  
Both bound and soluble VEGF are capable of activating VEGFR2, but they elicit 
different signalling responses (Lee et al., 2005).  It is possible that in the quiescent 
vasculature, cross-linking of the ECM, or HSPG conformation, may mean that matrix-
bound VEGF is not freely available for receptor binding, and VEGF is therefore 
sequestered by the matrix and can be released upon pro-angiogenic stimulus (Kalluri, 
2003).  Or, alternative splicing of VEGF may enable efficient formation of growth 
factor gradients, since the shorter forms would diffuse further, and activate endothelial 
cells via VEGF receptor binding at a distance to the angiogenic site, thus providing 
spatially regulated angiogenic cues to direct vascular morphogenesis (Ruhrberg et al., 
2002).  However, because the longer forms of VEGF are more mitogenic than the short 
forms, the angiogenic signal would be weaker at this distal site than closer to the 
matrix-bound VEGF (Ferrara, 2010).  VEGF can also bind the heparan II binding 
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domain of Fibronectin and activate endothelial cell proliferation, migration and Erk 
activation, but only when the VEGF-binding and cell-binding sites are in the same 
molecule, suggesting that both VEGFR2 and Integrin-α5β1, a Fibronectin cell-surface 
receptor, must be side by side to potentiate this response (Wijelath et al., 2006).  
Another example of ECM positively regulating growth factor signalling is PDGF-B 
binding to Heparan Sulfate.  The Heparan Sulfate binding domain on PDGF-BB is 
required for pericyte recruitment and PDGF-BB retention at the cell surface 
(Abramsson et al., 2003).  Similarly, reduced Heparan Sulfate N-sulfation in Ndst1-/- 
mice, which lack a N-deacetylase/N-sulfotransferase enzyme, resulted in reduced 
PDGF-BB binding in vitro and delayed pericyte migration towards and retention on the 
endothelium in vivo, thereby demonstrating a requirement for Heparan Sulfate binding 
for efficient PDGF-BB signalling (Abramsson et al., 2007).  On the other hand, HSPG 
sequestration of HB-EGF prevents proteolytic processing of the transmembrane form of 
the protein and release of the soluble form of HB-EGF, which induces cell proliferation 
and migration responses.  Instead, sequestration promotes juxtacrine HB-EGF signaling, 
which leads to growth inhibition (Prince et al., 2010).  
 
1.5.3 Contribution of EC and SMC to the vascular basement membrane 
 
The vascular basement membrane is produced by, and shared between endothelial and 
smooth muscle cells / pericytes.  Co-culturing endothelial cells with smooth muscle 
cells increases the amount of basement membrane proteins produced by both cell types, 
compared to that produced in single cell-type cultures, and the onset of basement 
membrane deposition in the quail embryo coincides with SMC recruitment to the blood 
vessels (Stratman et al., 2009a).  Although most work has concentrated on the function 
of basement membrane proteins in regulating endothelial cell behaviour, the basement 
membrane is also important for regulating smooth muscle cell behaviour and function.  
ECM derived from either SMC, macrophages or EC can induce SMC proliferation, but 
interestingly only ECM derived from SMC or macrophages can enhance SMC 
production of proteoglycans (Figueroa et al., 2004).  The in vivo effect of basement 
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membrane components on SMC behaviour and function has been investigated recently. 
For example, when Heparan-sulfate (HS) is deleted specifically from mural cells (MC) 
in vivo, it results in reduced pericyte recruitment and an increase in both sprouting and 
regression of nascent blood vessels.  Interestingly, the requirement for HS in mural cells 
seems to be spatially dependant; MC that are already in contact with the endothelium 
can still attach to the vessel; ie the deficiency can be rescued by deposition of 
endothelial-derived HS in the BM, whereas MC further from the endothelium require 
HS cell-autonomously in order to polarise and migrate to the nascent blood vessels 
(Stenzel et al., 2009).  Also, when a dominant negative missense mutation is inserted 
into the Col4a1 chain, which results in a highly conserved lysine residue being replaced 
by a glutamic acid, it leads to age dependent defects in both endothelial and smooth 
muscle cell function.  These defects include reduced contractile strength, impaired 
response to Nor-epinephrine in mice over 6 months old, and increased sensitivity to NO 
at 11 months old.  From this age endothelial cells also showed increase vasodilation 
responses to acetylcholine, suggesting an overall upregulation of the NO-cAMP 
pathway in Col4a1+/raw mice, which results in maintenance of the low blood pressure 
that is caused by a reduced red blood cell count in these mice (Van Agtmael et al., 
2010).  
 
1.5.4 Lymphatic basement membrane 
 
In contrast to the blood vasculature, very little is known about the composition of the 
lymphatic basement membrane and knowledge about the function of individual 
basement membrane components is fragmentary at best.  Although for a long time it 
was believed that lymphatic vessels were devoid of basement membranes, recent studies 
have identified an irregular basement membrane around lymphatic capillaries (Pflicke 
and Sixt, 2009, Vainionpaa et al., 2007).  However, although Pflicke and colleagues 
noted that the basement membranes around collecting vessels did not contain the same 
discontinuities that were observed in the capillaries, there has been little investigation of 
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the difference between basement membranes in collecting vessels vs. capillaries and 
how this might influence their individual vessel function.   
However, interactions of the lymphatic vessels with their extracellular environment are 
starting to be recognised as a potentially important modulator of lymphatic function (Ji, 
2006, Avraamides et al., 2008, Wiig et al., 2010, Paupert et al., 2011). 
One ECM protein known to be important for lymphatic function is Emilin-1, a major 
component of the anchoring filaments attaching lymphatic capillaries to the interstitial 
matrix.  Emilin-1 deficiency leads to a defect in lymph formation and the lymphatic 
capillaries become hyperplastic, vessel density increases and they fail to respond to 
changes in interstitial pressure (Danussi et al., 2008).  
Another well-characterised role for the ECM in lymphatic function is that of Integrin-
α9 and its ECM ligand, Fibronectin (FN) EIIIA.  Itga9 deficient mice develop 
chylothorax and die within 6-12 days of birth (Huang et al., 2000), and it was 
subsequently shown that Integrin-α9 could be up-regulated by Prox-1 (Mishima et al., 
2007), suggesting a role in lymphatic development.  Within the lymphatic vessels, 
Integrin-α9 is highly expressed in lymphatic valves and loss of Itga9 (in either a full 
mutant or endothelial-cell specific knock-out) leads to a failure to form functional valve 
leaflets (Bazigou et al., 2009).  Instead, ring-like constrictions develop, which do not 
have an organised matrix core between the valve leaflets and are incapable of 
preventing lymph backflow.  In vitro, Integrin-α9 binds to Fibronectin containing the 
EIIIA domain (FNEIIIA), Tenascin-C (TNC) and Osteopontin, but  failure to form 
normal valves in FNEIIIA mutants and disorganisation of the FNEIIIA matrix core in 
Itg-α9-/- mice identified FNEIIIA as the physiologically relevant Integrin-α9 ligand in 
lymphatic valve morphogenesis, and identified a functional role for this extracellular 
matrix component in lymphatic development (Bazigou et al., 2009).  More recent work 
has also implicated tumour-derived FNEIIIA in enhancing LEC tubulogenesis and 
branching in vitro, suggesting another potential role for this ECM protein in tumour 
induced lymphangiogenesis (Ou et al., 2010). 
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Other integrins have also been implicated in lymphangiogenesis, although their role is 
less well characterised. For example, Integrin-α5 small molecule inhibitors reduced 
lymphangiogenesis in vivo in a model of inflammatory corneal lymphangiogenesis.  
Interestingly, BECs were less sensitive to Integrin-α5 inhibition and at small inhibitor 
doses lymphangiogenesis could be selectively inhibited, without affecting angiogenesis 
(Dietrich et al., 2007).  Integrin-α4β1, another FN receptor, has also been implicated in 
both growth factor and tumour induced lymphangiogenesis.  It is expressed only on 
proliferative LECs and lymphatic vessels, and promoted LEC adhesion and migration 
on cellular FN in vitro.  In vivo, VEGF-C induced lymphangiogenesis was inhibited by 
Integrin-α4β1 antagonists or in mice lacking Integrin-α4 in endothelial cells (Garmy-
Susini et al., 2010). 
The role of other ECM proteins such as collagen and laminin in lymphatic development 
is even less well defined.  Clavin et al. (2008) showed that lymphatic regeneration after 
skin wounding was enhanced when a Collagen I gel was used to cover the wound.  This 
lead to down-regulation of TGFβ1, and a corresponding increase in infiltration and 
proliferation of LECs, alongside decreased inflammation and lymphoedema compared 
to mice lacking the Collagen I gel, which still expressed high levels of TGFβ1 in the 
ECM.  Over-expression of TGFβ1 in Collagen treated mice negated all the beneficial 
effects, demonstrating that Collagen I acted via regulation of TGFβ1 expression to 
enhance wound healing and lymphatic regeneration (Clavin et al., 2008).  Anti-
lymphangiogenic properties have also been suggested for Collagen XVIII and its 
proteolytic cleavage product, Neostatin-7, as is already known in the blood vasculature 
(Kojima et al., 2008). 
Evidence of a lymphatic function for laminin is sparse, and slightly spurious.  LEC 
medium was demonstrated to be chemotactic for melanoma cells, and this could be 
blocked with an anti-laminin 1 antibody.  Immunoprecipitating the LEC conditioned 
medium revealed the presence of laminin α4, β2 and γ1 chains, suggesting that this 
laminin isoform is secreted by the lymphatic endothelium and facilitates melanoma 
metastasis to the lymphatics (Saito et al., 2009). 
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Finally, the role of matrix mellatoproteinases (MMPs) in lymphangiogenesis is yet to be 
clearly defined.  In the blood vasculature, as well as processing individual BM proteins 
to release soluble or active fragments, degradation of the ECM by MMPs is an 
important first step in the induction of angiogenesis, allowing the EC greater mobility to 
sprout from the existing vessel (reviewed in (Arroyo and Iruela-Arispe, 2010)).  For 
example, Mmp1-/- mice displayed no angiogenic response to FGF stimulation in a 
corneal angiogenesis model, compared to the efficient sprouting induced in wild type 
mice (Zhou et al., 2000).  In addition, MT1-MMP is required for the formation of 
vascular guidance tunnels during EC lumenogenesis and tube formation in 3D collagen 
matrices.  Once these tunnels have formed, they allow free movement of EC within 
them, without the need for further proteolysis (Stratman et al., 2009b).  MMP inhibitors, 
such as Tissue Inhibitor of Metalloproteinase -2 (TIMP)-2 and TIMP3 can block EC 
migration and invasion into a 3D collagen, and TIMP3 treatment also prevents 
vasculogenesis and angiogenesis in the mouse embryo, further highlighting the 
importance of MMPs for angiogenesis (Saunders et al., 2006).   
Within the lymphatic vasculature, MMP-9 was strongly up-regulated in the vicinity of 
lymphatic regeneration in a skin wound model, although its expression levels declined 
before the onset of lymphangiogenesis.  Additionally, lymphatic regeneration was 
indistinguishable between wild-type and Mmp9-/- mice, suggesting that this protease is 
probably not involved in lymphangiogenesis (Rutkowski et al., 2006).  However, MMP-
2 was also up-regulated in the area of lymphatic regeneration, and its expression peaked 
at the onset of lymphangiogenesis.  The potential role for MMP-2 in lymphangiogenesis 
suggested by this study was further supported by 3D lymphatic ring cultures, where 
TIMP-2 and an inhibitor of MMP-2, MMP-9 and MMP-14 strongly inhibited lymphatic 
sprouting and network formation.  In addition to this, lymphangiomas grew less 
efficiently in Mmp2-/- than wild-type mice, suggesting that MMP-2 might be 
functionally important for lymphangiogenesis (Bruyere et al., 2008). 
Although the importance of ECM proteins in lymphatic development and function is 
starting to be recognised, there is still much more work to do to fully understand the 
composition and function of the lymphatic basement membrane, how this may differ 
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between lymphatic capillaries and collecting vessels and how the basement membrane 
can affect lymphatic vessel development and function.   
 
1.6 Reelin 
 
Reelin is an extracellular matrix protein that was found to be upregulated in cultured 
LEC compared to BEC in microarray analyses (Petrova et al., 2002), however its 
potential function in lymphatic vasculature is not known.  The full-length protein is 
3461 amino acids (aa) long, with an N-terminus consisting of 500aa that shares 25% 
homology with the N-terminus of F-spondin.  This is followed by eight 350-390aa 
repeats, each composed of two subdomains flanking a 30aa EGF motif.  After the eighth 
repeat, there is a stretch of basic amino acids, comprising the C-terminus (D'Arcangelo 
et al., 1995, Tissir and Goffinet, 2003)(Figure 1.6).  Two Reelin processing sites have 
been identified, one within the N-terminus, between repeats 2 and 3, and one at the C-
terminus, between repeats 6 and 7 (Jossin et al., 2004), which give rise to five smaller 
Reelin fragments (Figure 1.6).  A growing body of research has demonstrated that these 
proteolytic processing events are important for Reelin function (Jossin et al., 2007, 
Tinnes et al., 2011). 
 
Figure 1.6 Schematic of Reelin structure and cleavage products 
Adapted from Jossin et al., 2007. 
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The function and mechanism of Reelin signalling has been best characterised in the 
central nervous system, where it is involved in the development of laminar structures in 
the neocortex, hippocampus, cerebellum and spinal cord (Frotscher, 2010).  In fact, a 
recent report identifying Reelin involvement in mammary gland morphogenesis 
(Khialeeva et al., 2011), and data from the lymphatic system described herein are the 
only reports of Reelin function outside the nervous system to date.  The failure of 
correct cortical lamination is the primary, and most studied, defect in Reln deficient 
mice.  During normal development, the cortex forms by a closely regulated program of 
sequential neurogenesis.  Progenitor cells are located in the ventricular zone (VZ) and a 
thin primordium layer forms the pre-plate, just above it.  After exiting the cell-cycle, the 
first waves of post-mitotic neurons migrate from the VZ into the middle of the pre-
plate, thus splitting it into three layers; the marginal zone (MZ) on the surface, which 
remains cell-sparse throughout development and into adulthood, the cortical plate (CP), 
in which the newly migrated neurons reside, and the sub-plate (SP) underneath.  Each 
successive wave of newborn neurons migrates along radial glial fibres, through the sub-
plate and into the cortical plate, passing earlier-born neurons to reach their final 
position.  Thus, early-born neurons are pushed into deeper layers by the migrating late-
born neurons, which end up in the more superficial cortical layers – an ‘inside out’ 
pattern of cortical lamination (Dhavan and Tsai, 2001, Rice and Curran, 2001).  There 
are six neuronal layers in the adult cortex, where layer I is the most superficial, the 
marginal zone, and layer VI the deepest (Figure 1.7) 
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Figure 1.7 Normal cortical development.   
The laminar structure of the cortex develops by a series of orchestrated neurogenesis 
and migration events.  (A) During early embryogenesis, dividing neuronal progenitors 
occupy the ventricular zone (VZ), while a thin primordium layer makes up the pre-plate 
(PP). (B) The first neurons exit the cell cycle and migrate from the VZ through the 
intermediate zone (IZ), eventually resting within the pre-plate.  This ‘splits’ the pre-
plate into three layers, the marginal zone (MZ) at the top, nearest the pial surface, the 
cortical plate (CP) in the middle and the sub-plate (SP) underneath.  (C-E) Later-born 
neurons migrate by glia-guided locomotion past earlier-born neurons, to rest in a more 
superficial layer of the cortical plate, thus giving rise to the ‘inside out’ pattern of 
cortical lamination.  (E) The cortex is characterised by six distinct layers of neurons (I-
VI), with the earliest born neurons in deeper layers, and those born later more 
superficial.  Adapted from (Dhavan and Tsai, 2001). 
 
During development, Reelin is predominantly expressed by a layer of Cajal-Retzius 
neurons in the MZ of the cortex and in deeper layers of the hippocampus and olfactory 
bulb (D'Arcangelo et al., 1995), while in the adult brain it is expressed by a population 
of GABAergic interneurons (Weeber et al., 2002). 
In Reln deficient mice, post-mitotic neurons fail to split the pre-plate, which shifts 
towards the pial surface.  Later born neurons cannot migrate past their predecessors and 
so accumulate in an ectopic ‘super-plate’ – the shifted pre-plate - in an inverted manner, 
such that later born neurons stay within deeper layers, while early-born neurons remain 
superficial.  Furthermore, there is an ectopic accumulation of cells in the usually cell-
free MZ (Forster et al., 2002) (Figure 1.8).  Reelin mutation results in Norman-Roberts 
type Lissencephaly in humans, and deficiencies in Reelin function have also been 
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implicated in Alzheimer’s disease, schizophrenia, autism, bipolar disorder, depression 
and epilepsy (reviewed in (Herz and Chen, 2006)). 
 
 
Figure 1.8 Inverted neuronal positions in Reln deficient mice.   
Later born neurons in the Reeler mouse are born and specified correctly, but are unable 
to migrate past their earlier-born predecessors.  This results in an inversion of normal 
cortical lamination, with early born neurons accumulating ectopically in layer I and in 
layer II, while late-born neurons stay in deeper layers.  Adapted from (Rice and Curran, 
2001). 
 
The literature surrounding the mechanism of Reelin function in both the developing and 
adult central nervous system is both prolific and contradictory.  Despite years of 
research, the complex actions of this protein are yet to be definitively elucidated and 
many conflicting models and hypotheses have been proposed (reviewed in (Zhao and 
Frotscher, 2010)).   In order to discuss them, an understanding of the canonical 
signalling pathway is required first. 
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1.6.1 The canonical Reelin signalling pathway 
 
1.6.1.1 ApoER2, VLDLR and Dab1 
 
The major Reelin receptors are lipoprotein receptors ApoER2 and VLDLR, which are 
expressed in cortical and cerebellar layers adjacent to sources of Reelin signal. ApoER2 
and VLDLR are expressed in somewhat different patterns and mutations in either 
receptor alone result in slightly different neuronal phenotypes, but overall the mice are 
grossly normal (Trommsdorff et al., 1999).  However Apoer2-/-;Vldlr -/- double mutants 
develop ataxia, wide-gait, tremors and falling from P13 and display an identical 
neurological phenotype to Reln-/-, suggesting a high degree of redundancy in this 
pathway (Trommsdorff et al., 1999).  Reelin binding to ApoER2 and VLDLR results in 
phosphorylation of the intracellular adaptor protein Dab1, which is necessary for the 
transmission of Reelin signal (Howell et al., 1999, Howell et al., 2000) (Hiesberger et 
al., 1999).  Scrambler mice (Dab1Scm), which have a spontaneous mutation in Dab1, 
develop an identical phenotype to that of Reeler mice, thus defining Dab1 as a critical 
downstream component of the canonical Reelin signalling pathway (Howell et al., 
1997) (Sheldon et al., 1997).  ApoER2 and VLDLR have no intrinsic enzymatic 
activity, but Dab1 is phosphorylated by members of the Src family of kinases (SFK) 
and SFK activity is in turn increased by Phospho-Dab1 in a positive feedback loop, 
which may be achieved by ligand clustering at the membrane (Bock and Herz, 2003).  It 
is unknown how SFK are recruited to the Reelin signalling pathway, but a recent paper 
has suggested the involvement of EphrinBs (Senturk et al., 2011).  Lack of Fyn, a SFK 
member, results in accumulation of total Dab1 protein and mild neuronal defects 
reminiscent of, but less severe than, those in Reln-/- mice.  This suggests that Fyn is a 
likely candidate for the major mediator of Dab1 phosphorylation, but normal Phospho-
Dab1 in Fyn-/- mice suggests compensation by other SFKs, probably Src (Bock and 
Herz, 2003, Arnaud et al., 2003).  Reelin signalling also appears to be negatively 
regulated by Dab1 degradation, as stimulating primary neuronal cultures with Reelin for 
3-5 days lead to a 30% decrease in over-expressed Dab1 and an 80% reduction in 
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endogenous Dab1 (Feng et al., 2007).  Further experiments revealed that Reelin-induced 
Dab1 phosphorylation at a specific YXQI motif leads to recruitment of SOCS 
(Suppressor Of Cytokine Signalling) proteins, which target Dab1 for ubiquitination and 
degradation.  Electroporation of Cullin (Cul)5  shRNA in vivo and in vitro protected 
Dab1 from degradation and Cul5-/- mice had increased levels of phospho-Dab1, 
suggesting that Cul5, an E3 ubiquitin ligase was ultimately responsible for Dab1 
degradation (Feng et al., 2007).   
ApoER2/VLDLR binding and Dab1 phosphorylation have been clearly identified as 
upstream components of the Reelin signalling pathway through which the majority of 
Reelin signalling appears to be transmitted (Figure 1.9).  However, the downstream 
signalling pathway is more complex and consists of multiple strands. 
 
1.6.1.2 Regulation of Tau phosphorylation 
 
Tau proteins bind to and stabilise microtubules when in a hypophosphorylated state. 
Reelin inhibits Tau phosphorylation, thereby promoting stabilisation of microtubules, 
via activation of PI3K (Phosphatidylinositol 3-Kinase).  Recruitment of the p85α 
subdomain of PI3K to phospho-Dab1 allows PI3K activation, which is dependent on 
SFK (Bock et al., 2003).  PI3K activation stimulates Protein Kinase B (PKB), the main 
cellular kinase responsible for inhibition of Glycogen synthase kinase 3β, which 
phosphorylates Tau (Beffert et al., 2002).  Reeler, Apoer2-/-;Vldlr-/- and Dab1Scm brains 
show accumulation of hyperphosphorylated Tau, which leads to its dissociation from 
microtubules and disruption of the actin cytoskeleton, thus indicating a requirement for 
all upstream components of the canonical Reelin signalling pathway in regulation of 
Tau phosphorylation and microtubule stability (Hiesberger et al., 1999, Beffert et al., 
2002) (Figure 1.9). 
Chapter 1. Introduction 
 71 
1.6.1.3 C3G/Akt phosphorylation 
 
Another strand of the Reelin signalling pathway was elucidated by creation of a 
neuronal specific Crk/CrkL deficient mouse with defects strikingly similar to those of 
the Reeler mouse, including in the cortex, where there was a failure to split the cortical 
pre-plate, accumulation of neurons with no lamina structure in a super-plate below the 
pial surface and the presence of cells in the cell-free MZ.  Normal Dab1 
phosphorylation and turnover in these mice placed Crk and CrkL downstream of Dab1.  
Additionally, C3G and Akt, which regulate neuronal adhesion and migration, were not 
phosphorylated in Crk/CrkL deficient mice (Park and Curran, 2008).  Recently, 
migration defects in Dab1 mutant mice were recapitulated by interfering with Rap1 
signalling, which is controlled by C3G.  The same phenotype was also observed by 
expression of a dominant negative Cadherin construct, or Cadherin 2 shRNA in 
migrating neurons, suggesting that cadherins are required cell autonomously to stabilise 
the leading edge of migrating neurons.  Rescue of Rap1 disruption by cadherin 
overexpression placed cadherins, such as Cadherin 2, downstream of Rap1 (Franco et 
al., 2011) (Figure 1.9). 
 
1.6.1.4 N-cofilin-serine3 phosphorylation 
 
Finally, N-cofilin is an actin depolymerising protein that promotes disassembly of F-
actin, but when it is phosphorylated at Serine 3, it is no longer able to depolymerise F-
actin, thereby stabilising the cytoskeleton. Reelin increases N-cofilin phosphorylation at 
Serine 3, and LIMK1 activity (which is the major N-cofilin phosphorylating kinase) 
both in vivo and in vitro.  This effect was abolished when cortical slices were treated 
with PI3K inhibitors and in mice lacking Dab1, placing LIMK1 and N-cofilin 
downstream of Dab1 and PI3K (Chai et al., 2009). 
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Although complex, all strands of the signalling pathway elucidated thus far seem to link 
Reelin to regulation of cytoskeletal organisation and stability (Figure 1.9), although it is 
not known whether Reelin acts through all pathways simultaneously, or mediates 
different functions through different pathways; in which case it is unclear how one 
pathway is selected over another.  Combined with the migration defects visible in Reln-/- 
mice, there seems to be a clear involvement of Reelin in correct migration and 
cytoskeletal organisation of neurons and glia.  However, it is less clear whether this 
involvement involves regulation of migration initiation, continuation or termination. 
 
 
Figure 1.9 Reelin signalling pathway.   
Reelin canonical signalling pathways and downstream effectors.  Dashed arrows: AKT 
phosphorylation at serine 473 is positively regulated by Crk/CrkL(Park and Curran, 
2008), which suggests that these proteins may be upstream of the PI3K/Akt signalling 
pathway. 
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The following discussion of Reelin functions during development, concentrating on its 
roles in the cortex and hippocampus, as well as functions in the adult, will highlight 
some of these controversies and identify some possible models of Reelin function. 
 
1.6.2 Reelin as a pro-migratory signal 
 
There are two main mechanisms by which newborn post-mitotic neurons exit the 
ventricular zone.  Early-born neurons migrate via somal translocation, when distances 
are short, and the neuronal leading processes can reach from the VZ to the pre-plate.  As 
sequential waves of neurons are born and begin to migrate, the distance from the VZ to 
the superficial layers gets longer, and the leading processes no longer reach the entire 
distance.  In this case, neurons traverse the intermediate zone (IZ) and cortical plate via 
glia-dependant locomotion, which involves using radial glial fibres as a guiding 
scaffold.  These late-born neurons revert to somal translocation during their terminal 
migratory phase, when their leading process has reached the marginal zone and they 
have detached from the glia.  Both means of migration involve extension and 
stabilisation of the neuronal leading process, movement of the nucleus towards it, and 
retraction of the trailing edge (reviewed in (Frotscher, 2010). 
A requirement for Reelin for somal translocation has recently been identified.  It was 
previously established that, like Reeler mice, Dab1Scm neurons fail to extend processes 
into, or migrate into the pre-plate, suggesting that Reelin transmits a permissive signal 
to initiate migration (Sanada et al., 2004).  Detailed studies of a conditional Dab1 
knock-out mouse, in which Dab1 was deleted specifically in post-mitotic, but pre-
migratory neurons at varying developmental stages, determined that Dab1 was required 
for both initial and terminal neuronal somal translocation, which depends upon 
stabilisation of the leading edge by cadherins, via Rap1 (Franco et al., 2011).  However, 
in the absence of Dab1, late born neurons could still extend processes, polarise and 
migrate past early-born neurons normally, so Dab1 is not required for glia-guided 
Chapter 1. Introduction 
 74 
migration (Franco et al., 2011).  While this study suggested that Dab1 is not required for 
glial dependant migration, injection of Dab1 RNAi at E16, when glia-guided migration 
is underway, and analysis at E20 or E21 showed that Dab1 deficient neurons lagged 
behind their wild-type counterparts, suggesting that Reelin signalling does promote 
migration of late-born neurons in their glial-guided locomotion stage (Olson et al., 
2006).  However, this study used RNAi injection, rather than neuronal specific Dab1 
deletion, so concomitant deletion of Dab1 in glial cells and an effect of Reelin on glial-
guided locomotion by directly affecting glial cells cannot be ruled out. 
In fact, Reelin is also required for correct formation of the radial glial scaffold in both 
the cortex and the hippocampus.  Fewer glial cells extend long processes in Reeler 
mice, frequently failing to reach the MZ.  Culturing glial cells from Reeler mice in 
Reelin-containing medium induced process formation, thereby demonstrating that this is 
a direct effect of Reelin signalling on the glial cells (Hartfuss et al., 2003).  
Furthermore, stripe choice assays on hippocampal slice cultures revealed that while 
neurons and their processes showed no preference for Reelin or control stripes, GFAP+ 
radial glial cells strongly preferred Reelin stripes, and Reelin promoted branching of 
glial processes, similar to what is observed in the Reelin positive wild-type MZ (Forster 
et al., 2002). 
Additional evidence for a pro-migratory function for Reelin in cortical development 
comes from rescue experiments, where it was demonstrated that exogenous Reelin 
either applied globally to Reeler cortical slice cultures, or expressed ectopically in the 
VZ (where it is not usually expressed), were able to rescue initial migration defects, 
including splitting the pre-plate.  Global application of Reelin to cortical slice cultures 
was also able to rescue neuronal layer formation (Jossin et al., 2004), although ectopic 
Reelin expression in the VZ did not rescue cortical lamination and cell layers were even 
more mixed than in Reln-/- mice (Magdaleno et al., 2002).  This suggests that while 
Reelin might be initially performing a pro-migratory function, it may also be acting to 
promote cell-cell interaction to mediate proper migration and layer formation.  Another 
explanation as to why cortical lamination could not be completely rescued by ectopic 
Reelin expression in the VZ is that perhaps Reelin needs to be expressed in its normal 
location in order to fully rescue the Reeler phenotype.  This was observed in the 
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hippocampus, where addition of exogenous Reelin could rescue GFAP+ glial fibre 
length, but not orientation or granule cell (GC) lamination.  This could only be rescued 
by Reelin expression in its normotropic location, by wild-type co-culture with the 
Reelin-expressing dentate gyrus in close apposition to the Reeler granule cell layer 
(Zhao et al., 2004). 
 
1.6.3 Reelin as a stop signal  
 
While there is plenty of evidence for a pro-migratory function for Reelin during 
development, there is also evidence suggesting the opposite.  Firstly, the over-migration 
of neurons into the MZ in Reeler mice suggests that Reelin normally provides a ‘stop’ 
signal telling neurons that they have reached the correct destination (Frotscher et al., 
2009).  This is also observed in mutations in components of the signalling pathway, 
such as Apoer2-/-;Vldlr-/- and Cul5-./- (Trommsdorff et al., 1999, Feng et al., 2007).  
Dab1Scm neurons were shown by GFP electroporation and subsequent clonal analysis of 
radial glia and their neuronal progeny to be significantly closer apposed to the glial cells 
than wild-type neurons, which could suggest a failure to detach properly from the glial 
cell - an essential part of migration termination (Sanada et al., 2004).  Reelin-induced 
inhibition of neuronal migration and detachment from the radial glial scaffold was 
shown by timelapse photography in vitro and by addition of Reelin coated fluorescent 
microspheres to the cerebral wall in vivo.  This lead to a neuron-free area around the 
bead, suggesting either cessation of neuronal migration, avoidance of the Reelin coated 
bead, or premature neuronal detachment from the glia (Dulabon et al., 2000).  
Stabilisation of the actin cytoskeleton could also be indicative of a role for Reelin in 
terminating or preventing migration.  All the known downstream effectors of Reelin 
signalling are involved in maintenance of cytoskeletal stability.  For example, while 
hippocampal neurons extended processes equally onto Reelin or control substrate in a 
stripe choice assay, those processes on the Reelin stripes showed reduced filopodia and 
increased serine-3-phosphorylation of N-cofilin.  Time-lapse microscopy confirmed this 
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and showed continued growth of neuronal processes on control substrate, while those 
on Reelin stopped (Chai et al., 2009).   
 
1.6.4 Reelin in the adult brain 
 
Some Reelin functions in the adult may also give an insight into the mechanisms of 
Reelin function during development.  For example, temporal lobe epilepsy is 
accompanied by granule cell dispersion (GCD). Kainate (KA) injection, which induces 
focal epileptic regions and is a mouse model for temporal lobe epilepsy, also induces 
GCD and a decrease in Reelin expression.  Since GCD is also observed in Reln 
deficient mice, and when Reelin function is blocked by injection of the CR-50 function-
blocking antibody, it was hypothesised that the Reelin deficiency observed after KA 
injection might be the cause of GCD in models of temporal lobe epilepsy (Heinrich et 
al., 2006).  This was further demonstrated by the rescue of GCD (although not other 
cellular changes, such as KA-induced cell death, loss of neurogenesis or hypertrophy of 
the glial scaffold) by perfusion of exogenous Reelin (Muller et al., 2009).  Therefore, 
Reelin might play a role in maintaining the stability of the adult cyto-architecture by 
preventing further migration of mature neurons. 
Neurogenesis and neuronal migration continue after birth in the forebrain, where 
neurons migrate from their birthplace in the subventricular zone (SVZ) to the olfactory 
bulb, their final destination.  The mechanism of neuronal migration in this system is 
distinctive, with the neurons moving as a co-ordinated chain, and forming a well-
defined pathway called the rostral migratory stream (RMS) (Hack et al., 2002). In the 
postnatal olfactory bulb, Reelin is not required for the initiation or early stages of 
migration, as this occurs normally in Reeler mice, however individual cells fail to 
detach from the RMS, giving rise to a disorganised distribution of neurons over the 
entire granule cell layer, instead of forming organised layers (Hack et al., 2002).  This is 
supported by in vitro data, which showed Reelin promoting detachment of individual 
cells from tangentially migrating chains of neurons growing from subventricular zone 
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explants, thus suggesting a role for Reelin in mediating neuronal detachment from the 
RMS, which is an essential step for terminating migration and finally differentiating.  
These findings have recently been corroborated by experiments with a transgenic mouse 
line that over-expresses Reelin in the postnatal and adult forebrain, causing increased 
detachment of neuronal precursors from the RMS (Courtes et al., 2011).  However, 
contrary to detachment as a means to terminate migration, this study emphasises the 
potential for further migration of neuronal precursors detached from the RMS by 
ectopic Reelin, as evidenced by their increased dispersal.  This is given functional 
relevance by the observation that Reelin is up-regulated around lesions in the adult 
brain and that when Reelin is over-expressed, there is an increase in progenitor cell 
recruitment to the lesion, and a corresponding reduction in the number of progenitors 
around lesions in Reln deficient mice, potentially implicating Reelin as a therapeutic 
target in treatment of adult brain lesions (Courtes et al., 2011). 
 
1.6.4.1 Synapatic plasticity 
 
Studies of Apoer2-/- and Vldlr-/- single mutant mice identified a role for Reelin in 
modulating synaptic plasticity in the adult.  A widely used indicator of synaptic 
plasticity is measurement of long term potentiation (LTP), which is a long-term 
enhancement of signal transmission between two synapses and is believed to be a major 
cellular mechanism underlying learning and memory.  Both Apoer2-/- and Vldlr-/- mice 
show defects in fear conditioning and induction of LTPs, although this is much more 
severe in Apoer2 deficient mice.  Enhancement of LTPs after perfusing hippocampal 
slices with Reelin demonstrated that Reelin might induce LTPs, and the abrogation of 
Reelin induced LTP enhancement in either Apoer2-/- or Vldlr-/- mice suggested that 
these two receptors act in a non-redundant manner in this system (Weeber et al., 2002).  
The stronger LTP inhibition in Apoer2 deficient mice suggested a key role for this 
receptor in modulation of Reelin induced synaptic plasticity, which was subsequently 
demonstrated to rely upon an alternatively spliced domain in the intracellular region 
(Beffert et al., 2005).  The mechanism by which Reelin modulates synaptic plasticity 
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has now been described.  Reelin signalling, which in this system is still dependant on 
ApoER2, VLDLR, Dab1 and SFKs, increases synaptic responses to glutamate, by 
tyrosine phosphorylating and increasing Ca2+ flux through the NMDA receptor; a 
glutamate receptor that is thought to be the primary molecular device for modulating 
synaptic plasticity (Chen et al., 2005).  These studies all used addition of exogenous 
Reelin to elucidate its function at the synapse, but close analysis of Reln 
haploinsufficient mice also revealed a role for endogenous Reelin.  An extensive array 
of behavioural tests showed that Reln+/- mice showed hippocampus specific impairment 
in acquiring or retaining long-term associative fear conditioned memory.  This is 
coupled to reduced short and long-term synaptic plasticity, measured by reduced LTPs 
and paired pulse facilitation (PFF; an increase in post-synaptic potential evoked by a 
second impulse.  This is a widely used measure of short-term synaptic plasticity) (Qiu et 
al., 2006).  Molecularly, the reduction in synaptic plasticity of Reln haploinsufficient 
mice is accompanied by significant reductions in the post-synaptic proteins Postsynaptic 
density protein 95 (PSD-95), the NMDA receptor subunits NR2A and NR2B and the 
phosphatase PTEN, which were all shown by co-immunoprecipitation of the whole 
brain synaptosome to interact at the synapse, perhaps suggesting that Reelin not only 
regulates phosphorylation and Ca2+ flux through the NMDA receptors, but also 
expression of these essential post-synaptic proteins (Ventruti et al., 2011). 
In summary, the cellular functions and mechanisms of Reelin signalling are highly 
complex.  Reelin appears to be able to both initiate and terminate migration; both by 
modulating cytoskeletal stability, and to carry out different functions in different 
tissues.  Furthermore, within the same tissue Reelin appears to be able to mediate 
opposite effects on different cell types, for example increasing branching of glial 
processes (Forster et al., 2002), but inhibiting growth and branching of neuronal 
processes (Chai et al., 2009).  Some of this complex functionality may be regulated by 
signalling via different intracellular signalling pathways, or by interacting with (and 
moderating the function of) other signalling pathways, for example the NMDA 
receptors at the synapse.  Alternatively, some different Reelin functionality may be 
explained by differential signalling through either ApoER2 or VLDLR. 
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1.6.5 Differential roles of ApoER2 and VLDLR 
 
The expression patterns of ApoER2 and VLDLR are slightly different, for example 
Vldlr is abundant on the intermediate zone and cortical plate immediately adjacent to 
Reelin expressing cells, whereas Apoer2 is expressed in post-mitotic neurons en route 
to, or at their final destination (Trommsdorff et al., 1999).  Fate mapping studies of 
individual neurons in the single receptor mutants revealed divergent functions for each 
receptor.  In the absence of Apoer2, early-born layer V and some layer IV neurons 
migrate normally, but late-born layer IV and layer II-III neurons fail to migrate and stay 
close to the VZ (Hack et al., 2007).  This suggests a role for ApoER2 in facilitating 
proper migration of late-born neurons.  Conversely, VLDLR appears to mediate the 
Reelin ‘stop’ signal.  Mice lacking Vldlr show ectopic invasion of interneurons and 
pyramid cells, some of which are misoriented, into the usually cell-sparse MZ, 
recapitulating the over-migration phenotype in the Reeler cortex and suggesting the 
absence of a proper ‘stop’ signal (Hack et al., 2007).  Part of these different receptor 
functions may be dependant on their distinct membrane localisation and subcellular 
properties.  For example, ApoER2 is localised to lipid rafts domains of the cell 
membrane, while VLDLR is not, which gives rise to different endocytosis properties.  
Reelin is endocytosed rapidly upon binding to VLDLR, but Reelin bound to ApoER2 is 
stable (Duit et al., 2010).  Other differences include ApoER2 cleavage upon Reelin 
binding, which is also dependant on lipid raft localisation and ApoER2, but not 
VLDLR, degradation in lysosomes after endocytosis.  These specific subcellular 
properties of the Reelin receptors may influence their function – perhaps triggering 
activation of different intracellular signalling pathways, or determining the outcome of 
Reelin signalling (Duit et al., 2010). 
Chapter 1. Introduction 
 80 
1.6.6 Aims of this work 
 
The divergent functions of lymphatic capillaries and collecting lymphatic vessels in 
uptake and transport of lymph have been well characterised, but the process by which 
these two distinct vessel types develop from the uniform primary plexus and how the 
differences between them help to mediate their specific functions is less clear. 
The overall aim of my project was to investigate how defining features of collecting 
lymphatic vessels, such as SMC coverage and an intact BM, contribute to collecting 
vessel development and function. 
To accomplish this, the specific objectives in this project were:  
1) Characterisation of the events leading up to differentiation of dermal collecting 
vessels, such as SMC recruitment and BM deposition, by whole-mount 
immunofluorescence of mouse ear skin 
2) Identification of lymphatic-specific extracellular matrix proteins by microarray 
analysis of blood and lymphatic vessels 
From this, we identified Reelin as an ECM protein that was specifically expressed in the 
lymphatic vessels. The subsequent objectives of my project then became: 
3) Characterisation of Reelin expression in the developing and mature vasculature 
4) Determination of the function of Reelin in lymphatic development in vivo 
5) Investigation of the mechanisms of Reelin signalling in lymphatic vasculature 
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Chapter 2. Materials and Methods 
 
2.1 Mice 
 
Reeler (D'Arcangelo et al., 1995), Dab1Scm (Ware et al., 1997), Lyve1 (Gale et al., 2007) 
and R26-mTmG (Muzumdar et al., 2007) mice were obtained from the Jackson 
Laboratory. Apoer2-/- (Trommsdorff et al., 1999), Vldlr-/- (Frykman et al., 1995), Efnb2lx 
mice (Grunwald et al., 2004) and Efnb2GFP (Davy and Soriano, 2007) have been 
described previously and were obtained from their originators.  The Prox1-creERT2 line 
was generated by Taija Makinen as described in Bazigou et al., 2011. To induce Cre 
recombination, a single dose of 0.5mg 4-OHT dissolved in Peanut Oil was administered 
by intraperitoneal injection at P7 or P12, as indicated.  Dab1Scm mice were maintained in 
a C3HeB/FeJ * DC/Le background and Efnb2lx/lx;Prox1-creERT2 mice were maintained 
in a mixed 129Sv/BL6 background. All other strains were maintained in a C57Bl/6 
background.   
Animal care and husbandry was provided by Cancer Research UK Biological Resources 
Unit (BRU). 
I performed all experimental procedures myself.  All maintenance, breeding and 
experimental procedures were carried out in accordance with UK legal and ethical 
standards and in accordance with the UK Coordination Committee on Cancer Research 
UK guidelines and Home Office regulation. 
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2.2 Genotyping 
 
Ear and tail biopsies of mice, taken by members of the BRU or myself, were boiled at 
95°C for 45 minutes in ‘Hotshot’ Buffer (25mM NaOH, 0.2mM disodium EDTA. pH 
12).  Immediately afterwards, samples were placed on ice and neutralised with an equal 
volume of 40mM Tris-HCL pH 5.  Samples were stored at -20°C prior to commencing 
polymerase chain reaction (PCR). 
PCR was performed using DreamTaq (Fermentas), DreamTaq Buffer (Fermentas) and 
0.8mM dNTPs (Invitrogen). 1µL DNA sample was added to a total volume of 25µL 
PCR reaction. Details of primers, annealing temperatures and PCR conditions for each 
primer set are listed in Table 2.1.   
The PCR reactions were run on a 1.5-2% agarose gel (Invitrogen), diluted in TAE 
buffer (40mM Tris, 20mM Glacial Acetic Acid, 1mM EDTA) containing 0.01-
0.03mg/mL ethidium bromide (Sigma). 
Efnb2GFP mice were genotyped by visual examination of ear, tail or eye tissue to 
identify GFP-positive signal. 
Dab1Scm, Apoer2-/-;Vldlr-/- and Reln-/- mice were identified by visual observation of 
phenotype (smaller size than wild type littermates, trembling, falling and unsteady gait).  
Dab1 genotyping primers were designed against the insert responsible for the mutation, 
therefore the PCR reaction is not capable of distinguishing between mutant and 
heterozygous mice; identification of Dab1Scm mice relies on visual examination of the 
phenotype. 
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2.3 Cell Culture 
 
All cell lines were cultured at 37°C in 5% CO2. 1% Penicillin/Streptomycin (Pen/Strep), 
1% Glutamine and 0.1% Fungizone/Amphoterycin B (Sigma) was added to all growth 
media, unless otherwise stated. 
Human lymphatic endothelial cells (LEC) were isolated from primary dermal 
microvascular endothelial cell cultures (PromoCell) using rat antibody to human 
Podoplanin (NZ-1, Angiobio) and Mini/MidiMACS magnetic separation system 
(Miltenyi Biotech), by Sherry Xie as previously described (Makinen et al., 2001b).  The 
cells were cultured on 2µg/ml Fibronectin (FN; Sigma) coated plates in Endothelial Cell 
Growth Medium Kit MV (Promocell) in the presence of 50ng/ml VEGF-C (R&D 
systems).  Human venous smooth muscle cells (HUVSMC; Cellworks), or Human 
aortic smooth muscle cells (HAoSMC; Promocell) were cultured in Smooth Muscle 
Cell Growth Medium (Promocell) and used at passages 3-6.  For co-culturing of LEC 
and HUVSMC, LEC were plated on FN coated plates at 80% confluency at least 4 
hours before plating HUVSMC.   
For immunoprecipitation of cell medium, both LEC and SMC were plated as above, but 
incubated in endothelial cell growth medium with 5% IgG-stripped FBS (PAA), plus 
supplements (Promocell).  For culture of SMC in LEC-conditioned medium, LEC were 
cultured in IgG-stripped Endothelial Cell growth medium (as above) for two days.  The 
medium was then collected and centrifuged to remove cellular debris, before being re-
incubated on SMC, 50% pre-conditioned medium and 50% fresh IgG stripped medium.  
The same procedure was followed for incubation of LEC in SMC-conditioned medium. 
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2.3.1 Creating a fibroblast matrix 
 
To create a fibroblast matrix, NIH-3T3 cells were grown in DMEM + 10% FBS.  4mL 
0.2% gelatin was added to a 10cm dish and incubated for 1hr at 37°C, before washing 
with PBS.  NIH-3T3 cells were collected in matrix medium (growth medium + 50µg/ml 
L-ascorbic acid, sodium salt (Sigma), from a freshly prepared and filter purified 
50mg/ml stock solution) and 1x106 cells were seeded in the 10cm dish.  After 24 hours, 
the medium was changed to fresh matrix medium.  This was repeated every 48 hours for 
9 days, after which the medium was aspirated and the cells rinsed with PBS.  3ml of 
pre-warmed (37°C) extraction buffer (PBS + 0.5% Triton X-100 and 20mM NH4OH) 
was added to lyse the cells and incubated at room temperature until no intact cells could 
be seen.  2-3ml PBS was added to dilute the cell debris, which was removed gently 
using a pipette.  This step was repeated, then 10U/mL DNAse was added for 30 minutes 
at 37°C to minimize DNA debris, then washed twice with PBS, before covering the 
matrix-coated plates with PBS supplemented with 1% Penicillin/Streptomycin 
(Pen/Strep), 1% Glutamine and 0.1% Fungizone/Amphoterycin B.  Plates were sealed 
with Parafilm and stored at 4°C for no more than 2-3 weeks before use.  This protocol 
was obtained from Current Protocols in Cell Biology (2002). 
 
2.3.2 Generation of full-length Reelin 
 
Reelin expression and secretion after pCrl transfection into HEK 293 cells is a well-
established method for collecting full-length Reelin and all its cleavage products to use 
in subsequent cell treatments (Jossin et al., 2004, 2007), (Feng et al., 2007), (Chai et al., 
2009).  Briefly, HEK 293 cells, cultured in DMEM (Invitrogen) plus 10% FBS, were 
transfected with pCrl (full-length Reelin cDNA; obtained from Tom Curran, St Jude), 
using Lipofectamine 2000 (Invitrogen).  After two days, the transfected cells and 
untransfected control cells were counted and plated in equal numbers.  After settling, 
the medium was changed to 0% serum DMEM for two days and then collected and 
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centrifuged to remove cellular debris.   For chemotaxis and cell-stimulation 
experiments, supernatant from Reelin-transfected or untransfected control cells was 
concentrated approximately 25x using an Amicon ultra-15 centrifugal filter unit, 50kDa 
(Sigma), thus also removing any proteins smaller than 50kDa from the supernatant.  
 
2.4 Antibodies 
 
A full list of antibodies used for immunofluorescence experiments throughout this 
thesis can be found in Table 2.2 (primary antibodies) and Table 2.3 (secondary 
antibodies).  A full list of antibodies used for Western Blotting experiments within this 
thesis can be found in Table 2.4 (primary antibodies) and Table 2.5 (secondary 
antibodies). 
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Antibody Source Dilution 
Rabbit anti-mouse LYVE1 Reliatech 1:1000 
Rabbit anti-mouse Desmin Abcam 1:100 
Rabbit anti-mouse Collagen IV Serotec 1:100 
Rabbit anti-mouse Laminin-α5 (Ringelmann et al.) 1:400 
Rabbit anti-mouse GFP Invitrogen 1:200 
Rabbit anti-mouse Erp57 Abcam 1:100 
Rabbit anti-mouse Golph4 Abcam 1:200 
Rabbit anti-mouse Efemp1 Abcam 1:100 
Rabbit anti-mouse NG2 Chemicon 1:100 
Rabbit anti-mouse Fibronectin Abcam 1:200 
Rat anti-mouse PECAM-1 BectonDickinson 1:250 
Rat anti-mouse VE-Cadherin (Gotsch et al.) 1:100 
Rat anti-mouse LYVE-1 R&D Systems 1:500 
Goat anti-mouse Reelin R&D Systems 1:200 
Goat anti-mouse VLDLR R&D Systems 1:100 
Goat anti-mouse Integrin-α9 R&D systems 1:200 
Mouse anti-mouse acetylated αTubulin* Abcam 1:100 
Hamster anti-mouse Podoplanin (8.1.1) Developmental Studies 
Hybridoma Bank 
1:200 
Hamster anti-mouse PECAM-1 Chemicon 1:500 
Rat anti-human Podoplanin NZ1 AngioBio 1:50 
Rabbit anti-human LYVE-1 Reliatech 1:50 
Cy3-conjugated mouse anti-αSmooth 
Muscle Actin 
Sigma 1:500 
(wholemount) 
or 1:50 (cells) 
Table 2.2 Primary antibodies used for immunofluorescence experiments in this 
thesis 
 
Mouse anti-mouse acetylated αTubulin antibody was used together with Vector 
M.O.M. Blocking reagent.  After one hour blocking in PBS plus 3% milk, ears were 
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then blocked in PBS plus M.O.M blocking reagent (1 drop in 1.25mL PBS) for at least 
a further hour. 
 
Secondary Antibody Source Dilution 
Donkey anti-rat cy2, cy3 or cy5 Jackson ImmunoResearch 1:300 
Donkey anti-rabbit cy2, cy3 or cy5 Jackson ImmunoResearch 1:300 
Donkey anti-goat cy2 or cy3 Jackson ImmunoResearch 1:300 
Goat anti-syrian Hamster cy2, cy3 or cy5 Jackson ImmunoResearch 1:300 
Biotin Donkey anti-goat  Jackson ImmunoResearch 1:300 
Table 2.3 Secondary antibodies used for immunofluorescence experiments in this 
thesis 
 
Antibody Source Dilution 
Mouse anti-human Reelin Calbiochem 1:500 
Mouse anti-human CD31 Dako 1:1000 
Mouse anti-human α-tubulin Sigma 1:8000 
Cy3-conjugated mouse anti-αSmooth Muscle Actin Sigma 1:1000 
Rabbit anti-human Spock3 Abcam 1:1000 
Rabbit anti-human Efemp1 Abcam 1:1000 
Rabbit anti-human Nidogen2 Immundiagnostik 1:1000 
Table 2.4 Primary antibodies used for Western blotting in this thesis 
 
Secondary Antibody Source Dilution 
Goat anti-mouse HRP Jackson Immunoresearch 1:5000 
Goat anti-rabbit HRP Jackson Immunoresearch 1:5000 
Table 2.5 Secondary antibodies used for Western blotting in this Thesis 
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2.5 Immunofluorescence staining 
 
Mice were killed by schedule 1 methods:  CO2 and cervical dislocation, or cervical 
dislocation alone.  The outer ears were removed by cutting along the base of the ear, 
closest to the head.  These were opened by teasing apart the dorsal layer of the ear skin 
from the base using forceps, being careful to leave all the cartilage on the ventral side of 
the ear.  The opened dorsal ear skin was then fixed. 
To obtain embryos for embryonic skin samples, the mother was killed by cervical 
dislocation, the abdominal space opened and the embryos removed into PBS.  The 
embryos were removed from the amniotic sac using forceps and culled by decapitation.  
The skin was carefully dissected, using microscissors to cut around the dorsal edges of 
the skin and then pulled away using forceps.  The skin was pinned flat and then fixed.   
 
2.5.1 Immunofluorescence staining of whole-mount ears and embryonic 
skin 
 
For whole-mount staining of ears and embryonic skin, tissues were fixed in 4% PFA 
(Paraformaldehyde) overnight at 4°C, washed several times in PBS, permeabilised in 
0.3% Triton X-100 (Acros Organics) in PBS (PBSTx) and then blocked in 3% milk or 
BSA (Bovine Serum Albumin, Sigma) in PBS for at least 2 hours.  Primary antibodies 
(Table 2.2) were added to the blocking buffer and incubated at 4°C overnight.  After 2 
hours washing in PBSTx, the tissue was incubated with fluorochrome-conjugated 
secondary antibodies (Table 2.3) in 1% milk or 3% BSA in PBS for 2 hours at room 
temperature (RT), washed for 2 hours in PBSTx and mounted in Mowiol mountant 
(25% w/v glycerol, 1% w/v Mowiol, 100mM Tris (final concentration) and 2% w/v N-
propyl-gallate to a final volume of 24mL in H20).  
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For NG2 staining (Figure 3.3 A-B’), ears were blocked overnight in PBLEC (1% 
Tween-20, 0.1mM CaCl2, 0.1mM MgCl2, 0.1mM MnCl2 in PBS, pH 6.8) at 4°C, before 
incubation with rabbit anti-mouse NG2 antibody, diluted in PBLEC overnight at 4°C.  
After 2 hours washing and a further 1 hour blocking in PBSTx + 3% milk, other 
primary antibodies were added and the normal immunofluorescence protocol was 
resumed. 
 
2.5.2 Signal amplification  
 
Alternatively, for signal amplification using the TSA Fluorescein Tyramide Reagent 
Pack (Perkin Elmer), the primary antibody (Table 2.2) was incubated in PBSTx +3% 
milk overnight at 4°C, washed for two hours and then incubated with biotin-conjugated 
secondary antibodies (Table 2.3), diluted in TNB buffer (0.1M Tris-HCl pH7.5, 0.15M 
NaCl, 0.5% blocking buffer (supplied in kit)) overnight at 4°C.  Samples were then 
washed for two hours in PBSTx, incubated with SA-HRP (used at 1:750 in TNB buffer) 
for 30 minutes at RT, washed for 1 hour, incubated with Biotinyl Tyramide-FITC (used 
at 1:1000 in amplification diluent) for 10 minutes at RT, washed for another hour and 
then incubated with other (non amplified) primary antibodies in PBSTx + 3% milk, 
before resuming normal immunofluorescence protocol.  
For VLDLR staining (Figure 6.1 C-D’), goat anti-mouse VLDLR antibody (R&D 
systems) was preabsorbed with a Vldlr-/- ear in TNB buffer overnight, before resuming 
normal amplification and immunofluorescence protocol. 
For immunofluorescence staining of unpermeabilised tissue, all steps were carried out 
in the absence of Triton X-100. 
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2.5.3 Image Acquisition 
 
All samples were analysed using a Zeiss LSM 510 scanning confocal microscope, 
except for Apoer2-/-;Vldlr-/- and Dab1Scm mice and their wild type controls, which were 
analysed using a Zeiss LSM 710 scanning confocal microscope.  All confocal images, 
unless otherwise stated, represent 3D projections of Z-stacks. 
 
2.5.4 Immunofluorescence staining of cells on coverslips 
 
For immunofluorescence staining of cells on coverslips, samples were fixed in 4% PFA 
for 10 minutes at RT, permeabilised with 0.5% Tween-20 (Acros Organics) in PBS 
(PBST) and then incubated with primary antibodies (Table 2.2) in 5% normal goat 
serum (NGS) in PBS for 30 minutes at RT.  After 30 minutes washing in PBST, the 
samples were incubated with fluorochrome-conjugated secondary antibodies (Table 2.3) 
in 5% NGS/PBS for 30 minutes at RT, washed and mounted in Mowiol, or incubated 
for 5 minutes with DAPI (Invitrogen; 1:1000 in dH2O), dipped in dH2O and mounted in 
Mowiol, before imaging with a Zeiss Axio Observer inverted microscope. 
 
2.6 Relative Quantitative PCR 
 
2.6.1 RNA extraction 
 
For RELN, APOER2, VLDLR and EFNB2 gene expression analysis, RNA was extracted 
from 2 or 3 independent samples (as indicated in figure legends) of Lymphatic 
Endothelial Cells (LEC), Blood vascular Endothelial Cells (BEC) Human Aortic (HAo) 
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and Human Venous Smooth Muscle Cells (HUVSMC), using the RNEasy Mini kit 
(Qiagen) according to the manufacturer’s protocol.  
For LYVE1 mRNA analysis, LEC were cultured alone or together with SMC for 48 
hours before RNA extraction, using RNeasy Mini kit, as above. 
For Reelin stimulation, LEC were starved overnight in serum free Endothelial Cell 
Growth Medium (Promocell), supplemented with 0.2% BSA, hEGF-5 and HC-500.  
The next morning, cells were stimulated with full-length Reelin supernatant, diluted 
1:20, control supernatant, diluted 1:20, 1ug/mL recombinant mouse Reelin (R&D), or 
left untreated for 4, 8 or 24 hours.  RNA was extracted at the end of each timepoint 
using RNeasy Mini kit, as above. 
 
2.6.2 Reverse Transcription 
 
RNA was reverse transcribed using Superscript III Reverse Transcriptase (Invitrogen).  
Briefly, 500ng RNA, diluted up to 10µl in RNAse-free dH2O, was incubated with 
2.5µM OligoDT and 2mM dNTPs (all Invitrogen) per reaction, and put at 65°C for 5 
minutes.  After 1 minute on ice, 4µl 5x first strand buffer, 1µl 0.1mM DTT, 40 units (U) 
RNAse out and 200U Superscript III RT (all Invitrogen) was added to each reaction and 
put at 50°C for 60 minutes and 70°C for 15 minutes.  The RT reactions were then put on 
ice while 2U RNAse H was added, before being incubated at 37°C for 20 minutes. 
cDNA samples were kept on ice for immediate use or at -20°C for short-term storage.    
 
2.6.3 Relative quantitative PCR 
 
For RELN, APOER2, VLDLR, LYVE1 and EFNB2 gene expression analysis, Platinum 
SYBR Green qPCR super mix-UDG with ROX (Qiagen) detection system was used.  
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Each reaction mixture was made up as follows: 12.5µl SYBR Green, 1µl forward 
primer (10µM), 1µl reverse primer (10µM) and 9.5µl RNAse-free dH20 and 1µl cDNA. 
For MCP1, PDGFB, HBEGF, ANGPT2 and TGFβ1 gene expression analysis, Taqman 
probes (Applied Biosystems) were used and each reaction mixture was made up as 
follows:  10µl Taqman mastermix, 8µl RNAse-free dH20, 1µl Taqman probe and 1µl 
cDNA. 
cDNA was amplified in duplicate by quantitative real-time PCR (ABI 7900HT), with 
cycling conditions as follows: step 1, 2 minutes at 50°C; step 2, 10 minutes at 95°C; 
step 3, 15 seconds at 95°C and step 4, 1 minute at 60°C.  Steps 3 and 4 were repeated 
35-40 times.  Ct values were exported and ΔΔCT was calculated using either the 
complementary computer software or in Excel. In all cases, except LYVE1 expression in 
LEC/SMC co-cultures compared to LEC alone, relative quantifications of gene 
expression were normalised to expression of the endogenous gene, GAPDH. In the case 
of LYVE1, expression was normalised to PECAM1. 
The primers used were:  RELN:  5’-GTTTTGCAAATTGGGAGCAT-3’ and 5’-
CCGTTGTTGACGCTGTATTG-3’, APOER2: 5’- GCGGAACTATTCACGCCTCA-
3’ and 5’-TGCGATTGGTGGCAACTTC-3’, VLDLR: 5’- 
CATTGCTGTTGATTGGGTGT-3’ and 5’- CCAGTAAACAAAGCCAGACAGTG-
3’; PECAM1: 5’-GAGAGGACATTGTGCTGCAA-3’ and 5’-
GGGTTTGCCCTCTTTTTCTC-3’, LYVE1: 5’-GCTTTCCATCCAGGTGTCAT-3’ and 
5’-AGCCTACAGGCCTCCTTAGC-3’, EFNB2: 5’-CTGCTGGATCAACCAGGAAT-
3’ and 5’-GATGTTGTTCCCCGAATGTC-3’ and GAPDH: 5’- 
GAAGGTGAAGGTCGGAGTC-3’ and 5’-GACAAGCTTCCCGTTCTCAG-3’ (All 
custom made from Sigma). 
Taqman probes (Applied Biosystems) were: PDGFB; Hs00966522_m1, ANGPT2; 
Hs01048042_m1, TGFβ1; Hs00998133_m1, HBEGF; Hs00181813_m1, CCL2/MCP1; 
Hs00234140_m1 and GAPDH; Hs99999905_m1. 
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2.7 Vessel Dissection and Microarray 
 
2.7.1 Vessel Dissection and RNA extraction 
 
For RNA extraction from murine lymphatic vessels, arteries and veins, dissection plates 
were first incubated overnight in RNAse away solution, washed several times in DEPC 
treated H2O and then incubated for a further hour in 70% EtOH.  Dissection tools were 
also incubated overnight in 70% EtOH.   
P6 or P7 wild type (C57Bl/6) pups were culled by cervical dislocation, then the whole 
mesenteries were dissected using sterile scissors and forceps and taken straight into 
DMEM plus 10% FBS.  Although our previous analysis of lymphatic collecting vessel 
differentiation had been done in the dermal lymphatic vasculature, we used mesenteric 
vessels for our array, due to the accessibility of this tissue for dissection. P6 and P7 
mice were chosen for vessel dissection for practical reasons.  At this stage, the vessels 
are large enough to make dissection possible, but the perivascular adipose tissue that 
obstructs the vessels, making clean dissection impossible, has yet to be deposited.  
Regional gene expression changes between mesenteric and dermal lymphatic vessels 
need not affect the usefulness of data gained from this array since, as with any screen, 
specific expression of the gene of interest must be validated by further expression 
studies, as was performed for Efemp1, Nidogen 2 and Spock 3 (Figure 3.12) and Reelin 
(Figure 4.1 A-A’).  All the mice used in this array were in a C57Bl/6 background, and 
so possible strain specific differences must be taken into account if applying data from 
this array to mice bred into a different genetic background.  It should also be noted that 
the pups were not starved prior to sacrifice.  Mesenteric lymphatics are only visible 
when full of chyle, so clean dissection of lymphatic vessels would be extremely difficult 
in starved pups.  However, the importance of the lymphatics in fat absorption means 
that recent feeding may affect gene expression, again highlighting the need for further 
validation of microarray data.   
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Samples waiting to be dissected were kept on ice.  The mesenteries were put onto the 
dissection plate in DEPC-PBS.  Lymphatic vessels were dissected by gently holding the 
vessel at the end nearest the mesenteric root using forceps and then gently pulling away, 
carefully tweezing excess fibrous tissue from the mesenteric membrane away from the 
vessel.  The other end of the vessel was then cut using micro-scissors.  The vessels were 
placed in a drop of lysis buffer RLT, plus β-Mercaptoethanol (1:100) from the RNeasy 
Micro kit (QIAGEN) while the remaining vessels were excised.  Arteries and veins 
were dissected using a similar technique, but were first separated from each other using 
forceps, and as much fibrous tissue pulled away from the vessel as possible.  Once all 
the vessels from one mesentery had been dissected, they were cut into small pieces, to 
assist efficient lysis and put into ~100µl buffer RLT plus β-Mercaptoethanol.   
When all the mesenteries had been dissected, and tissue lysed, the lysis buffer 
containing the vessel segments was heated at 37°C for 10-15 minutes, and vortexed to 
increase the eventual RNA yield, before storage at -80°C.  Upon removal from -80°C, 
samples were heated at 37°C for 5-10minutes then RNA was extracted using the 
RNeasy micro kit (QIAGEN), according to the manufacturer’s instructions.  Samples 
from 9 pups (all the pups from two litters) were pooled prior to RNA extraction.  
 
2.7.2 Microarray and analysis 
 
100ng RNA from two independent samples of lymphatic vessels, arteries and veins 
were sent on dry ice to the Cancer Research UK Paterson Institute, where the Paterson 
Institute Microarray Service amplified the RNA using WT-Ovation Pico RNA 
Amplification System (NuGEN) and used it for expression profiling using the Mouse 
exon 1.0 ST Array (Affymetrix), according to manufacturer’s instructions.  The 
Affymetrix exon array is comprised of 25-mer probes synthesised in situ on the 
GeneChip.  The probes are grouped into ‘probe sets’ of 4 probes, all directed against the 
same exon, although there can be more than one probe set per exon.  Analysis can be 
carried out at this level to give ‘exon level’ data, including information on alternative 
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splicing events.  Alternatively, the probe sets can be grouped again into ‘transcript 
clusters’, which are grouped by mapping the probe sets to mRNA sequences collated 
from various databases (eg RefSeq and Ensembl) to give ‘core level’ analysis at gene 
level.  This level of analysis was used in our project. Quantification was run using apt-
1.10.0 from Affymetrix.  The read-out from each probe is a measure of signal intensity, 
which was processed using RMA (robust multichip average) (Irizarry et al., 2003).  This 
algorithm calculates the average signal intensity from all the probes across a transcript 
cluster, simultaneously looking for consistency in the rank of signal intensity between 
probes and probe sets on all chips to weight against less robust readings, whose signal 
intensity ranking is not maintained across all samples.  The algorithm also includes 
quantile normalisation, which assumes similar signal distribution across all chips and 
corrects for differences in RNA concentrations and reaction efficiencies between chips 
to ensure that they are comparable.  Gene changes were selected using a linear model 
and multiple testing correction, and a false discovery rate (fdr) of <0.05, was applied to 
correct for errors generated in a large dataset.  Lymphatic specific transcriptional 
changes were selected for.  All annotation was taken from Affymetrix and all analysis 
carried out in Bioconductor (Gentleman et al., 2004) using Limma by Phil East in the 
Cancer Research UK Bioinformatics and Biostatistics department.  
 
2.7.3 Identification of extra-cellular matrix related genes 
 
Genes that were expressed at least 2-fold higher in lymphatic vessels compared to 
arteries or veins, and in arteries and veins compared to lymphatic vessels were 
identified.  All the genes in this list were searched in Uniprot (www.uniprot.org) and 
those where the subcellular localisation was identified as extracellular matrix were 
selected to give a list of all genes that encode proteins involved in extracellular matrix 
structure, assembly or degradation and are expressed at least 2-fold higher in lymphatic 
vessels, arteries or veins. 
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2.8 Western Blot Analysis and Immunoprecipitation 
 
Whole cell lysate for Western Blot analysis was collected by washing cells in cold PBS 
then lysing in Triton X-100 lysis buffer (50 mM Tris [pH 7.5], 120 mM NaCl, 10% 
glycerol, 1% Triton X-100), supplemented with Complete Protease inhibitors (Roche). 
All samples (cells and medium) were kept on ice or at 4°C. 
 
2.8.1 Measuring protein concentration 
 
For LEC/BEC analysis, a BCA protein assay (Pierce) was performed to measure total 
protein concentration, according to manufacturers instructions.  An equal amount of 
protein was then added to each lane of a 7.5% SDS-PAGE gel. 
For LEC/LEC-SMC co-culture, equal volumes of lysate were added to the gel, and a 
loading control was used to confirm that equal numbers of cells were used. 
 
2.8.2 SDS gel electrophoresis and immunoblotting 
 
Gels were run at 0.02A in 1x SDS-PAGE running buffer (25mM Tris, 0.2M Glycine, 
3.5mM SDS).  The gel was run until the blue dye ran out the bottom of the gel.  Protein 
separation was visualized using Full-Range Rainbow Molecular Weight Marker 
(Amersham) loaded in the gel.   
All gels were transferred onto a polyvinyidene difluoride (PVDF) membrane 
(Amersham) using the X Cell II Blot Module (Invitrogen) in 1x Tris-Glycine-Methanol 
transfer buffer (25mM Tris, 0.2M Glycine, 20% Methanol). Efficient transfer was 
achieved at 30V for one hour (one gel) or 60V for one hour (2 gels).  After transfer, the 
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membrane was rinsed in TBST (1x TBS plus 0.1% Tween-20) then blocked in TBST 
plus 5% milk.  1x TBS is 20mM Tris, 0.14M NaCl, pH 7.6. 
Membranes were incubated with primary antibodies (Table 2.4) in TBST plus 5% BSA 
overnight at 4°C, washed for one hour in TBST, incubated with HRP-conjugated 
secondary antibodies (Table 2.5) in TBST plus 5% BSA for 2 hours at RT, washed for a 
further hour and then developed using the ECL chemiluminescence detection system 
(Amersham) with exposure on autoradiography film (Amersham). 
 
2.8.3 Immunoprecipitation 
 
For analysis of secreted Reelin, IgG-stripped medium was collected after 2 days culture 
from LEC, HUVSMC and LEC/HUVSMC co-culture and centrifuged at 4°C to remove 
dead cells.  
For Reelin immunoprecipitation, samples were pre-cleared with Protein G beads 
(Sigma) for 2 hours at 4°C then centrifuged at 4°C.  The supernatant was incubated with 
1µl mouse anti-human Reelin antibody (Calbiochem) at 4°C overnight with gentle 
rocking.  Protein G beads were then incubated with the sample for 2 hours at 4°C, 
centrifuged and the supernatant removed.  20µl of 2x Laemmli Sample Buffer (LSB) 
was added to the beads, which were then washed gently in PBS, vortexed, boiled at 
95°C for 5 minutes, vortexed again and centrifuged briefly, before running equal 
volumes in a pre-cast NuPAGE Novex 7% Tris-Acetate gel (Invitrogen) with 1x 
NuPAGE Tris-Acetate SDS running buffer (Invitrogen).  The gel was run at 120V, until 
the blue dye ran out the bottom of the gel.  HiMark pre-stained protein standard 
(Invitrogen) loaded in the gel was used to visualize protein separation.  The rest of the 
protocol was completed as for a Western Blot (above). 
Quantification of the signal intensity of Reelin bands in the medium and lysate of LEC 
cultured alone compared to those co-cultured with SMC was carried out using ImageJ.  
The Reelin signal in LEC and LEC/SMC co-cultures was normalized to CD31 by 
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dividing the Reelin value by its respective CD31 value.  A ratio of Reelin in LEC to 
LEC/SMC co-cultures was then calculated by dividing both values by the LEC value. 
 
2.9 Whole Vessel Imaging and analysis 
 
Images were captured using the x20 objective on the Zeiss 510 Scanning confocal 
microscope (Reln-/- and wild-type controls, Efnb2lx/lx;Prox1-creERT2, and R26-mTmg; 
Prox1-creERT2), or the Zeiss 710 Scanning confocal microscope (Apoer2-/-;Vldlr-/-, 
Dab1Scm and wild-type controls).  Pictures were taken along the length of 3 randomly 
chosen collecting lymphatic vessels from the ears of each of 5 Reln-/- mice and 4 wild- 
type controls, 3 Apoer2-/-;Vldlr-/- mice, Dab1Scm mice and 3 of each of their respective 
wild-type controls and 3 Efnb2lx/lx;Prox1-creERT2 mice.   
The images were aligned and processed using Adobe Photoshop CS3 and CS4.   
Thresholding and quantification were performed using MetaMorph Imaging software 
(Molecular Devices) (Figure 2.1 A-A’).  Briefly, the colour channels of the image were 
separated and an exclusive threshold applied to the red (αSMA) channel, so that the 
background was captured by, while all SMC were excluded from, the threshold (Figure 
2.1 A’).  The length of the vessel was measured and divided into quarters (Apoer2-/-
;Vldlr-/-, Dab1Scm and their wild-type controls) or 500 pixel regions (Reln-/- and wild-
type controls), using the line tool.  A region of interest (ROI) was drawn around each 
vessel segment in the original, non-colour separated image (ROIs excluded any 
overlapping blood vessels, which had a high SMC coverage and would skew the 
results)(Arrows, Figure 2.1 A’) and copied onto the red, thresholded channel.  SMC 
coverage was calculated by measuring the percentage thresholded area of the ROI and 
subtracting this from 100%.  In the case of the Reln-/- and wild-type control vessels, the 
total number of 500 pixel regions in each vessel was calculated and divided by 4 to 
represent a quarter of the vessel.   
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The mean SMC coverage for each vessel quarter was calculated and plotted and an 
unpaired Student’s T-test used to calculate the significance of the difference between 
wild-type and mutant mice.   
A similar thresholding technique, but including the whole vessel, was used to quantify 
the percentage of LVYE-1 immunofluorescence. The line tool in MetaMorph was used 
to measure the width of the widest and narrowest vessel points. 
All graphs, calculations and statistics were performed using Prism 5 software.   
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2.10 	  Visualisation and quantification of lymphatic vessel 
function 
 
2.10.1 FITC Dextran injection 
 
For FITC-Dextran injection, 3-week old mice were anaesthetised by IP injection of 75-
100µL Hypnorm (VitaPharma)/Hypnovel (Roche)/PBS mixed in the ratio 1:1:2, using a 
25G needle. Once the mice were deeply asleep (assessed by lack of reaction to a slight 
pressure from forceps on the foot, or no ability to right themselves when turned on their 
side), a minimal volume of FITC-Dextran (Sigma, 8mg/mL in PBS) was injected into 
the hindlimb footpads (n = 5 each wild-type and Reln-/-), or intra-dermally into the ears 
(n = 7 each wild-type and Reln-/-).  The mice were culled after 15 minutes by cervical 
dislocation.  The skin was removed by using scissors to make an incision around the 
waist of the animal and then gently peeling it away.   The hindlimb lymphatic vessels 
were imaged using a Leica stereomicroscope and the Planapo 0.63x objective at 100x 
magnification.  The images were acquired using the complementary computer software 
(Leica).  Ears were processed as for immunofluorescence. 
  
2.10.2 Whole body imaging 
 
The back legs and hindquarters of 3-week old mice were shaved and the remaining hair 
removed by application of Veet hair removal cream one day prior to the procedure.   
To image the lymphatic flow, the mice (n = 4 each wild-type and Reln-/-) were first 
anaesthetised using Isofluorane-Vet 100% Inhalation Vapour (Merial) in the chamber of 
a Xenogen XGI-8 Gas Anaesthesia System.  Once deeply asleep, the mice were 
transferred to the IVIS Spectrum Whole Body Imaging Chamber (Caliper Life 
Chapter 2. Materials and Methods 
 104 
Sciences) and positioned so that their noses were inside the anaesthesia nose cone.  2µL 
of ICG dye (Sigma, 1% in dH2O) was injected into the footpad.  The injection site was 
covered with black tape and the door to the chamber shut.  Image acquisition was 
started immediately, using Living Image 3.0 software (Caliper Life Sciences).  The 
settings were as follows:  Exposure: 2, Binning: 8, F/stop: 2, Excitation wavelength: 
745, Emission wavelength: 840, Field of View (FOV): B, Height: 0.3cm.  The dynamic 
distribution of the ICG was monitored over time by sequential acquisition of 70 images, 
with a 0 second delay between acquisitions resulting in one image every 5-6 seconds.  
This is the maximum speed of the system. 
For qualitative analysis, the accumulation / lack of accumulation of fluorescence within 
the lymph node at the end of imaging provides a first readout.  In order to quantify the 
efficiency of lymphatic function, a small region of interest (ROI) was drawn around the 
vessel, approximately half way between the knee and the lymph node.  The ROI was 
copied to all images in the sequence and fluorescence intensity measurements taken 
using the ‘ROI measurements’ tool. For a given animal the same ROI was used for all 
measurements, although between mice, the position of the ROI varied depending on 
their positioning within the image frame.  Fluorescence intensity was expressed in 
‘Efficiency’ units, as recommended by the manufacturer of the imaging system.  This is 
the ratio between the number of photons used for excitation over the number of emitted 
photons, expressed as a percentage.  It gives a measurement of signal intensity that is 
independent of the acquisition parameters (exposure, binning and F-stop) and is related 
to the local concentration of dye, so can thus be used as a quantitative measurement of 
lymphatic function. 
 
2.10.3 Evans Blue injection 
 
After IVIS spectrum imaging, the mice were kept anaesthetised for a further 5 minutes, 
while 2µL Evan’s Blue dye (2%; Sigma) was injected into the other footpad (n = 4 
wild-type and n = 5 Reln-/-).  After 5 minutes, the mice were culled by cervical 
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dislocation.  The lymph nodes were dissected out, by first removing the skin, then using 
forceps to hold one end of the lymph node and pulling gently to remove it.  Any excess 
tissue was removed, and the lymph nodes put in an Eppendorf tube with 5µL 
formamide at 60°C overnight.  The following morning, the absorbance of the 
formamide was measured at 620nm, using a nanodrop.   
 
2.11 Human phospho-kinase array 
 
To identify novel downstream components of the Reelin signalling pathway, the 
Proteome Profiler Human Phospho-Kinase Array Kit (R&D Systems) was used.  
LEC and HUVSMC were cultured as above.  Prior to protein stimulation, cells were 
washed with PBS, serum starved overnight in serum free Endothelial Cell Growth 
Medium plus 0.2% BSA plus supplements (LEC) or serum free DMEM + 0.2% BSA 
(HUVSMC), then washed twice in starvation medium and incubated for a further 2 
hours.  To stimulate the cells, either Full-Length Reelin, Control DMEM (both 50% 
total medium), 1µg/ml mouse recombinant Reelin fragment (R&D systems), 50ng/ml 
VEGF-C (LEC; R&D systems) or 50ng/ml recombinant rat PDGF-BB (HUVSMC; 
R&D systems) was added to the culture medium for 20 minutes at 37°C.  
The phosphoarray was carried out as per the manufacturer’s instructions.  Briefly, after 
protein stimulation, LEC or HUVSMC were rinsed with PBS and then solubilised with 
Lysis Buffer 6 at 1 x 107 cells/mL.  The membranes were blocked for one hour at RT 
and then incubated with cell lysate, diluted in Array Buffer 1, overnight at 4°C on a 
rocking platform.  The membranes were then washed for 3 x 10 minutes in Wash 
Buffer, incubated with Detection Antibody A or B for 2 hours at RT then washed for a 
further 3 x 10 minutes.   The membranes were then incubated with Streptavidin-HRP 
for 30 minutes at RT, before another 3 x 10 minutes washes, and development using the 
ECL chemiluminescence detection system (Amersham) with exposure on 
Chapter 2. Materials and Methods 
 106 
autoradiography film (Amersham).   The key provided with the kit (appendix, Figure 
8.1) allowed identification of protein kinases with increased phosphorylation levels.  
 
2.12 Timelapse analysis of Reelin effect on HUVSMC motility 
 
A 24-well plate was coated with either PBS, 2µg/mL FN (Sigma), 9µg/mL recombinant 
mouse Reelin, 1µg/mL recombinant mouse Reelin, Full length Reelin or control 
DMEM (3 wells per treatment condition) and left on the shaker at 4°C overnight.  The 
next day, the wells were washed with PBS and then 7.5x104 HUVSMC were plated per 
well, in SMC culture medium.  After 6 hours, when the cells had attached to the plate, 
they were washed twice with DMEM plus 0.5% FBS and then incubated with 500µL 
DMEM plus 0.5% FBS.  The cells were imaged using a Zeiss Axio Observer Inverted 
microscope every 4 minutes for 4 hours, using a x10 objective and imaging one field of 
view for each well.  Following acquisition of the data, 20 cells from each well were 
tracked using Metamorph software.  Briefly, gridlines were drawn over the image stack, 
so as to divide the picture into 20 regions.  From each region, the cell closest to the 
centre that did not migrate out of the field of view over the course of the timelapse was 
selected for tracking (Figure 2.2).  Each cell was tracked manually using the ‘track 
point’ tool and the data exported to an Excel file.  The total distance each cell migrated 
was calculated in Excel, and the final data was copied into Prism for statistical analysis.   
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Figure 2.2 Cell tracking.   
Time-lapse aquisitions were opened in Metamorph as ‘stack’ files.  A grid was drawn 
over the image using the region tool, identifying 20 equal sized squares.  The cell 
closest to the centre of each square (that didn’t leave the frame over the course of the 
acquisition) was tracked manually, using the ‘track point’ tool (tracks shown by 
coloured lines).  Data was exported to excel and the total distance travelled by each cell 
calculated. 
 
2.13 Adhesion assay of Reelin effect on SMC adhesion 
 
Wells of a non-tissue culture treated 96 well plate were coated with either PBS, 2µg/mL 
FN (Sigma), 9µg/mL or 10µg/mL recombinant mouse Reelin, 1µg/mL recombinant 
mouse Reelin, Full length Reelin or control DMEM and left on the shaker at 4°C 
overnight.  The next day, the plate was washed with PBS, then 5X104 HUVSMC were 
plated in each well in DMEM plus 2% FBS.  After 3-4 hours, the medium was 
removed, the cells washed once in PBS and then fixed with 0.5% crystal violet solution 
(2.5g crystal violet (Sigma) in 500ml 25% methanol) for 8 minutes on a shaker.  After 
this, the plate was washed thoroughly in tap water and air-dried overnight.  Next, the 
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cells were solubilised in 100µL 0.1M sodium citrate solution (14.705g sodium citrate 
(Sigma) in 500mL 50% ethanol) and the absorbance was read at OD550nm.  This 
experiment was carried out once with 9µg/mL Reelin (3 wells per treatment condition) 
and once with 10µg/mL Reelin (3 wells per treatment condition).  No difference was 
observed between the two Reelin concentrations. 
 
2.14 Chemotaxis assay of Reelin effect on SMC directional 
migration 
 
0.75 x105 Smooth muscle cells were seeded in 100µl serum depleted endothelial cell 
growth medium (1% FCS, supplemented with HC500 and hEGF-5) in the top well of a 
6.5mm Transwell with 8µm pore polycarbonate membrane insert (Corning) in a 24 well 
plate. 600µl untreated serum depleted endothelial cell growth medium, serum depleted 
medium supplemented with Full-length Reelin (1:20) or Control supernatant (1:20) or 
48hr LEC-conditioned serum depleted medium was added to the lower chamber and the 
assay was incubated for 8-8.5 hours at 37°C.  After this time, the medium was aspirated 
from the inserts and they were transferred to clean wells containing 400µl Cell Stain 
Solution (Cell Biolabs) and incubated for 10 minutes on a rocker at room temperature.  
Inserts were then washed several times with water and cells removed from the inside of 
the insert by wiping with a damp cotton swab.  After air-drying, the inserts were imaged 
using a Leica stereomicroscope and the Planapo 0.63x objective at 16x magnification.  
Images were opened in Metamorph and 5 regions of interest drawn in the well.  An 
exclusive threshold was applied to capture everything except the migrated cells and the 
thresholded area was measured.  The threshold was set individually for each ROI to 
compensate for uneven light distribution over the image; ie an accurate threshold for 
ROI 1 may not have been accurate for ROI 5 (Figure 2.3). The mean thresholded area 
from all five ROIs was calculated and subtracted from 100% to give the area covered by 
migrated SMCs, representing SMC density.   
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Figure 2.3 Quantification of SMC density after chemotaxis assay.   
The image was colour separated the green channel was set to monochrome.  5 equally 
spaced regions of interest (ROI; white boxes) were drawn around the insert.  An 
exclusive threshold (orange) was applied individually to each ROI to compensate for 
unequal light distribution.  Here, the threshold is set for ROI 1 (dashed box), and is 
inaccurate for ROI 2, 3 and 5, whose thresholds were set independently.  Percentage 
thresholded area was measured for each ROI and the mean was calculated and 
subtracted from 100, to leave % coverage by SMC, representing SMC density. 
 
2.15 Statistical Analysis 
 
P values for experiments shown in Figures 4.8 D, 5.1 C-D, 5.2 C, 5.6 B, 6.2 D-E, 6.4 D, 
6.8 A-B and 6.9 were calculated using unpaired two-tailed Student’s T-test.
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Chapter 3. Characterisation of dermal collecting 
lymphatic vessel differentiation events 
 
3.1 Smooth Muscle Cell Recruitment and LYVE-1 
Downregulation 
 
Upon sprouting from the blood vasculature, lymphatic vessels form a LYVE-1 positive 
primary plexus, which is then remodelled into a hierarchical network of collecting 
lymphatic vessels and capillaries.  One of the earliest steps in the remodelling of the 
lymphatic vasculature is the formation of luminal valves in the collecting lymphatic 
vessels, a process that requires Integrin-α9 and its extracellular matrix ligand, 
Fibronectin EIIIA (Bazigou et al., 2009), EphrinB2 (Makinen et al., 2005) and FoxC2 
(Petrova et al., 2004).  The events and gene expression changes involved in the early 
steps of mesenteric lymphatic collecting vessel differentiation have recently been 
described (Norrmen et al., 2009).  However, the timing of these events is temporally 
distinct in different tissues and the sequence of later events in dermal lymphatic 
collecting vessel maturation, such as LYVE-1 down-regulation, SMC recruitment and 
extracellular matrix deposition have yet to be described.  
 
3.1.1 Smooth Muscle Cell recruitment to prospective lymphatic collecting 
vessels 
 
Mouse ear-skin allows clear visualisation of the lymphatic network in whole-mount 
tissue, and is thus a useful model for studying postnatal lymphatic remodelling.  To 
investigate the timing of SMC recruitment to lymphatic collecting vessels we used 
antibodies against α-smooth muscle actin (αSMA) and desmin, markers of SMC and 
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pericytes respectively.  In the ear, the dermal lymphatic plexus develops by sprouting 
and is initially uniformly LYVE-1 positive.  This continues throughout the first weeks 
of postnatal life.  By postnatal day (P)12 LYVE-1 was starting to be down-regulated in 
the lymphatic plexus, often with no corresponding SMC recruitment (arrows, Figure 3.1 
A-A’’’), although sometimes SMC could be found loosely attached to the vessels at this 
stage (data not shown).  At P14 the developing collecting vessels acquired SMCs, 
which became established around the vessels predominantly in areas of low/no LYVE-1 
expression (Figure 3.1 B-B’’’), and by P16 lymphatic collecting vessels were easily 
identified by low levels of LYVE-1 expression and the regular, but discontinuous 
coverage of SMC that characterises mature collecting vessels (Figure 3.1 C-C’’’). 
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Figure 3.1 Smooth muscle actin as a marker of SMC recruitment to lymphatic 
collecting vessels.   
(A-C’’’) Immunofluorescence of whole-mount ear-skin at indicated developmental 
stages with antibodies against LYVE-1 (green), αSMA (red) and PECAM-1 (green).  
Arrows in A indicate areas of LYVE-1 downregulation prior to SMC recruitment.  
Scale bars = 50µm. 
 
3.1.2 Differential expression of smooth muscle cell / pericyte markers in 
blood and lymphatic vessels 
 
To ensure that we were visualising all lymphatic SMC and to control for the possibility 
that not all lymphatic smooth muscle cells would be α-smooth muscle actin positive, we 
repeated the time-course using antibodies against the vascular pericyte markers desmin 
and NG2.  In the blood vasculature, desmin has been published as an early marker of 
differentiating SMC, whereas αSMA is a late marker (Hughes and Chan-Ling, 2004), 
although there are differences in vascular pericyte marker expression between different 
tissues (Armulik et al., 2005).  However, we found that while the number of desmin 
positive SMC increased from P12 to P16 (Figure 3.2 A-C’’’), there were always fewer 
desmin positive SMC around the vessel than at the corresponding stage of the αSMA 
time-course, suggesting that in contrast to the blood vascular system, desmin is not a 
marker of early differentiating lymphatic SMC.   
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Figure 3.2 Desmin is not a marker of early lymphatic SMC.   
(A-C’’’) Immunofluorescence of whole-mount ear-skin at indicated developmental 
stages with antibodies against LYVE-1 (green), Desmin (red) and PECAM-1 (blue).  
Scale bars = 50µm. 
 
We also looked at the vascular pericyte marker NG2 (Gerhardt and Betsholtz, 2003), in 
both the immature and mature lymphatic vasculature but found that while staining could 
be seen around the blood vessels at both P15 and P21 (Arrows Figure 3.3 A-B’), none 
was visible around the lymphatic vessels (Arrowhead, Figure 3.3 A-B’), suggesting that 
NG2 is not expressed in lymphatic smooth muscle.  However, we cannot rule out the 
possibility of low expression that this antibody is not sensitive enough to detect, since 
extra permeabilisation steps (see Materials and Methods) were necessary to enable 
detection even in the blood vasculature using this antibody. 
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Figure 3.3 NG2 is not expressed in lymphatic SMC. 
(A-B’) Immunofluorescence of whole-mount ear-skin at indicated developmental 
stages, using antibodies against NG2 (green), αSMA (red) and podoplanin (blue).  Scale 
bars = 50µm. 
 
3.1.3 LYVE-1 down-regulation is associated with SMC recruitment 
 
In agreement with previous expression data suggesting that SMC recruitment plays a 
direct role in LYVE-1 down-regulation (Tammela et al., 2007), we found that LYVE1 
mRNA was down-regulated in dermal LEC that had been co-cultured with venous SMC 
for 48 hours (Figure 3.4 A).  However, our expression data suggests that LYVE-1 
down-regulation occurs prior to SMC recruitment in vivo (Figure 3.1 A-A’’’), and we 
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also readily observed LYVE-1 positive LEC in direct contact with SMC, even after 72 
hours in culture, with no obvious decrease in LYVE-1 expression compared to LEC 
cultured alone (Figure 3.4 B-C).  Together these data suggest that while it is likely that 
LYVE-1 down-regulation is associated with the presence of SMC, it may not be a direct 
consequence of SMC contact. 
 
 
Figure 3.4 Co-culture of LEC and SMC does not reduce LYVE-1 protein levels, 
but LYVE1 mRNA is reduced. 
(A) RT-PCR data showing LYVE1 mRNA levels normalised to PECAM1 in LEC co-
cultured with SMC for 48 hours, relative to LEC cultured alone.  Mean fold change of 2 
experiments ± SEM is shown. Immunofluorescence of LEC (B) and LEC and SMC (C) 
cultured for 72 hours with antibodies against LYVE-1 (green) and αSMA (red) and 
DAPI staining. Scale bars = 60µm 
 
3.1.4 Loss of LYVE-1 does not affect collecting lymphatic vessel 
development 
 
Despite being one of the most commonly used lymphatic markers and the earliest 
marker of lymphatic commitment (Tammela and Alitalo, 2010), the function of LYVE-
1 in the lymphatic system is unknown.  Beginning with polarised expression in the 
venous endothelium at E9, earlier even than induction of Prox1 expression (Alitalo et 
al., 2005), LYVE-1 continues to be expressed in the lymphatic plexus, until its eventual 
down-regulation in differentiated collecting vessels, suggesting a possible role in 
specification or maintenance of lymphatic fate. 
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Previously published studies of Lyve1-/-mice (Huang et al., 2006, Gale et al., 2007) 
concentrated on analysis of the lymphatic capillary network and function.  However, 
since we had observed that SMC were preferentially recruited to areas of low/no 
LYVE-1 expression in prospective collecting lymphatic vessels, we investigated the 
possibility that LYVE-1 could act as a negative regulator of lymphatic remodelling and 
SMC recruitment.   
To test this hypothesis, we stained Lyve1-/- and heterozygous mice for PECAM-1, 
αSMA and VE-cadherin.  With this set of markers, we could see not only the smooth 
muscle cell coverage of the collecting lymphatic vessels, but also the overall vessel 
morphology, luminal valve morphology and the individual cell shape, since both 
PECAM-1 and VE-cadherin stain endothelial cell junctions (Baluk et al., 2007) and 
PECAM-1 also clearly delineates the leaflets of the luminal valves (Bazigou et al., 
2009).   
We chose to look initially at P21 mice, because at this stage the collecting lymphatic 
vessels are fully developed and any changes to SMC coverage or cell morphology 
would be visible.  However, we saw no striking defects (data not shown).  Since Lyve1-/- 
mice are viable, we made preliminary observations in 6 week old adult mice, in which 
the dermal lymphatic vasculature is fully matured, so that we could detect any defect 
that may have become increasingly severe with age.  However, even at 6 weeks we 
could still see no obvious phenotype in the collecting vessel network of the Lyve1-/- 
mice.  The overall vessel morphology appeared normal (Figure 3.5 A-D), and we could 
observe no difference in the SMC coverage of Lyve1-/- and heterozygous mice (Figure 
3.5 A and C).  It was possible that LYVE-1 could have been involved in the change of 
endothelial cell morphology between oak-leaf shaped cells in lymphatic capillaries, to 
brick shaped cells in the collecting lymphatic vessels.  However, staining with both VE-
cadherin and PECAM-1 revealed no defects in cell morphology in the lymphatic 
capillaries or collecting vessels of Lyve1-/- mice (Figure 3.5 A-D).  Finally, the luminal 
valves also appeared normal in Lyve1-/- mice (data not shown). 
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Figure 3.5 Lyve1 mutant mice have no detectable phenotype 
Immunofluorescence of Lyve1 heterozygous (A-B) or mutant (C-D) mice at 6 weeks, 
with antibodies against VE-cadherin (green), αSMA (red) and PECAM-1 (blue).  Scale 
bars = 50µm. 
 
In the absence of any striking phenotype in the lymphatic collecting vessels, we did not 
follow up these preliminary observations for a more thorough characterisation of the 
phenotype of collecting vessels in Lyve1-/- mice, so we cannot rule out the possibility of 
more subtle deficiencies or age-dependant defects occurring in older mice.  At least 
from these preliminary experiments, it does not seem that LYVE-1 is a negative 
regulator of SMC recruitment, or involved in the regulation of lymphatic endothelial 
cell morphology.  
Chapter 3. Characterisation of dermal collecting lymphatic vessel differentiation events 
 118 
3.2 Extracellular matrix deposition 
 
In contrast to the original dogma that lymphatic vessels, particularly lymphatic 
capillaries, have no or very rudimentary basement membranes (BMs), recent studies 
have identified a discontinuous basement membrane around dermal lymphatic 
capillaries, comprising Laminin (but not Laminin-α5), Perlecan, Collagen IV, Collagen 
XVIII and Nidogen (Vainionpaa et al., 2007, Pflicke and Sixt, 2009). Pflicke et al. also 
describe a difference between the basement membrane of lymphatic capillaries and 
collecting vessels: while the BM of lymphatic capillaries is perforated to allow entry of 
dendritic cells into lymphatic vessels independently of integrin-mediated adhesion, the 
basement membrane of collecting vessels is continuous and more extensive (Pflicke and 
Sixt, 2009). 
To establish whether we could use the deposition of basement membrane proteins 
around prospective collecting lymphatic vessels as a marker of collecting vessel 
differentiation, we examined the expression of Collagen IV, Laminin-α5 and 
Fibronectin in ear-skin between P12 and P18.   
 
3.2.1 Collagen IV is deposited by LEC, prior to SMC recruitment 
 
Interestingly, the expression patterns and timing of deposition of Collagen IV and 
Laminin-α5 were very different.  Collagen IV started to be deposited around 
prospective collecting lymphatic vessels prior to LYVE-1 down-regulation and SMC 
recruitment (arrows, Figure 3.6 A-B’’’), suggesting that Collagen IV was 
predominantly expressed by LEC, and expression remained high throughout collecting 
lymphatic vessel development (Figure 3.6 C-C’’’).   
 
Chapter 3. Characterisation of dermal collecting lymphatic vessel differentiation events 
 119 
 
Figure 3.6 Collagen IV deposition around prospective lymphatic collecting vessels. 
(A-C’’’) Immunofluorescence of whole-mount ear-skin at indicated developmental 
stages using antibodies against Collagen IV (green), αSMA (red) and LYVE-1 (blue).  
Arrows in A-B show collagen IV deposition in LYVE-1 positive vessels, prior to 
LYVE-1 down-regulation and SMC recruitment.  Scale bars = 50µm. 
 
In the adult, we could see Collagen IV expression in the lymphatic capillaries, but it 
was expressed to a much lower level than in the collecting lymphatic vessels (Figure 3.7 
A-B’).  This result is in line with those of Pflicke et al. and gives rise to the possibility 
that either the SMC also contribute directly to Collagen IV deposition in adult 
collecting lymphatic vessels or that SMC increase Collagen IV deposition by LEC.  The 
latter hypothesis is supported by a recent study demonstrating both in vitro and in vivo 
that pericyte recruitment to developing blood vessels can increase ECM (including 
Collagen IV) deposition by endothelial cells (Stratman et al., 2009a).  We observed 
what looks like the outline of a Collagen IV-positive SMC in the adult collecting vessel 
(Figure 3.7 A-A’), suggesting that both LEC and SMC contribute to Collagen IV 
expression in the mature collecting lymphatic vessels. 
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Figure 3.7 Collagen IV expression in the mature lymphatic vasculature.   
(A-B’) Immunofluorescence of whole-mount ear-skin at P21 in collecting vessels (A-
A’) and capillaries (B-B’) with antibodies against Collagen IV (green), podoplanin (red) 
and LYVE-1 (blue).  Arrow in A indicates Collagen IV positive SMC.  Scale bars = 
50µm. 
 
3.2.2 Laminin-α5 is predominantly deposited by SMC, except in luminal 
valves 
 
In contrast to Collagen IV, no Laminin-α5 expression could be detected in the 
prospective collecting lymphatic vessels until SMC were recruited and established 
around the vessel (Figure 3.8 A-C’’’; asterisk, Figure 3.8 A-A’).  However, in line with 
previously published results, we detected Laminin-α5 expression in luminal valves 
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(arrows, Figure 3.8 A-A’, B-B’) (Bazigou et al., 2009).  In mature collecting lymphatic 
vessels, Laminin-α5 staining highlighted the SMC (arrowheads, Figure 3.8 C-C’’), a 
strong indication that, excepting LEC in the luminal valves, these cells are its main 
source.   
 
 
Figure 3.8 Laminin α5 expression in the developing lymphatic system.  
(A-C’’’) Immunofluorence of whole-mount ear-skin at indicated developmental stages 
with antibodes against Laminin-α5 (green), αSMA (red) and LYVE-1 (blue).  Arrow in 
A indicates Laminin-α5 expression in the luminal valves, asterisk indicates LYVE-1 
positive, Laminin-α5 negative immature lymphatic vessel.  Arrowheads in C show 
Laminin-α5 positive collecting lymphatic vessels.  Scale bars = 50µm. 
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3.2.3 Fibronectin is not a specific marker of ECM deposition in the 
lymphatic vasculature 
 
Fibronectin is a major component of the vascular basement membrane.  We examined 
its expression in the developing and mature lymphatic vasculature, in order to establish 
whether we could gain any new insights into lymphatic vessel maturation.  We observed 
a dense network of Fibronectin fibrils in the vasculature and surrounding tissues, but 
could not detect any change in expression between the developing and mature 
lymphatic vasculature (Figure 3.9 A-B’).  Since no specific collecting lymphatic vessel 
maturation events could be related to changes in Fibronectin expression, we concluded 
that Fibronectin is not a useful marker of lymphatic collecting vessel differentiation.  
However, it should be noted that a specific isoform of Fibronectin containing the EIIIA 
domain is expressed specifically in the matrix core of luminal valves at the onset of 
Integrin-α9 expression and is required for proper formation of the valve leaflets 
(Bazigou et al., 2009). 
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Figure 3.9 Fibronectin is not a useful marker of collecting lymphatic vessel 
development.  
(A-B’) Immunofluorescence of whole-mount ear-skin at indicated developmental stages 
using antibodies against Fibronectin (green), αSMA (red) and LYVE-1 (blue).  Scale 
bars = 50µm. 
 
Together, these data show that both LEC and SMC contribute to the formation of the 
basement membrane around lymphatic collecting vessels, and that extracellular matrix 
deposition may be one of the first signs of collecting vessel specification.   
We have summarised these results into a timeline of events leading up to lymphatic 
collecting vessel differentiation (Figure 3.10). 
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Figure 3.10 Timeline of collecting lymphatic vessel development.   
Schematic, summarising the timing of dermal lymphatic collecting vessel differentiation 
events in the ear. Collagen IV deposition occurs just prior to LYVE-1 down-regulation, 
which in turn usually begins prior to SMC recruitment.  Deposition of Laminin-α5 
occurs after SMC are established around the collecting vessels. 
 
3.3 Microarray analysis of lymphatic extracellular matrix  
 
The composition of the lymphatic extracellular matrix and any differences to that of the 
blood vasculature has not been extensively studied.  In order to better characterise the 
lymphatic extracellular matrix, we carried out a microarray study, using RNA samples 
extracted from mouse postnatal mesenteric lymphatic vessels, arteries and veins. 
Previous microarrays have compared the gene expression profiles of cultured primary 
LEC and BEC.  However, using this approach, it is difficult to rule out the possibility of 
time in culture affecting gene expression.  It is also impossible to distinguish between 
arterial and venous gene expression.  Using whole vessels avoided these issues, and also 
allowed for the contribution of both SMC and EC to the lymphatic / vascular 
extracellular matrix.  Furthermore, our in vivo approach allowed for the likelihood that 
the 3D environment and interactions between SMC and EC might affect deposition of 
vascular basement membrane and perhaps expression changes in the genes encoding 
extracellular matrix related proteins. 
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3.3.1 The Affymetrix GeneChip Array System 
 
A microarray is an ideal tool for comparison of gene expression profiles from different 
samples.  The Affymetrix system uses probes designed against exons from both 
established cDNA sequences and predicted gene structures, allowing a comprehensive 
profile of expression data to be generated.  The probes are engineered onto a glass or 
silicone chip (an Affy chip) and then incubated with fluorophore-conjugated, sense-
strand cDNA generated from the RNA samples we supplied.  The cDNA binds to the 
complementary antisense strand of the probe, and after washing off non-specifically 
bound sequences, only strongly bound sequences remain.  The amount of target sample 
bound to each probe will determine the strength of the signal from that spot.  The 
Affymetrix system is a single-channel microarray, which provides intensity data for 
each probe on the dataset, giving a relative abundance compared to the other samples in 
the same experiment that have been processed using the same conditions.  This can be 
expressed as a fold-change in expression for a gene in one sample, compared to the 
same gene in another sample (Figure 3.11).  Further details about analysis of this data 
are given in materials and methods. 
In this experiment, we used a Mouse Exon 1.0 Sense Target (ST) array (Affymetrix).  
This array uses around 4 probes per exon, or about 40 probes per gene, to allow either 
‘exon-level’ or ‘gene-level’ analysis.  The exon-level dataset allows detection and 
analysis of alternative splicing events and differential expression of each exon within a 
gene.  For the purposes of this experiment however, we concentrated on ‘gene-level’ 
analysis.  In this case, all the probes on different exons within a gene are collated into 
one data point, which represents expression of all the transcripts derived from that gene.  
Due to the high number of probes per gene, this array method allows a highly sensitive 
read-out of gene expression and generates statistically robust results. 
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Figure 3.11 Microarray analysis of lymphatic vessels, arteries and veins.  
Lymphatic vessels, arteries and veins were dissected from P6-7 wild type pups and the 
RNA extracted.  Two independent samples of each vessel type were analysed using a 
Mouse Exon 1.0 ST Array (Affymetrix).  Briefly, RNA is amplified, converted to 
cDNA, which is flourophore-conjugated and hybridised to an Affychip.  Readout of the 
array is relative expression of a given gene in each vessel type. 
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3.3.2 Identification of lymphatic specific extracellular matrix related 
genes 
 
Within our dataset we identified several known markers of lymphatic vessels, arteries 
and veins and confirmed that they were up- or downregulated in the expected pattern, 
thus confirming the reliability of our dataset (Table 3.1).  However, since this array 
method does not provide absolute gene expression levels, we cannot rule out the 
possibility of slight cross-contamination across the samples, or from smaller blood 
capillaries and other tissue, such as nerves, which emphasises the importance of 
validating the specificity of target gene expression.   
 
 
 
Gene 
Symbol 
Lymphatic v 
Vein 
Lymphatic v 
Artery 
Artery v Vein 
Lymphatic markers Prox1 5.1 17.8 -3.5 
 Pdpn 2.3 2.8 -1.3 
 Lyve1 2.6 3.6 -1.4 
 Flt4 (Vegfr3) 4.6 3.8 1.2 
 Stab1 1.7 2.0 -1.2 
Blood vessel 
markers 
Vegfc -3.8 -5.4 1.4 
 Figf (Vegfd) -3.3 -1.8 -1.9 
 Flt1 (Vegfr1) -2.7 -1.9 -1.4 
 Pdgfrb -2.0 -1.6 -1.2 
 Vwf -7.6 -4.3 -1.8 
Arterial markers Efnb2* 1.7 -1.1 1.9 
 Hey1 1.2 -1.3 1.6 
 Dll4 1.3 -1.4 1.9 
Venous markers Ephb4* -1.1 1.7 -1.9 
 Nrp2* 1.5 3.5 -2.4 
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Table 3.1 Validation of microarray data: known markers of lymphatic vessels, 
arteries and veins show expected expression.   
The fold change in expression of each gene in lymphatic vessels compared to veins and 
arteries, and arteries compared to veins. A number >0 indicates up-regulation and <0 
indicates down-regulation. Known lymphatic, blood vessel, arterial and venous markers 
are up or down-regulated in the expected pattern. * indicates arterial/venous genes with 
known expression also in the lymphatics. Fold changes represent mean of two 
independent samples 
 
To identify differential expression of extracellular matrix proteins between the 
lymphatic and blood vasculature, we selected all genes that were up- or down-regulated 
in lymphatic vessels compared to arteries and/or veins by a factor of 2 or more and 
carried out a Uniprot search on these genes to identify extracellular matrix proteins. We 
identified 14 genes involved in the formation, composition or degradation of the ECM 
that were expressed at least 2-fold higher in lymphatic vessels compared to arteries or 
veins (Table 3.2), and 15 genes of the same description that were expressed at least 2-
fold higher in arteries and/or veins, compared to lymphatic vessels (Table 3.3).   
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Gene 
Symbol 
Gene Name Lymphatic v 
Vein 
Lymphatic v 
Artery 
Artery v 
Vein 
Egfl6 EGF-like protein 7.5 10.9 -1.4 
Reln Reelin 5.0 1.7 2.9 
Efemp1 Fibulin-3 4.0 5.4 -1.4 
Prelp Prolargin 3.4 3.3 1.0 
Spock3 Osteonectin 3.2 4.5 -1.4 
E330026B
02Rik 
Collagen, Type VI, alpha6 2.9 3.5 -1.2 
Ltbp1 TGFbeta1 binding protein 2.5 1.0 2.4 
Lgals3bp Galectin-3 binding protein 2.4 2.1 1.2 
Thsd4 Thrombospondin, type 1, 
domain containing 4 
2.2 -1.1 2.4 
Adamts19 ADAM metallopeptidase 
with thrombospondin type 1 
motif, 19 
2.1 2.6 -1.2 
Nid2 Nidogen 2 2.1 1.9 1.1 
Fras1 Extracellular matrix protein 
FRAS1 
1.9 3.1 -1.7 
Comp Cartilage oligomeric matrix 
protein 
1.7 2.7 -1.6 
Mmp19 Matrix metalloproteinase 19 1.5 2.1 -1.4 
Table 3.2 Extracellular matrix associated proteins that are up-regulated in 
lymphatic vessels compared to arteries and/or veins.  
Genes associated with extracellular matrix structure, function, assembly or degradation 
that are up-regulated ≥2-fold in lymphatic vessels compared to veins or arteries in an 
Affymetrix GeneChip array.  Fold change represents mean of two independent samples. 
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Gene 
Symbol 
Gene Name Lymphatic v 
Vein 
Lymphatic v 
Artery 
Artery v 
Vein 
Ctgf* Connective tissue growth 
factor 
-2.2 -4.4 2.0 
Spon1* F-spondin -2.1 -3.6 1.7 
Col8a1 Collagen, type VIII, alpha 1 1.4 -3.5 5.1 
Eln* Tropoelastin -2.4 -3.2 1.4 
Adamts8 ADAM metallopeptidase 
with thrombospondin type 1 
motif, 8 
-1.6 -2.7 1.2 
Mamdc2 Mamcan -2.3 -2.7 1.2 
Mmrn2 Emilin-3 -1.8 -2.5 1.4 
Kazald1 Kazal-type serine protease 
inhibitor domain 1 
-1.2 -2.4 2.0 
Acan Aggrecan 1.0 -2.2 2.3 
Mia1* Melanoma inhibitory 
activity protein 
-3.0 -2.2 -1.4 
     
Chad Chondroadherin -5.0 -1.1 -4.5 
Adamts18 ADAM metallopeptidase 
with thrombospondin type 1 
motif, 18 
-3.1 1.1 -3.3 
Tnc Tenascin C -2.9 -1.9 -1.5 
Egflam EGF-like, fibronectin type 
III and laminin G domains 
-2.1 -1.7 -1.3 
Adamts2 ADAM metallopeptidase 
with  
-2.1 -2.0 -1.1 
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Table 3.3 Extracellular matrix associated proteins that are up-regulated in arteries 
or veins compared to lymphatic vessels.  
Genes associated with extracellular matrix structure, function, assembly or degradation 
that are up-regulated ≥2-fold in veins or arteries compared to lymphatic vessels in an 
Affymetrix GeneChip array. * indicates genes that are up-regulated ≥2-fold in both 
arteries and veins compared to lymphatic vessels. Fold changes represent mean of two 
independent samples 
 
We validated these results by examining lymphatic vs blood vascular expression by 
either immunostaining of whole-mount ear skin, or immunoblotting.  Due to a lack of 
suitable antibodies, we were only able to obtain in vivo expression data for Efemp1.  In 
corroboration of the microarray data that showed Efemp1 expression as 4-5 fold higher 
in lymphatic than blood vessels (Table 3.2), we observed Efemp1 expression 
specifically in the lymphatic vasculature (arrowhead, Figure 3.12 A-A’), while the 
blood vasculature remained negative (arrows, Figure 3.12 B-B’).  We also confirmed 
preferential expression of Efemp1, Spock3 and Nid2 in LEC compared to BEC by 
immunoblotting (Figure 3.12 C-D), thus further validating the microarray results and 
strengthening the identification of new lymphatic specific basement membrane 
components, which may be of interest for future studies. 
Our microarray results not only confirm that the lymphatic extracellular matrix is more 
complex than originally thought, but also identify several differences in gene expression 
between the extracellular matrices in the lymphatic and blood vasculature, allowing 
speculation that some of the genes highly expressed in the lymphatic extracellular 
matrix may be of specific functional importance. 
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Figure 3.12 Validation of extracellular matrix genes identified as upregulated in 
lymphatic compared to blood vessels in the array.   
(A-B’) Immunofluorescence of whole-mount ear-skin at P21 with antibodies against 
Efemp-1 (green), αSMA (red) and podoplanin (blue).    Arrowhead in A indicates 
Efemp1 positive lymphatic vessel, while arrow in B points to Efemp-1 negative blood 
vessel.  (C-D) Immunoblot with indicated antibodies, showing increased expression of 
Efemp-1 (C), Nid2 and Spock3 (D) in cultured LEC compared to BEC.  α-tubulin was 
used as a loading control in both cases. 
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Chapter 4. Reelin expression in the vasculature 
 
4.1 Identification of Reelin as a lymphatic specific extracellular 
matrix protein 
 
From our microarray, we identified Reln as a gene that was expressed 5-fold higher in 
lymphatic vessels than veins (Table 3.2).  Reelin is a large extracellular matrix protein, 
whose expression and function has been extensively studied in the developing and 
mature central nervous system (Rice and Curran, 2001, Forster et al., 2010).  The 
lymphatic-specific Reelin expression is consistent with in vivo data from rats and 
humans, where Reelin immunoreactivity was described in lymphatic, but not blood 
vessels (Samama and Boehm, 2005).  However, despite its previous identification in 
non-neural tissues, little is known about Reelin function outside of the central nervous 
system.  We decided that this would be an interesting candidate to follow up on, 
particularly since some human patients with a RELN mutation suffer from 
lymphoedema (Hong et al., 2000), which could potentially give our study clinical 
relevance.   
 
4.1.1 Reelin expression in lymphatic development 
 
We chose to analyse Reelin expression in the dermal lymphatic vasculature at three 
stages: embryonic, P14 and P21, so that we could clearly visualise expression in the 
immature plexus (E16), vessels that are actively undergoing remodelling (P14) and in 
the mature lymphatic vasculature (P21).  The timing of development differs between 
tissues, so the developmental stage of the vasculature is not comparable between tissues 
at the same age; for example P0 in the dorsal skin is probably equivalent to P15 in the 
ear, and at P7 the mesenteric lymphatic vessels are fully mature, while the ear still 
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resembles the primitive plexus.  For this reason, it is important to consider rather the 
developmental stage of the tissue of interest, rather than the age of the animal.  
While Reelin immunoreactivity was readily detected from embryonic stages in the 
LYVE-1 positive, PECAM-1 positive lymphatic endothelium (arrowhead, Figure 4.1 A-
A’), we could not identify any Reelin expression in LYVE-1 negative, PECAM-1 
positive blood vessels (arrows, Figure 4.1 A-A’).   
 
Figure 4.1 Reelin expression in the developing lymphatic vasculature. 
Immunofluorescence of whole-mount dorsal skin (A-A’) or ear-skin (B-B’) at indicated 
developmental stages, using antibodies against Reelin (green), LYVE-1 (red) and 
PECAM-1 (blue; A).  Scale bars = 50µm. 
 
Reelin expression appeared intracellular in the immature lymphatic vasculature, even 
postnatally (arrow, Figure 4.1 B-B’) and we confirmed its sub-cellular localisation by 
co-staining with Golgi and endoplasmic reticulum (ER) markers.  Consistent with 
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reports that Reelin resides in the neuronal ER prior to secretion (Tinnes et al., 2011), we 
found that intracellular Reelin was mainly located in the ER (arrows, Figure 4.2 A-A’’), 
and to a much lesser extent in the Golgi (arrows, Figure 4.2 B-B’’). 
 
Figure 4.2 Sub-cellular Reelin localisation.   
Immunofluorescence staining of whole-mount ear-skin at indicated developmental 
stages with antibodies against the ER marker, Erp57 (green; A-A’), the Golgi marker, 
Golph 4 (green, B-B’), Reelin (red) and PECAM-1 (blue).  Images are single confocal 
z-stacks to show co-localisation. Arrows indicate areas of co-localisation.  Scale bars = 
15.87µm. 
 
4.1.2 Reelin expression in the mature lymphatic vasculature 
 
Amplification of Reelin immunostaining confirmed specific expression in the mature 
collecting lymphatic vessels and capillaries (Figure 4.3 A-B).  We also observed 
positive staining in scattered single cells in these samples (asterisk Figure 4.3 B), but 
using the secondary antibody only revealed this to be a non-specific artefact of the 
amplification procedure (Figure 4.3 C-C’).  
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Figure 4.3 Reelin continues to be expressed in the mature lymphatic vasculature.   
Immunofluorescence staining of whole-mount ear-skin at P21 using antibodies against 
Reelin (amplified, green; A-B) or secondary antibody only (green; C) and PECAM-1 
(red).  Asterisks indicate non-specific signal amplification in scattered cells.  Scale bars 
= 50µm. 
 
Upon amplification, we also detected Reelin expression in the nerves (open arrowhead, 
Figure 4.4 A-A’), as well as low levels of Reelin expression in the veins (arrows, Figure 
4.4 A-B’), but not in the arteries (closed arrowhead, Figure 4.4 A-B’).  It is likely that 
the apparent arterial Reelin expression suggested by the microarray (Table 3.2) is in fact 
due to contamination of the arterial sample with Reelin positive nervous tissue, which is 
not visible without staining, but lies in close apposition to the blood vessels (Figure 4.4 
A-A’). 
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Figure 4.4 Amplification allows detection of weak Reelin signal in nerves and 
veins, but not arteries.   
Immunofluorescence of whole-mount ear-skin in wildtype (A-A’) or Efnb2GFP (B-B’) 
mice using antibodies against Reelin (amplified, green), acetylated α-tubulin (red, A-
A’), GFP (red, B-B’) and PECAM-1 (blue).  Arrow in A indicates weakly Reelin-
positive vein, empty arrowhead in A shows Reelin positive nerve and filled arrowhead 
shows close apposition of arteries and nerves.  Arrow in A indicates weakly Reelin 
positive vein, filled arrowhead shows Reelin negative artery and empty arrowhead 
points to GFP-expressing arterial EC nuclei.  Scale bars = 50µm. 
 
Closer examination of endogenous Reelin expression in the mature lymphatic 
vasculature revealed interesting differences in Reelin localisation between collecting 
lymphatic vessels and capillaries.  We observed intense punctuated, perinuclear Reelin 
staining in the capillaries (Figure 4.5 A-A’), whereas in the collecting vessels, Reelin 
immunoreactivity was weaker and more diffuse (Figure 4.5 B-B’).  This suggested that 
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the lymphatic endothelial cells might secrete Reelin into the extracellular matrix of the 
collecting lymphatic vessels, while it is retained within the endothelium in capillaries.  
 
 
Figure 4.5 Reelin is localised differently in collecting vessels and capillaries. 
Immunofluorescence of whole-mount ear-skin at P21 using antibodies against Reelin 
(green), αSMA (red) and LYVE-1 (blue).  Scale bars = 50µm (A,B) and 16.67µm (A’, 
B’) . 
 
We tested this hypothesis by immunofluorescence and amplification of Reelin signal in 
non-permeabilised tissue, so that we only visualised extracellular Reelin.  We observed 
very low Reelin staining around the lymphatic capillaries (arrow, Figure 4.6 A-A’), 
suggesting that the expression we had previously observed was indeed intracellular, 
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while much greater immunoreactivity was retained around the lymphatic collecting 
vessels (Figure 4.6 B-B’), which is indicative of secretion into the extracellular matrix. 
 
 
Figure 4.6 Reelin is secreted from the collecting vessels, but not the capillaries. 
Immunofluorescence of non-permeabilised whole-mount ear-skin using antibodies 
against Reelin (green, amplified) and PECAM-1 (red).  Arrowhead indicates low-level 
of Reelin secretion from lymphatic capillaries.  Scale bar = 50µm. 
 
Taken together, these data indicate that Reelin expression is specific to the lymphatic 
endothelium in both the developing and mature dermal vasculature in vivo, but it is only 
efficiently secreted into the extracellular matrix of the collecting lymphatic vessels. 
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4.2 Interaction between LEC and SMC leads to release and 
processing of Reelin 
	  
We confirmed that lymphatic endothelial specific Reelin expression was maintained in 
vitro by qPCR analyses of RNA extracted from cultured primary human lymphatic 
endothelial cells (LEC), blood endothelial cells (BEC), umbilical vein- (HUV-) and 
aortic smooth muscle cells (HAoSMC) (Figure 4.7).  This is consistent with the results 
of an earlier microarray, which identified Reln expression in cultured LEC, but not BEC 
(Petrova et al., 2002).   
 
 
Figure 4.7 Lymphatic specificity of Reelin expression is maintained in vitro.   
RT-PCR data showing RELN expression in 3 independent samples of LEC, BEC, 
HUVSMC and 2 of HAoSMC, relative to LEC1.  Mean ± SEM is plotted. 
 
Immunoprecipitation and Western blotting analysis of LEC and SMC using an antibody 
that recognises an epitope at the N-terminus of Reelin (Figure 4.8 A) also confirmed 
that Reelin protein is only produced by LEC in vitro (Figure 4.8 B). 
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Figure 4.8 SMC enhance Reelin secretion from LEC and proteolytic processing. 
(A) Schematic of Reelin cleavage products, adapted from Jossin et al. (2007).  Asterisk 
indicates antibody binding site.  Arrow and arrowheads indicate cleavage products 
detected by the antibody.  Analysis of whole cell lysate (B) and medium (C) of LEC 
and SMC cultured either alone or together, by immunoprecipitation and Western blot 
with antibodies to Reelin. Arrow indicates full length Reelin, arrowheads indicate 
cleavage products, eg 370 kDa and 180 kDa fragments in (C) . Analysis of whole cell 
lysate in (B) by Western blot with antibodies to CD31/PECAM-1 (for LEC) and aSMA 
(for SMC) show that equivalent numbers of cells were used. (D) Quantification of full-
length Reelin protein levels, normalised to CD31/PECAM-1, in whole cell lysate (black 
bars) and culture medium (grey bars) of LEC cultured alone or together with SMC. 
Data represent mean (n= 3 experiments) ± SEM. (E) Quantification of Reelin N-
terminal cleavage products, normalized to CD31/PECAM-1, secreted into the medium 
from LEC (black bars) and LEC+SMC co-cultures (grey bars).  Data represent mean (n 
= 2 experiments) ± SEM. 
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We focussed on our observation that Reelin is secreted from the LEC of collecting 
vessels, but not the capillaries, as a way to investigate the mechanism of Reelin 
signalling in the lymphatic system.  Since one of the main morphological differences 
between collecting vessels and capillaries is the presence of SMC around the former, we 
speculated that the release of Reelin into the extracellular matrix could be related to the 
recruitment of SMC.  To test this, we analysed Reelin production and secretion by LEC 
that were cultured either alone or together with SMC.  Examination of the whole cell 
lysate by immunoprecipitation and Western blot analysis revealed that LEC produced 
the full-length 450 kDa Reelin polypeptide (arrow, Figure 4.8 B).  Analysis of the 
medium from LEC cultured alone showed that the full-length protein was secreted 
(arrow, Figure 4.8 C) and partially cleaved within the C-terminus, as described 
previously (Jossin et al., 2007), to give rise to another fragment of 370 kDa (closed 
arrowhead, Figure 4.8 C).  Upon LEC co-culture with SMC, secretion of the full-length 
Reelin polypeptide was increased, with a corresponding increase in production of the 
370 kDa fragment (Figure 4.8 C-E), although the production of Reelin was not affected 
(Figure 4.8 D).  There is also a second processing event within the N-terminus, which 
gives rise to a 180 kDa fragment (open arrowhead, Figure 4.8 C, E), as well as the 190 
kDa central Reelin fragment, which is capable of binding and activating the Reelin 
receptors ApoER2 and VLDLR (Jossin et al., 2007). 
Incubation of SMC with LEC conditioned medium suggested that SMC can mediate the 
second N-terminal processing event (Figure 4.9 A). Although we sometimes also 
observed the 180kDa Reelin fragment in LEC cultured alone (Arrowhead, Figure 4.9 
C), we were unable to determine whether LEC are also able to mediate this cleavage 
event in some cases, or whether this cleavage was due to the presence of contaminating 
BEC in our LEC culture, which may produce proteases that are not expressed in LEC.  
No increase in Reelin secretion or processing was seen when LEC were cultured in 
SMC conditioned medium (Figure 4.9 B) or on fibroblast-derived extracellular matrices 
(Figure 4.9 C), suggesting that the changes we observed upon LEC/SMC co-culture 
required the presence of SMC.  Apparently lower Reelin levels in LEC cultured on a 
fibroblast matrix than on FN alone may reflect a reduced requirement for endogenous 
matrix protein secretion when a more complete matrix is provided exogenously, 
although this hypothesis would require further experimental evidence to confirm. 
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Figure 4.9 SMC can mediate Reelin processing.  
(A) Analysis of LEC-conditioned medium alone or after incubation with SMC. (B) 
Analysis of medium from LEC cultured in normal medium, or SMC-conditioned 
medium.  Note there is no change in Reelin secretion or processing.  (C) Analysis of 
medium from LEC cultured in normal conditions or on a fibroblast-derived matrix.  
Note no change in Reelin secretion or processing. 
 
Our results show that SMC can stimulate Reelin secretion from the LECs.  Upon 
secretion, Reelin undergoes proteolytic processing and our experiments indicate that 
both SMC and LEC are involved in this process.  Together these results suggest that 
SMC recruitment to the lymphatic collecting vessels activates Reelin signalling. 
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Chapter 5. Analysis of the in vivo function of Reelin 
in lymphatic vasculature 
 
5.1 Collecting vessel development is impaired in Reln mutant 
mice 
 
In order to assess the physiological function of Reelin in the lymphatic vasculature, we 
examined Reelin (encoded by Reln) deficient mice (D'Arcangelo et al., 1995).  The 
Reeler mouse, which carries a spontaneous mutation in the Reln gene, was described 
long before the Reln gene was identified.  Reeler mice are smaller than their wild-type 
siblings and suffer from severe ataxia, resulting in frequent trembling and falling over – 
a phenotype that when first described was likened to extreme inebriation (Falconer, 
1951).  Reln deficient mice initially develop normally, but neuronal defects become 
noticeable from approximately E14.5, once the first wave of post-mitotic neurons have 
migrated into the cortical plate in wild-type mice, but neurons in Reln-/- mice fail to 
reach their proper location (Tissir and Goffinet, 2003).  Despite severe neurological 
defects, Reln-/- mice are initially grossly normal and are born in correct Mendelian 
ratios.  The size difference between Reln-/- and wild-type siblings becomes apparent at 
about P10, and from approximately P14 onwards they start to display the characteristic 
ataxic gait, which becomes increasingly severe.  Early reports indicate that some Reln-/- 
mice can surive to adulthood, although males are sterile.  However, most Reln mutants 
die at around 3 weeks after birth, and they rarely survive weaning (even when this is 
delayed) (Falconer, 1951).  We have not kept Reln-/- mice beyond 3 weeks of age in this 
study. 
We studied the lymphatic vasculature of Reln-/- mice in the ear skin.  In the ear, the 
vasculature develops by sprouting outwardly from proximal (near the head) to distal 
(outermost tip) regions of the ear.  The characteristics of collecting vessels in this tissue 
vary along their length, for example in the degree of smooth muscle cell coverage, 
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which is generally denser at the proximal than distal end, where the collecting vessels 
terminate with the lymphatic capillaries.  For this reason, detailed phenotypic analysis 
can be complicated by the necessity of comparing similar vessel regions between 
samples and the difficulties involved in achieving this in a reproducible manner, 
particularly when comparing samples of different sizes, as is the case for Reln-/- mice 
and their wild-type siblings.  Therefore, to give us a detailed and reliable representation 
of the lymphatic phenotype of Reln-/- mice, we imaged along the entire length of 
individual vessels from proximal to distal ends of the ear.  This approach revealed 
striking defects in Reln mutant (Reeler) collecting lymphatic vessels (Figure 5.1 A-B 
and see appendix, Figure 8.1 for original vessel images).  In comparison to wild type 
vessels, Reeler collecting vessels retained abnormally high levels of LYVE-1 (Figure 
5.1 A-C), and exhibited an irregular diameter, with abnormal constrictions and 
swellings along the length of the vessel (Figure 5.1 A-B, D).  Vessel constrictions 
mainly seemed to occur at the sites of luminal valves, which developed normally in 
Reeler mutants (Figure 5.1 E-F), indicating that early stages of collecting vessel 
differentiation proceeded normally.  Reeler mice also displayed reduced SMC coverage 
compared to wild type mice (Figure 5.2 A-C); by dividing the vessels into quarters from 
proximal (Q1) to distal (Q4) (Figure 5.1 A-B), we could quantify the degree of SMC 
coverage along the vessel.  Despite maintaining a similar pattern of proximal to distal 
decrease, Reln mutants displayed significantly lower SMC coverage than wild type 
mice in each vessel quarter (Figure 5.2 C).  
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Figure 5.1 Reln mutation leads to collecting vessel defects.  
(A-B) Immunofluorescence of whole-mount ear-skin of wild-type (A) and Reln-/- (B) 
mice using antibodies against LYVE-1 (green) and podoplanin (red).  Images 
(projections of confocal z-stacks) were aligned to trace the entire length of the vessel 
from proximal (Q1) to distal (Q4).  Surrounding blood vasculature was removed for 
clarity (original images shown in appendix, Figure 8.1).  (C) Quantification of LYVE-1 
positive vessel area in wild-type and Reln-/- vessels.  Data represent mean (n=6 vessels) 
± SEM. (D) Quantification of widest and narrowest vessel points, and the difference 
between the two (n= 12 (Wt) and 15 (Reln-/-) vessels). Box represents interquartile 
range, line indicates mean and whiskers indicate minimum and maximum values. (E-F) 
Immunofluorescence of whole-mount ear-skin of wild-type (E) and Reln-/- (F) mice with 
antibodies against integrin-α9 (green), αSMA (red) and PECAM-1 (blue).  Scale bars = 
200µm (A-B), 50µm (E-F). 
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Figure 5.2 Reln mutation causes reduction in SMC coverage of collecting 
lymphatic vessels.   
(A-B) Immunofluorescence staining of whole-mount ear-skin from wild-type (A) and 
Reln-/- (B) mice, taken from approximately the middle of the vessel (Q3).  Note the 
reduction in SMC around the Reln-/- vessel, and SMC attachment to areas of high 
LYVE-1 expression, which is not seen in the wild-type.  Scale bars = 50µm. (C) 
Quantification of smooth muscle cell coverage in vessel quarters. Data represent mean 
(n= 12 (Wt) and 15 (Reln-/-) vessels) ± SEM. 
 
We looked at deposition of other extracellular matrix proteins around Reln-/- collecting 
vessels to assess the impact of Reelin deficiency on the lymphatic basement membrane.  
We found that Collagen IV deposition occurred normally in Reln mutant mice (Figure 
5.3 A-B’), another indication that early stages of collecting vessel differentiation occur 
normally in the absence of Reelin.  Conversely, deposition of SMC-derived Laminin-α5 
was strongly disrupted (Figure 5.3 C-D’), most likely as a consequence of reduced SMC 
coverage.   
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Figure 5.3 Collagen IV expression is not disrupted by Reln mutation, but less 
Laminin-α5 is deposited.  
(A-D’) Immunofluorescence staining of whole-mount wild-type (A-A’, C-C’) and Reln 
mutant (B-B’, D-D’) ear-skin using antibodies against Collagen IV, (green; A-B’), 
Laminin-α5 (green; C-D’), αSMA (red) and LYVE-1 (blue).  Arrows indicate Laminin-
α5 positive luminal valves.  Scale bars = 50µm. 
 
In addition to early collecting vessel differentiation events, the capillary beds also 
formed normally in Reln mutant mice (Figure 5.4 A-B), making it unlikely that the 
collecting vessel defects we observed were part of a general failure of lymphatic 
remodelling.  These defects were also not secondary to nervous system defects, as we 
observed normal patterning of the nerves in Reln mutant mice (Figure 5.4 C-D).  
Together, these results demonstrate that Reelin deficiency leads to specific defects in 
collecting lymphatic vessel formation.   
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Figure 5.4 Capillary and nerve networks are not affected by Reln mutation.   
(A-D) Immunofluorescence staining of whole-mount wild-type (A, C) and Reln-/- (B, D) 
ear-skin using antibodies against LYVE-1 (green; A-B), αSMA (red; A-B), acetylated 
α-tubulin (green; C-D) and PECAM-1 (red; C-D).  Arrow in B points to LYVE-1 
positive collecting vessel in Reln-/-.  Scale bars = 200µm. 
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5.2 Lymphatic flow is impaired in Reln mutant mice 
 
Uptake of lymph occurs through the lymphatic capillaries, when changing pressure 
gradients between the vessel interior and the interstitium result in fluid influx.  Lymph 
drains from the capillaries into the collecting lymphatic vessels, where SMC 
contractions aid lymph propulsion and forward movement, and luminal valves maintain 
unidirectionality.  
To investigate whether the collecting vessel defects we observed had functional 
consequences, we injected FITC-Dextran intradermally into the ear.  In this assay, 
Dextran injection into the interstitium increases interstitial pressure, leading to uptake of 
dye by the lymphatic capillaries.  The high molecular weight of the Dextran means that 
it can only be absorbed by the lymphatic, and not the blood vasculature and visualising 
the fluorescent signal allows qualitative assessment of the subsequent movement of dye 
through the lymphatics, and efficiency of uptake/drainage, although dye that was free 
within the lumen is likely to be washed away during tissue fixation.  In wild type mice, 
dye was efficiently taken up into the vessels surrounding the injection site (Arrow, 
Figure 5.5 A), and drained into LYVE-1 negative collecting lymphatic vessels 
(Arrowhead, Figure 5.5 B).  Dye was rarely seen in LYVE-1 positive capillaries in wild 
type mice (Arrow Figure 5.5 B), with the exception of vessels in the immediate vicinity 
of the injection site.  In contrast, in Reln mutant mice, we frequently observed no FITC-
Dextran in vessels near the injection site (Arrow, Figure 5.5 C), while dye was retained 
in LYVE-1 positive vessels (Arrow, Figure 5.5 D), suggesting impaired lymphatic 
function.  It is possible that the apparent retention of FITC-Dextran at the vessel edges 
in the Reln-/- ear (Figure 5.5 C) is indicative of dye leakage from the vessel and 
retention within the basement membrane, further suggesting functional deficiencies in 
the collecting vessels of these mice, but this would require further experimental 
confirmation.  
In order to make a quantitative assessment of lymphatic function in Reln-/- mice, we 
looked at the larger collecting lymphatic vessels in the hindlimb.  Earlier FITC-Dextran 
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injections into the footpad had revealed that although a minority (1 out of 5 mice 
injected) of Reln mutant mice showed morphological abnormalities in the hindlimb 
collecting lymphatic vessels (data not shown), after 15 minutes the dye is readily 
detectable in both wild type and mutant vessels and there is no evidence of vessel 
leakiness or backflow of dye, such as has been reported for mice with luminal valve 
deficiencies (Bazigou et al., 2009) (Figure 5.5 E-F).  We were unable to carefully 
control the volume of dye that was injected in these experiments, which although kept 
as low as possible, was usually quite large.  It is possible that this increases the pressure 
in the footpad and enhances lymph uptake beyond the physiological norm.  Therefore to 
quantitatively assess efficiency of lymphatic function in Reln mutant mice, we needed 
to employ a more sensitive method of dye delivery and detection.   
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Figure 5.5 FITC-Dextran injection into Reln mutant ears suggests functional 
impairment of collecting lymphatic vessels.  
(A-D) P21 wild-type (A, C) and Reln-/- (B, D) ear skin, injected with FITC-Dextran 
(green) and co-stained with antibodies against aSMA (red; A, B) and LYVE-1 (blue; A, 
B and red; C, D). Dashed line in (A, B) indicates the injection site, arrows point to 
adjacent collecting lymphatic vessels. Arrows in (C, D) point to LYVE-1 positive 
capillaries, arrowhead in (C) indicates LYVE-1 negative collecting vessel filled with 
FITC-dextran.  Scale bars = 100µm. (E-F) Wild-type (E) and Reln-/- footpad injected 
with FITC-Dextran and collecting vessels imaged in the hindlimb.  Dye is readily 
detectable in both wild-type and Reln-/- collecting vessels. 
 
To this end, we injected 2ul of 1% ICG dye into the footpads of Reln mutant and control 
littermate mice using a Hamilton needle, followed by real-time imaging of uptake and 
measurement of fluorescent signal in a defined region of the vessel.  We saw abnormal 
dye uptake in the Reln-/- compared to control mice (Figure 5.6 A).  All but one Reln 
mutant mice showed decreased lymphatic function, while one showed abnormally fast 
dye uptake.  In the wild type mice, the dye reached the inguinal lymph nodes within 5-6 
seconds Figure 5.6 A’), but in most of the mutant mice, no dye was visible in the lymph 
node even at the end of 5 minutes of imaging (Figure 5.6 A’’).  In addition, measuring 
the dye content of the inguinal lymph nodes 5 minutes after Evan’s blue injection into 
the footpad, revealed significantly more dye in control littermate than Reln mutant mice 
(Figure 5.6 B-B’’), thus further confirming impaired lymphatic function in Reeler mice. 
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Figure 5.6 Impaired function in Reln-/- collecting lymphatic vessels.  
(A-A’’) Efficiency of fluorescent signal, representing efficiency of lymphatic function, 
in a defined region of a vessel after ICG injection into the hind limb footpad over time. 
After 5 minutes of injection, dye has reached inguinal lymph node (*) in wild type (A’), 
but not in Reln-/- mice (A’’). (B) Quantification of Evan’s blue dye content in inquinal 
lymph nodes of wild type and Reln-/- mice after 5 minutes of injection into the hind limb 
footpad. Mean and SEM are plotted (n= 4 (Wt) and 5 (Reln-/-)). Insets show 
representative images of wild type (B’) and Reln-/- (B’’) lymph nodes before dye 
extraction. 
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Chapter 6. Reelin signalling in the lymphatic system 
 
6.1 The canonical Reelin receptors, ApoER2 and VLDLR in the 
lymphatic system 
 
6.1.1 Lymphatic expression of canonical Reelin receptors 
 
In the nervous system, Reelin signals mainly via the low-density lipoprotein receptors, 
ApoER2 and VLDLR (Trommsdorff et al., 1999), which results in phosphorylation of 
the intracellular adapter protein Dab1 (Howell et al., 2000).  We were interested to see 
whether this signalling pathway was conserved in the lymphatic vasculature.  Our 
microarray data indicated that both Apoer2 (also known as Lrp8) and Vldlr were 
expressed at similar levels in blood and lymphatic vessels in vivo (Figure 6.1 A), and 
RT-PCR analysis confirmed that LEC and SMC express both receptors in vitro, 
although VLDLR is expressed at a lower level in HUVSMC than LEC (Figure 6.1 B).  
In the absence of absolute expression data, we are unable to comment on the relative 
expression of each receptor compared to the other.  We were also able to confirm 
VLDLR expression in the lymphatic endothelium in vivo by immunofluorescence 
(Figure 6.1 C), but unfortunately due to a lack of available antibodies, we could not use 
this technique to analyse ApoER2 expression in vivo. 
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Figure 6.1 Lymphatic expression of canonical Reelin receptors, ApoER2 and 
VLDLR.   
(A) Fold change in expression of Apoer2 and Vldlr in lymphatic vessels versus veins 
and arteries in Affymetrix analysis.  (B) Relative expression of Apoer2 and Vldlr in 2 
independent samples of LEC, BEC, HUVSMC and HAoSMC.  Mean ± SEM is plotted.  
(C-D’) Immunofluorescence staining of P21 ear skin in wild type (C, C’) and Vldlr-/- 
(D, D’) mice, using antibodies against VLDLR (green; signal amplified), aSMA (red) 
and PECAM-1 (blue). Absence of signal in (D, D’; arrow) demonstrates specificity of 
staining in (C, C’; arrow), (*) indicates non-specific staining in scattered cells. 
Chapter 6. Reelin signalling in the lymphatic system 
 157 
6.1.2 Apoer2-/-;Vldlr-/- and Dab1Scm mice do not recapitulate the Reeler 
phenotype in collecting lymphatic vessels 
 
The gross phenotype of Apoer2-/-;Vldlr-/- mice is the same as that of Reln-/- mice.  The 
mutant mice are smaller than their wild-type siblings and suffer from severe ataxia, 
indicating that, as previously published, the neuronal phenotype is also the same as 
Reln-/- mice (Trommsdorff et al., 1999).  The neuronal phenotype of mice lacking Dab1 
is also reportedly identically to that of Reln-/- mice (Howell et al., 1997, Sheldon et al., 
1997).  However, in the C3HeB/FeJ * DC/Le genetic background, the gross phenotype, 
and therefore presumably also the neuronal phenotype, is milder than that of Reln-/-
mice; in this background Dab1Scm mice are still smaller than their wild-type siblings, but 
the ataxia is less pronounced.  
Surprisingly, analysis of Apoer2-/-;Vldlr-/- mice revealed normal lymphatic collecting 
vessels (Figure 6.2 A-B and see appendix, Figure 8.2 for original vessels).  Likewise, 
Dab1Scm mice showed no demonstrable defects in collecting lymphatic vessel formation 
(Figure 6.2 A,C). In both cases, all parameters measured were normal (Figure 6.2 D-E 
and Figure 6.4 D), with the exception of a slight decrease in SMC coverage in Apoer2-/-
;Vldlr-/- mice, particularly in the distal-most quarter, which could indicate a mild defect 
in SMC recruitment (Figure 6.2 D).   
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Figure 6.2 Normal lymphatic collecting vessels in Apoer2-/-;Vldlr-/- and Dab1Scm 
mice.  
(A-C) Immunofluorescence staining of P21 ear-skin from wild type (A), Apoer2-/-;Vldlr-
/- (B) and Dab1Scm (C) mice, using antibodies against LYVE-1 (green), aSMA (red) and 
Podoplanin (blue). Individual images (projections of confocal z-stacks) were aligned to 
trace the length of the vessel from proximal to distal end and the overlapping blood 
vasculature was blacked out for clarity. Segment from middle section of each vessel 
displayed (original images shown in Appendix, Figure 8.2) Scale bars = 200µm. (D) 
Smooth muscle cell coverage in vessel quarters. Data represent mean (n=12 (Wt) and 
n=6 (Apoer2-/-;Vldlr-/- and Dab1Scm) vessels) ± SEM. All differences were non-
significant, except where indicated. (E) Quantification of widest and narrowest vessel 
points and the difference between the two in wild type (W), Apoer2-/-;Vldlr-/- (AV) and 
Dab1Scm (D) mice. Box represents interquartile range, line indicates mean and 
whiskers indicate minimum and maximum values. All differences were non-significant. 
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Overall, the absence of a similar lymphatic phenotype to that observed in Reln-/- mice in 
Apoer2-/-;Vldlr-/- or Dab1Scm mice was surprising, suggesting that this pathway is 
dispensable for normal lymphatic development, and furthermore implies the 
involvement of alternative receptor(s).  
 
6.2 EphrinB2 as a putative Reelin receptor in the lymphatic 
system 
 
6.2.1 Lymphatic expression of EphrinB2 
 
EphrinBs have been recently suggested as novel Reelin receptors (Senturk et al., 2011).  
To investigate their potential involvement in mediating Reelin signalling in the 
lymphatic system, we first used Efnb2GFP reporter mice to analyse expression of 
EphrinB2, the major EphrinB protein implicated in vascular development (Makinen et 
al., 2005, Foo et al., 2006, Wang et al., 2010).  Efnb2GFP mice have an H2B-GFP cDNA 
cassette inserted into exon 1 of the Efnb2 gene, which results in nuclear GFP expression 
in Efnb2 expressing cells (Davy and Soriano, 2007). We observed strong reporter 
expression in lymphatic and arterial endothelial cells (Figure 6.3 A, Ly), as well as in 
blood vascular SMC, as previously reported (Foo et al., 2006) (arrow, Figure 6.3 A’).  
However we could detect no GFP reporter activity in lymphatic SMC (arrowhead, 
Figure 6.1 A’’).  In addition, RT-PCR data demonstrated higher expression of EFNB2 
in cultured primary LEC than HUVSMC (Figure 6.3 B).  Together, these data suggest 
that the target cell type responsive to Reelin signalling via Ephrin B2 in the lymphatic 
system is LEC.  
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Figure 6.3 EphrinB2 is expressed in LEC, arterial EC and blood vascular SMC, 
but not lymphatic SMC.   
(A-A’’) Immunofluorescence staining of whole-mount Efnb2GFP ear-skin with 
antibodies against GFP (green) and αSMA (red).  Boxes indicate areas magnified in 
(A’) and (A’’).  (A’) shows Efnb2-GFP positive arterial (Ar) EC nuclei.  Arrow points 
to Efnb2 positive vascular SMC. (A’’) shows Efnb2-GFP positive Lymphatic (Ly) EC 
nuclei.  Arrowhead indicates Efnb2 negative lymphatic SMC nuclei.  Scale bars =  
50µm (A) and 6.25µm (A’-A’’).  (B) Expression of EFNB2 in HUVSMC relative to 
LEC.  Mean fold change of 2 experiments is plotted ± SEM. 
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6.2.2 Lymphatic endothelial specific deletion of Efnb2 resembles Reeler 
phenotype in collecting lymphatic vessels 
 
Complete deletion of EphrinB2 results in embryonic lethality, due to failure of blood 
vascular development (Adams et al., 1999).  Therefore, to allow for the requirement of 
EphrinB2 in early development and to ensure that any defects we observed were not 
secondary to a requirement for EphrinB2 in the vasculature, we specifically deleted 
EphrinB2 postnatally in the lymphatic endothelium.  We crossed Efnb2lx mice with a 
tamoxifen-inducible Prox1-CreERT2 line and induced Efnb2 deletion just prior to the 
onset of collecting vessel development at P7, or at P12 by intraperitoneal injection of 4-
OHT (Figure 6.4 A-B. See appendix, Figure 8.3 for original vessels), which lead to 
efficient Cre recombination (Figure 6.4 C and data not shown).  Given the well 
documented role of Ephrin B2 in formation and maintenance of lymphatic valves 
(Makinen et al., 2005), (Wang et al., 2010), (Bazigou et al., 2011), the absence of valves 
in Efnb2lx/lx;Prox1-creERT2 collecting vessels is strong evidence for efficient Efnb2 
deletion (Figure 6.4 A-B).  However, in the absence of suitable antibodies, we were 
unable to confirm this at the protein level.  In both cases, LEC-specific Efnb2 deletion 
resulted in similar lymphatic defects to those observed in Reln mutants, including high 
LYVE-1 expression and a reduction in SMC coverage of the collecting vessels (Figure 
6.4 A-B and D).   
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Figure 6.4 Collecting vessel defects following lymphatic-specific Efnb2 deletion 
resemble those of Reln-/- mice.  
(A-C) Immunofluorescence of P21 ear-skin from Efnb2lx/lx;Prox1-creERT2 (A-B) or 
R26-mTmG;Prox1-creERT2 (C) mice, administered with 4-OHT at P7 (A, C) or P12 (B) 
and analysed at P21 using antibodies against LYVE-1 (green; A-B), αSMA (red; A-B), 
PECAM-1 (blue; A-B) and GFP (green; C). Individual images (projections of confocal 
z-stacks) were aligned to trace the entire length of the vessel.  Middle segment of each 
vessel is shown, with surrounding blood vasculature blacked out for clarity in (A-B).  
Original vessels are shown in appendix, Figure 8.3.  Scale bars = 200µm. (D) 
Quantification of LYVE-1 positive area in wild-type, Apoer2-/-;Vldlr-/- , Dab1Scm and 
Efnb2lx/lx;Prox1-creERT2 vessels. Data represent mean (n= 12 (Wt) and n= 6 (each 
mutant) vessels) ± SEM. Differences were non-significant except where indicated 
 
SMC recruited to Efnb2 deficient collecting vessels were often found around areas of 
the lymphatic endothelium that still expressed high levels of LYVE-1 (arrows, Figure 
6.5 B, D), a situation that is rarely observed in wild type vessels, but is again 
reminiscent of Reln-/- collecting lymphatic vessels.  It is also important to note that 
Efnb2lx/lx siblings appeared as wild-type (Figure 6.5 A, C), with regular SMC coverage 
and no LYVE-1 expression in collecting lymphatic vessels, thus ruling out the 
possibility that the Efnb2lx/lx;Prox1-creERT2 phenotype was secondary to either 
tamoxifen injection, or homozygosity for the allele containing the LoxP flanked Efnb2 
exon. 
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Figure 6.5 SMC are found at areas of high LYVE-1 expression in Efnb2lx/lx;Prox1-
creERT2 mice.   
Immunofluorescence staining of whole-mount ear-skin from Efnb2lx/lx (A-C) or 
Efnb2lx/lx;Prox1-creERT2 mice (B-D), administered with 4-OHT at P7 (A-B) or P12 (C-
D) and analysed at P21 using antibodies against PECAM-1 (green), αSMA (red) and 
LYVE-1 (blue).  Note that Efnb2lx/lx mice appear as wild-type; regular SMC coverage 
and no LYVE-1 expression in collecting lymphatic vessels. Arrows in (B) and (D) point 
to SMC that have attached in areas of high LYVE-1 expression.  Scale bars = 50µm. 
 
As in the case of Reln mutant mice, Efnb2 deficient collecting lymphatic vessels 
generally appeared wider than wild type vessels.  However they did not display the 
constrictions we observed in the Reln-/- vessels, which is likely due to the absence of 
luminal valves in Efnb2 deficient mice (Figure 6.4 and data not shown).  The Reelin-
independent requirement for Efnb2 in formation and maintenance of luminal valves has 
been previously reported (Makinen et al., 2005)(Bazigou et al., 2011), and served as a 
useful marker of efficient Cre recombination in Efnb2lx/lx;Prox1-creERT2 collecting 
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vessels.  Another indication that EphrinB2 has Reelin-independent functions in the 
lymphatic endothelium was the observation that lymphatic capillaries in Efnb2 deficient 
mice appeared abnormal and less branched, unlike the situation in Reln-/- mice (Figure 
6.6 A-C).  However, this phenotype would need to be quantified and investigated in 
more detail before being confirmed. 
 
 
Figure 6.6 Abnormal lymphatic capillary network in Efnb2lx/lx;Prox1-creERT2 
mice.   
(A-C) Immunofluorescence staining of whole-mount ear-skin from Efnb2lx/lx;Prox1-WT 
(A) or Efnb2lx/lx;Prox1-creERT2 (B-C), administered with 4-OHT at P7 (A-B) or P12 (C) 
and analysed at P21 using antibodies against LYVE-1 (green) and PECAM-1 (red).  
Arrow indicates LYVE-1 positive collecting vessel in Efnb2lx/lx;Prox1-creERT2 mice.  
Scale bars = 200µm. 
 
A preliminary observation suggested that Reelin remained intracellular in some Efnb2 
deficient collecting lymphatic vessels (Figure 6.7 B-B’), similar to the case in the 
developing lymphatic endothelium, while in the wild type siblings, Reelin expression in 
the collecting vessels was characteristically weak and diffuse (Figure 6.7 A-A’).  This 
may be a result of either incomplete collecting vessel differentiation, or of the reduction 
in SMC coverage, although it would require further analysis to confirm and distinguish 
between these hypotheses. 
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Figure 6.7 Reelin appears intra-cellular in Efnb2lx/lx;Prox1-creERT2 collecting 
vessels. 
Immunofluorescence staining of whole-mount ear-skin from Efnb2lx/lx and 
Efnb2lx/lx;Prox1-creERT2 mice, administered with 4-OHT at P7 and analysed at P21 
using antibodies against Reelin (green), αSMA (red) and PECAM-1 (blue).  Arrows 
indicate areas where Reelin signal appears intracellular.  Scale bars = 50µm (A-B), 
25µm (A’-B’). 
 
Overall, our in vivo data suggest EphrinB2 as a likely candidate for mediating Reelin 
signalling in the lymphatic endothelium. 
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6.3 Cellular mechanism of Reelin function in vascular cells 
 
6.3.1 Reelin does not directly promote SMC adhesion or motility 
 
The reduction in SMC coverage of Reln-/- collecting vessels suggested that Reelin might 
have a direct effect on SMC, for example by promoting SMC migration either towards 
or along the length of the vessel, which would be consistent with a role for Reelin in 
positively regulating neuronal migration (Jossin et al., 2004), (Sanada et al., 2004).  
Alternatively, Reelin might promote or secure SMC attachment to the vessel.  Since we 
did not know which fragment of the protein may be active in the lymphatic system, we 
used Reelin secreted into the medium of HEK 293 cells, which contains predominantly 
full-length Reelin, but also its cleavage products in our in vitro experiments.  We also 
used the commercially available Reelin central fragment.  Application of only the 
central fragment of Reelin to cortical slice cultures is sufficient to rescue the neuronal 
phenotype of Reeler mice (Jossin et al., 2004), however it is important to note that we 
do not have a positive control for the efficacy of this fragment in the lymphatic system, 
and so were unable to confirm the functionality of the commercially available fragment 
prior to beginning experiments.  Contrary to our hypothesis, in vitro investigations 
revealed no difference in the motility of untreated HUVSMC compared to those treated 
with either Reelin medium or the central Reelin fragment (Figure 6.8 A).  Likewise, 
neither form of Reelin promoted SMC attachment to a non-adhesive surface (Figure 6.8 
B).  
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Figure 6.8 Reelin does not directly mediate HUVSMC adhesion or motility.   
(A) Cell motility in each treatment condition.  Each dot represents one cell (total 60 
cells from 3 wells per condition).  Bar represents mean distance ± SEM. (B) 
Absorbance reading, representing cell adhesion in each treatment condition.  Mean ± 
SEM is plotted.  N = 6 wells per condition. 
 
We performed chemotaxis assays to determine whether Reelin could promote 
directional migration of SMC.  We did not observe increased SMC migration in 
response to either Reelin medium, or the central fragment (data not shown), but 
consistent with previously published reports, we observed increased SMC migration 
towards LEC-conditioned medium (Veikkola et al., 2003) (Figure 6.9).  
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Figure 6.9 SMC migrate in response to LEC conditioned medium.  
SMC density, representing number of cells migrated through Transwell membrane 
towards either untreated, or LEC-conditioned starvation medium.  Mean ± SEM of 5 
Regions of interest (ROI) per well (full description given in Materials and Methods) 
from 2 wells per condition is plotted.  Graph is representative of 3 experiments. 
 
6.3.2 Phospho-Kinase array did not reveal downstream components of 
the Reelin signalling pathway in vascular cells 
 
In an attempt to determine which cell type was responsive to Reelin signalling and to 
identify downstream components of the Reelin signalling pathway in either LEC or 
HUVSMC to see if this gave us any mechanistic insights, we used Proteome Profiler 
Human Phospho-Kinase Array Kits (R&D Systems), in which antibodies against 46 
different phosphorylated proteins are spotted onto a nitrocellulose membrane.  Upon 
PDGF-BB stimulation of SMC, we saw increased phosphorylation of CREB 
(Nomiyama et al., 2006), Erk 1/2 (Hansmann et al., 2008), (Millette et al., 2005) and 
Akt (Millette et al., 2005), (Rauch et al., 2000), all known effectors of PDGF-BB 
signalling in SMC, indicating that the assay was working properly (Figure 6.10 A’-A’’).  
However we saw no difference in phosphorylation levels of any proteins between 
untreated SMC and those stimulated with the central Reelin fragment (Figure 6.10 A’’-
A’’’).  We obtained a similar result with LEC.  VEGF-C stimulation induced increased 
phosphorylation of CREB (Heckman et al., 2008), Akt (Lahdenranta et al., 2009), 
(Tvorogov et al., 2010) and Erk 1/2 (Cao et al., 2004, Tvorogov et al., 2010), again 
indicating that the assay had worked, since the phosphorylation levels of known 
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effectors of VEGF-C signalling in LEC were increased (Figure 6.10 B’-B’’).  However, 
once more we were unable to identify any differences in phosphorylation levels 
between untreated LEC and those treated with the central Reelin fragment (Figure 6.10 
B’’-B’’’). 
 
 
Figure 6.10 No change in phosphorylation levels of proteins after Reelin 
stimulation of LEC or SMC.   
(A-B) Phospho-kinase array of HUVSMC (A) or LEC (B), stimulated with PDGF-BB 
(A’), VEGF-C (B’), un-stimulated (A’’, B’’) or stimulated with Reelin central fragment 
(A’’’, B’’’).  PDGF-BB stimulation of HUVSMC, or VEGF-C stimulation of LEC 
causes increased phosphorylation of CREB, Erk1/2 and Akt, as indicated, but there is 
no change after Reelin stimulation.  Co-ordinates are marked only on (A’) for clarity. 
See appendix, Figure 8.4 for array key. 
 
6.3.3 Reelin stimulation of LEC increases production of SMC proliferation 
factor MCP1 mRNA 
 
Our earlier results indicated that Reelin signalling in the lymphatic vasculature may 
involve interaction between LEC and SMC, and since we were unable to detect a direct 
effect of Reelin on SMC motility or adhesion, but LEC-conditioned medium did 
promote SMC migration, we hypothesised that Reelin might stimulate LEC to produce 
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SMC-recruitment factors.  While neither Reelin medium, nor the central Reelin 
fragment induced increased expression of PDGFB, HBEGF, ANGPT2, or TGFβ1 
mRNA, stimulation with Reelin medium induced a greater than 2 fold increase in 
MCP1 production after both 4 and 8 hours, compared to control medium stimulated 
cells (Figure 6.11 A-B).  After 24hr of Reelin stimulation, the difference in MCP1 
production by Reelin medium, compared to control medium stimulated, LEC was 
smaller, but still apparent (Figure 6.11 C).  Interestingly, we did not see the same 
increase in MCP1 expression in response to the central Reelin fragment, which together 
with our earlier negative results from the phosphoarray, may suggest that contrary to the 
case in the nervous system, the central fragment alone is not sufficient for activation of 
Reelin signalling in LEC.  
Our results suggest that LEC can respond to Reelin by upregulating expression of 
MCP1, a known SMC recruitment and proliferation factor (Selzman et al., 2002), (Jay 
et al., 2010).  
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Figure 6.11 Reelin medium stimulates production of MCP1 mRNA.   
(A-C) Fold change in expression of SMC recruitment genes after 4 (A), 8 (B) or 24 (C) 
hours stimulation with either Reelin central fragment, Reelin medium or control 
medium, relative to expression in untreated LEC.  Note strong increase in MCP1 
expression in Reelin medium stimulated compared to control-stimulated LEC after 4 
and 8 hours, with no change in expression of any other SMC recruitment genes.  Mean 
± SEM of 2 experiments at each time point is plotted 
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6.4 Proposed model of Reelin action in the lymphatic 
vasculature 
 
Our results suggest that initially all LEC express Reelin intracellularly, but upon 
differentiation of the collecting lymphatic vessels, SMC recruitment stimulates Reelin 
release and proteolytic processing.  Secreted Reelin then increases endothelial MCP1 
expression, which leads to further SMC recruitment.  The canonical Reelin receptors 
ApoER2 and VLDLR were not involved in this process, but in vivo data suggests the 
involvement of EphrinB2 in LEC in mediating Reelin signalling in lymphatic 
development, although the role of EphrinB2 requires further investigation (Figure 6.12). 
 
 
Figure 6.12 Proposed model of Reelin signalling during collecting lymphatic vessel 
formation.  
Reelin (red star) is produced by LEC (grey cells). Upon SMC (brown cells) recruitment 
Reelin is secreted from LEC (red cells) and cleaved to release diffusible fragments (red 
gradient).  Reelin can also up-regulate expression of MCP1, which encodes MCP-1 
protein known to enhance SMC recruitment. 
 
 
Chapter 7. Discussion 
 174 
Chapter 7. Discussion 
 
The initial aim of this work was to characterise the process of collecting lymphatic 
vessel remodelling in the ear-skin.  To accomplish this, we used in vivo observations of 
wild-type tissue at differing postnatal stages and carried out microarray analysis to 
explore the largely un-investigated differences between the lymphatic and blood 
vascular basement membranes.  We identified Reelin as a potentially interesting 
candidate for further study and so set about identifying its possible role in lymphatic 
vessel development.  This was achieved by combining in vivo observations of Reln-/- 
(Reeler) mice with in vitro studies into the mechanism of Reelin activation and its 
cellular function within the lymphatic vasculature.  Our findings are discussed in more 
detail below. 
 
7.1 Dermal lymphatic collecting vessel differentiation 
 
The gene expression and morphological changes involved in collecting vessel 
differentiation and maturation have been described in the embryonic mesenteric vessels, 
where it was found that Foxc2 is a critical regulator of this process (Norrmen et al., 
2009).  Likewise, the development of luminal valves, an early step in collecting vessel 
differentiation, has also been described (Bazigou et al., 2009). However, the timing of 
lymphatic remodelling varies between tissues, and so determining the postnatal stage at 
which some of the processes involved in collecting vessel differentiation occur in the 
ear skin, for example LYVE-1 down-regulation, SMC recruitment and BM deposition, 
and the order in which these events occur, provided us with a useful tool for detailed 
assessment of this process in mutant mouse strains that might show a lymphatic 
phenotype. 
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7.1.1 SMC regulation of LYVE-1 down-regulation 
 
While studying the timing of SMC recruitment to the lymphatic collecting vessels, we 
made some interesting observations concerning the relationship between SMC 
recruitment and LYVE-1 down-regulation.  Our in vivo observations seemed contrary to 
previous suggestions that SMC recruitment leads to LYVE-1 down-regulation 
(Tammela et al., 2007), since we frequently saw areas of no LYVE-1 expression that 
were also devoid of SMC, suggesting that LYVE-1 down-regulation occurs prior to 
SMC recruitment. However, we also found that co-culturing LEC and SMC lead to 
down-regulation of LYVE1 mRNA, which does suggest a role for SMC in regulation of 
LYVE-1 expression.  LEC in direct contact with SMC in vitro still maintained LYVE-1 
expression, which suggests that LYVE-1 down-regulation is not prerequisite for 
SMC/LEC contact, at least in vitro, and may indicate that LYVE-1 has a particularly 
long half-life, since protein expression was still maintained in co-culture while mRNA 
was down-regulated over the same period of time.  Preliminary observations in Lyve1-/- 
mice indicated that the absence of LYVE-1 does not increase SMC recruitment to the 
collecting vessels, again suggesting that LYVE-1 does not normally inhibit SMC 
attachment. 
Further evidence for a correlative relationship between LYVE-1 expression and SMC 
recruitment came from analysis of Reln-/- and Efnb2lx/lx;Prox1creERT2 mice, which 
showed abnormally high levels of LYVE-1 expression in the collecting lymphatic 
vessels, concomitant with a reduction in SMC coverage.  A similar phenomenon was 
reported in a mouse model of hypercholesterolemia in mice lacking the lipoprotein 
ApoE.  Although ApoE-/- lymphatic collecting vessels initially formed normally, with 
regular SMC coverage and no LYVE-1 expression, after 16 weeks on a high-fat diet, 
they started to lose SMCs, which was accompanied by up-regulation of LYVE-1 (Lim 
et al., 2009).  All of these data point to a relationship between SMC recruitment and 
LYVE-1 down-regulation, but this may not be a direct effect.   
Since the function of LYVE-1 in the lymphatic vasculature is unknown, it might be 
interesting to explore this relationship further.  Culturing LEC in conditioned medium 
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from SMC and examining LYVE-1 expression at both the protein and mRNA level 
might address the issue of whether a SMC-derived secreted factor is responsible for 
LYVE-1 down-regulation.  It would also be interesting to take advantage of live 
imaging techniques, such as the explant cultures used by Pflicke et al. to image DC 
entry into the lymphatic vessels, in order to investigate SMC recruitment (Pflicke and 
Sixt, 2009).  However, the tools do not yet exist that would enable real-time 
visualisation of LYVE-1 expression changes. 
 
7.1.2 Composition and function of the lymphatic extracellular matrix  
 
The deposition of BM proteins such as Collagen IV and Laminin-α5 proved useful 
indicators of collecting vessel maturation.  However, in contrast to the situation in the 
blood vasculature, where the importance of the BM in maintenance of vessel structure 
and biological function is widely recognised, very little is known about the composition 
and function of the lymphatic basement membrane.  Our microarray analysis revealed 
that a number of extra-cellular matrix related genes are specifically up-regulated in 
lymphatic vessels, compared to arteries or veins.  This might suggest that the 
composition of the lymphatic basement membrane is more complex than previously 
suspected and may also indicate specific roles for these proteins in lymphatic 
development or function that would warrant further investigation.  In one such example 
of this, we have identified Reelin as the first lymphatic specific extracellular matrix 
protein and a novel regulator of lymphatic collecting vessel development and function. 
We identified Reelin expression in both the lymphatic capillaries and collecting vessels, 
but found that it was only secreted from the collecting vessels.  Consistent with this, we 
found that lymphatic capillaries developed normally in the absence of Reelin, while 
there were specific defects in collecting lymphatic vessel formation.  Together with our 
own and previously published observations of differential Collagen IV deposition 
between lymphatic collecting vessels and capillaries (Pflicke and Sixt, 2009), this 
suggests differences in the composition of lymphatic capillary and collecting vessel 
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BM.  The differences in BM between different types of lymphatic vessel have been 
largely ignored to date, but are likely to be important given the functional differences 
between lymphatic capillaries and collecting vessels in mediating fluid uptake and 
transport respectively (Tammela and Alitalo, 2010).  Further investigation into the 
differences between lymphatic capillary and collecting vessel BM may reveal whether 
ECM proteins have a part in regulating these distinct functions. 
 
7.1.3 Role of smooth muscle cells in lymphatic function 
 
To our knowledge, Reln-/- mice provide the first example of a mouse model with a 
lymphatic specific reduction in SMC coverage, without concomitant blood vascular, or 
other major lymphatic defects.  The role of SMC and pericytes in maintenance of blood 
vessel stability has been well established by studies of mouse models lacking various 
elements required for proper mural cell recruitment (Hellstrom et al., 2001), 
(Abramsson et al., 2007), (Stenzel et al., 2009).  However, severe vascular defects and 
embryonic lethality make these models unsuitable for examining the role of SMC in 
lymphatic collecting vessel development and function.  As well as reduced SMC 
coverage, Reln-/- collecting vessels were enlarged, exhibited variable diameters, and 
expressed abnormally high levels of the lymphatic capillary marker LYVE-1.  These 
defects are reminiscent of the blood vascular defects of Pdgfb/Pdgfrβ mutants, which 
fail to recruit pericytes to the blood vascular capillaries (Hellstrom et al., 2001), and 
may suggest that lymphatic SMC play a similar role to blood vascular mural cells in 
restricting the calibre and promoting the maturation of lymphatic collecting vessels.  
However, there are interesting functional differences between lymphatic and blood 
vascular smooth muscle, predominantly in their contractile properties.  While the 
driving force for blood flow around the body comes from the heart, lymphatic vessels 
must act as both pump and conduit to regulate lymphatic flow (Quick et al., 2009).  The 
forces driving lymph flow come from both extrinsic sources, such as skeletal muscle 
contractions or movement of the diaphragm during breathing, and intrinsic forces, 
generated by smooth muscle cell contractions (reviewed in (Zawieja, 2009)).  In order 
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to achieve the force necessary for lymph propulsion, lymphatic SMC take on 
characteristics of both blood vascular and cardiac smooth muscle (reviewed in 
(Muthuchamy and Zawieja, 2008)).  Tonic contractions that regulate vessel tone are 
similar to those seen in blood vascular SMC, but rapid phasic contractions, which 
swiftly decrease collecting vessel diameter and push the lymph through the downstream 
valve, more closely resemble cardiac muscle contractions.  The impaired lymphatic 
function observed in Reln-/- mice may be indicative of a defect in SMC contractility or 
lymph pumping, which might have clinical significance, since some human patients 
with RELN mutations suffer from congenital lymphoedema (Hong et al., 2000).  It 
would therefore be interesting to test lymphatic vessel contractility in Reln-/- mice 
directly.  It would also be interesting to test the implications of reduced SMC coverage 
and impaired lymphatic function of Reln-/- mice in light of new insights into solute 
exchange in the lymphatic collecting vessels, and physiological levels of collecting 
vessel ‘leakiness’ (Scallan and Huxley, 2010).  It is possible that the discontinuous 
coverage of SMC around collecting lymphatic vessels aids solute exchange, and 
therefore we might expect to see increased exchange or a corresponding increase in 
lymph protein concentration in Reln-/- vessels with reduced SMC coverage.  This may 
be reflected in the possible FITC-Dextran leakage from Reln-/- vessels in Figure 5.5 C. 
 
7.2 Reelin signalling in the lymphatic vasculature 
 
The majority of Reelin research has pointed towards it signalling through the canonical 
receptors, ApoER2 and VLDLR, which leads to phosphorylation of the intracellular 
adaptor protein Dab1 and elicitation of the downstream response (reviewed in (Forster 
et al., 2010), (Frotscher et al., 2009)).  Therefore, the development of normal collecting 
lymphatic vessels in Apoer2-/-;Vldlr-/- and Dab1Scm mice was very unexpected.  The 
milder neuronal phenotype in Dab1Scm mice in the C3HeB/FeJ * DC/Le background 
may indicate that any lymphatic phenotype would also be reduced.  However, our 
negative data from the Apoer2-/-;Vldlr-/- mice, which were in the same background as 
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the Reeler mice and showed a strong neuronal phenotype, but no lymphatic phenotype, 
makes this unlikely.  A mild reduction in SMC coverage in Apoer2-/-;Vldlr-/- mice 
means that a role for the canonical signalling pathway in SMC recruitment cannot be 
completely ruled out (especially since it is possible that we would have seen a similar 
reduction in Dab1Scm mice had they been in the same genetic background), but a failure 
to recapitulate the Reln-/- phenotype makes the involvement of alternative receptors 
likely.  A number of alternative Reelin receptors have been proposed, but the veracity of 
their Reelin binding properties is controversial, as will be discussed below. 
7.2.1 CNR1 
 
Cadherin related neuronal receptor 1 (CNR1) seemed to be expressed in a likely pattern 
to transmit Reelin signalling, with expression in the cortical plate, but not the marginal 
zone and binding assays demonstrated binding of the extracellular domain to the N-
terminus of Reelin (Senzaki et al., 1999).  This binding could be blocked by the CR-50 
antibody, and seemed to identify an attractive candidate for a Reelin receptor, because 
Fyn also docked to the cytoplasmic tail of CNR1, thus identifying a mechanism 
whereby SFK could be brought into the Reelin signalling complex (Senzaki et al., 
1999).  However, this study used the extracellular domain of CNR1 purified from cell 
lysates and not secreted protein, raising the possibility that it may not have been folded 
into its proper structure.  A second study reassessed CNR1 Reelin binding activity using 
both the entire extracellular domain of secreted CNR1, or just the first ectodomain, 
where Reelin binding is supposed to occur (Jossin et al., 2004).  In this case, no Reelin 
binding to either form of CNR1 could be observed, while strong receptor binding to 
ApoER2 and VLDLR was observed in all constructs containing the Reelin central 
fragment (Jossin et al., 2004).  This suggests that a conformational change upon CNR1 
secretion leaves it unable to bind Reelin in a physiological setting and therefore means 
that CNR1 cannot be a Reelin receptor. 
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7.2.2 Integrin-α3 
 
Integrin-α3β1 is co-expressed with Dab1 in migrating neurons and has also been 
proposed as a Reelin receptor following binding experiments where it was co-
immunoprecipitated with both the CR-50 antibody and Reelin coated beads (Dulabon et 
al., 2000).  Furthermore, loss of Itgb1 in neuronal and glial precursors lead to a similar, 
but much less severe, disruption of the radial glial scaffold to that seen in Reeler mice 
(Forster et al., 2002).  However, whether this is really due to Reelin-Integrin-α3β1 
binding is again questionable.  Dab1 phosphorylation is required for neuronal 
detachment from the glia, and in the process of detaching, neurons downregulate 
Integrin-α3 (Sanada et al., 2004).  However, Dab1 phosphorylation is not induced by 
Reelin binding to Integrin-α3β1 (Dulabon et al., 2000), which suggested that while 
Integrin-α3β1 is likely important for the correct formation of the radial glial scaffold, 
and for neuronal detachment from glia, this is more likely to be a downstream effect of 
Reelin signalling via ApoER2/VLDLR than induced directly by Reelin-Integrin-α3β1 
binding (Sanada et al., 2004).  Perhaps the most convincing evidence against Integrin-
α3β1 as a Reelin receptor comes from the lack of genetic data to support it.  Itgb1 
deletion in migrating neurons has no effect on cortical patterning; the layers form 
correctly and there is no ectopic neuronal migration into the marginal zone (Belvindrah 
et al., 2007).  This suggests that the requirement for Integrin-β1 for correct cortical 
development is in glia, rather than neurons.  Furthermore, Itga3-/- mice also show no 
cortical patterning defects, or layer inversion, making it unlikely that in the absence of 
Integrin-β1, another β chain integrin substitutes for it and demonstrating that Integrin-
α3 is not essential for Reelin signalling (Belvindrah et al., 2007). 
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7.2.3 EphrinBs 
 
Recently, EphrinBs were also proposed as novel Reelin receptors (Senturk et al., 2011).  
Since EphrinB2 is highly expressed in the lymphatic vasculature, and known to be 
involved in lymphatic remodelling (Makinen et al., 2005), this seemed a likely 
candidate for a Reelin receptor in the lymphatic vasculature.  Indeed, lymphatic 
endothelial specific deletion of Efnb2 resulted in collecting vessel defects resembling 
those seen in Reln-/- mice, which was suggestive of a role for this protein in the Reelin 
signalling pathway.  
However, given the controversy in the literature surrounding the existence of alternative 
Reelin receptors or co-receptors, it is important to have both strong genetic and 
biochemical data before drawing a firm conclusion.  It will also be beneficial to confirm 
Reelin signalling through EphrinB2 in the lymphatic system by establishing whether 
Reelin can induce enhanced MCP1 expression in LEC lacking EphrinB2, as we 
observed in wild-type LEC. 
To this end, the current focus of this project is to confirm Reelin binding to EphrinB2 
with binding assays.  Preliminary data (not shown) suggests that EphrinB2 can bind to 
Reelin, as shown by Senturk et al., and furthermore that it binds to the N-terminal 
fragment.  This has interesting implications in the context of our previous results, and 
perhaps tallies with our earlier conclusions that ApoER2 and VLDLR are not the major 
Reelin receptors in the lymphatic vasculature since, as discussed below, ApoER2 and 
VLDLR bind the central fragment of Reelin.  
It should be noted that although an ApoER2/VLDLR and Dab1 independent function 
for Reelin is unusual, it is not unprecedented.  Rossel and colleagues discovered a novel 
function for Reelin in neuronal migration in the hindbrain that was dependant on Dab1, 
but not on ApoER2/VLDLR (Rossel et al., 2005).  Likewise, Cariboni and colleagues 
discovered an inhibitory function for Reelin in the migration of Gonadotropin-releasing 
hormone neurons that was independent of both ApoER2/VLDLR and Dab1 (Cariboni et 
al., 2005).  Together with our data, this work suggests that Reelin signalling is more 
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complex than previously thought and that research to identify new Reelin binding 
proteins should consider not only the possibility of co-receptors for ApoER2/VLDLR, 
but also receptors that may function completely independently of the canonical 
signalling pathway.  Greater diversity in Reelin signalling than previously imagined is 
also highlighted by our own work, and that of others, in identifying novel systems 
outside the CNS in which Reelin is functioning (Khialeeva et al., 2011).  
 
7.3  Reelin activity in the lymphatic vasculature 
 
In the developing cortex, Cajal Retzius cells in the marginal zone secrete Reelin, which 
signals to both the migrating neurons and closely apposed radial glial cells to direct 
correct cortical patterning (Tissir and Goffinet, 2003), (Sanada et al., 2004), (Hartfuss et 
al., 2003).  Despite the close apposition between these cell types, it is not known 
whether cell-cell interactions are involved in activation or modulation of Reelin 
signalling in the developing nervous system.  We confirmed in vitro that within the 
lymphatic system, Reelin was expressed specifically by LEC, but the presence of SMC 
enhanced its secretion and proteolytic processing.  This suggests a previously un-
described role for cell-cell interactions in activation of Reelin signalling.   
While all reports seem to agree that proteolytic processing affects Reelin function, there 
is widespread controversy as to both the consequence of processing for Reelin 
signalling efficiency and the functional importance of the resulting fragments in 
mediating Reelin’s biological actions.  
 
7.3.1 The ‘active’ fragment in Reelin signalling 
 
The central fragment of Reelin (repeats 3-6) binds to the canonical receptors, ApoER2 
and VLDLR, is sufficient to activate Reelin signalling in both cultured neurons and 
Chapter 7. Discussion 
 183 
cortical explants and can even partially rescue neuronal migration defects in Reeler 
cortical slices (Jossin et al., 2004).  Other reports suggest that the N-terminal fragment 
is necessary for the full efficacy of Reelin signalling, probably by mediating Reelin 
aggregation, and perhaps thus concentrating the signal (Utsunomiya-Tate et al., 2000).  
Further evidence for the importance of the N-terminal fragment for Reelin function 
comes from the fact that the CR-50 antibody, raised against an antigen in the N-
terminus of Reelin, can inhibit Reelin function (Ogawa et al., 1995), (Zhao et al., 2004). 
This may even imply a signalling function for the N-terminus beyond protein 
aggregation.  The highly basic C-terminus has also been implicated in Reelin function. 
There is 100% conservation in the C-terminus sequence at the amino acid level, and 
92% conservation at the nucleotide level between all mammals whose sequences are 
obtainable, which is already suggestive of functional importance (Nakano et al., 2007). 
In the Orleans variant of Reln mutants (Relnrl-Orl), a frameshift mutation results in 
production of a C-terminus truncated protein, which is produced, but not secreted, in 
homozygous mutants (de Bergeyck et al., 1997).  Relnrl-Orl mice exhibit an identical 
phenotype to Reln-/- mice (Rice and Curran, 2001), demonstrating that Reelin secretion 
is essential for its function.  The C-terminus is also reportedly necessary for efficient 
activation of the downstream signalling cascade of Reelin, and stable binding to the 
canonical receptors (Nakano et al., 2007).  This may involve a conformational change in 
the protein, resulting in a close association between the C-terminus and the 
neighbouring eighth Reelin repeat, which then allows efficient signalling, or binding to 
a co-receptor (Kohno et al., 2009b).   
Given this body of literature, it appears that the identity of the ‘active’ Reelin fragment 
is still open to debate, although the evidence for central fragment binding to ApoER2 
and VLDLR and activating Reelin signalling in the nervous system is convincing 
(Jossin et al., 2007), (Jossin et al., 2004).  However, even in this scenario there is room 
for additional, or alternative scenarios, as antibodies against ApoER2 or VLDLR were 
capable of binding their respective receptors and inducing Dab1 phosphorylation, but 
this was not sufficient to rescue the Reeler phenotype in cortical slice cultures (Jossin et 
al., 2004), suggesting that an additional Reelin signalling mechanism, independent of 
Dab1, may also be in play.  
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Overall, while one report suggests that Reelin cleavage at the N-terminus abolishes 
Reelin signalling capacity (Kohno et al., 2009a), most reports agree that Reelin 
processing is important for its function.  For example, prevention of Reelin processing, 
either by application of MMP inhibitors, or as a result of epileptic activity, impairs 
Reelin signalling and results in cortical development defects or granule cell dispersion 
respectively, which are both characteristics of the Reeler phenotype (Jossin et al., 2007), 
(Duveau et al., 2010), (Tinnes et al., 2011). 
 
7.3.2 Reelin processing in the lymphatic vasculature 
 
In the nervous system, Reelin processing appears to be MMP-dependant (Lambert de 
Rouvroit et al., 1999), (Jossin et al., 2007), (Tinnes et al., 2011), and since the Reelin 
cleavage products we identified in LEC/SMC co-cultures were identical to those 
previously documented, it is likely that the same mechanism of processing occurs in the 
lymphatic vasculature.  
We found that co-culture with SMC enhanced Reelin secretion, and presumably 
therefore signal activation.  We also saw that following secretion, Reelin was 
proteolytically processed at both the N- and C-termini, likely by both LEC and SMC.  
We presume that this is again evidence of signal activation, possibly as proposed in the 
nervous system, by releasing the active fragment, although we do not know which part 
of the protein is active within the lymphatic system.  Our results so far indicate that the 
central Reelin fragment alone is unlikely to be sufficient to activate Reelin signalling in 
the lymphatic vasculature.  Since this is the fragment known to bind ApoER2 and 
VLDLR (Jossin et al., 2004), this seems compatible with our finding that lymphatic 
collecting vessels develop normally in Apoer2-/-;Vldlr-/- mice and do not recapitulate the 
phenotype we observe in Reln-/- collecting vessels.  Our recent preliminary observations 
that EphrinB2 binds the N-terminus of Reelin also support the suggestion that the 
central Reelin fragment may not be the major active fragment in Reelin signalling in the 
lymphatic vasculature. 
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Despite the possibility of a different active fragment being involved in the lymphatic 
vasculature, it is easy to envision how the model proposed by Jossin et al. could be 
applicable to this system: the authors suggest that full-length Reelin is secreted into, and 
likely anchored to, the ECM, but that its subsequent processing releases the smaller, 
diffusible active fragment, which signals to the target cells (Jossin et al., 2007).  
Although binding to any specific ECM protein is yet to be experimentally confirmed, 
immunofluorescence of neonatal cortical slices with antibodies against the individual 
Reelin fragments (N-terminus, C-terminus and central fragment) demonstrated that full-
length Reelin remains in the MZ near the Cajal-Retzius cells from which it is secreted, 
thus suggesting that it may be anchored to the ECM.  In contrast, the central and N-
terminal fragments were detected in cortical plate at some distance from the MZ (Jossin 
et al., 2007).  Our results suggest that in the lymphatic system, SMC recruitment to the 
collecting vessels enhances release of full-length Reelin, which is subsequently 
processed.  The active fragment might then diffuse to signal either to migrating SMC, or 
further along the lymphatic vessels - perhaps further distally to locations that have not 
yet recruited SMC - and signal to other LEC, trigger increased production of factors 
involved in SMC recruitment and enhance SMC recruitment to distal parts of the vessel. 
Retention of full-length Reelin close to the cells from which it is secreted in the cortex 
(Jossin et al., 2007) may also be consistent with Reelin secretion from and signalling 
back to the lymphatic endothelium. 
However, we cannot yet exclude the alternative hypothesis that Reelin cleavage is a 
mechanism of limiting Reelin function (Kohno et al., 2009a).  In this situation, we 
might envision that the protein conformation of Reelin is critical for signalling and that 
cleavage at either one or both sites disrupts the protein structure and diminishes Reelin 
signalling capacity.  Therefore, while secretion of full-length Reelin from the LEC upon 
SMC recruitment may lead to increased LEC-derived MCP-1 expression, and enhanced 
SMC recruitment, subsequent processing may limit this response and prevent over-
migration of SMC to the collecting lymphatic vessels.  Such a mechanism could 
contribute to the discontinuous SMC coverage of lymphatic collecting vessels, 
compared to the complete investment of SMC seen around arteries and veins. 
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Now that we have an assay with a positive read-out of Reelin activity, namely increased 
LEC MCP1 expression, it will be interesting to distinguish between these hypotheses, 
by examining MCP1 expression following LEC stimulation with either totally or 
partially cleaved Reelin fragments. Furin Inhibitor 1 could be used to block baseline 
processing by the HEK-293 cells (Kohno et al., 2009a).  Alternatively, expression 
constructs encoding different Reelin fragments can be used (Jossin et al., 2004).  If any 
fragment alone were capable of increasing MCP1 expression, this would suggest it as 
the active fragment. Our preliminary results of EphrinB2 binding to the N-terminus 
suggest that this fragment will be particularly interesting in this regard.  If the partially 
cleaved constructs that included this fragment were also able to increase MCP1 
expression, this might suggest that Reelin processing may release the fragment to allow 
increased signal diffusion, but doesn’t ‘activate’ signalling.  However, if only full-
length, or partially cleaved, Reelin was able to induce MCP1 expression, it would 
suggest that conformational changes to the protein structure caused by processing 
disrupted Reelin signalling capability.  
 
7.3.3  Role of proteolytic processing in matrix biology 
 
It is interesting to note that proteolytic processing has important implications for the 
biological function of many extracellular matrix molecules, in some cases even 
resulting in a cleavage product with an opposite function to that of the parent molecule, 
for example Endorepellin, generated by Perlecan cleavage, has anti-angiogenic 
properties, counter to the pro-angiogenic properties of its parent molecule (Mongiat et 
al., 2003), (Goyal et al., 2011).  Many large extracellular matrix proteins, such as 
proteoglycans and Fibronectin bind growth factors, which enables them to either 
enhance growth factor signalling, perhaps by providing several binding sites and 
concentrating the signal, or inhibit signalling, by ‘sequestering’ growth factors 
(reviewed in (Hynes, 2009), (Kalluri, 2003)).  In this case, proteolytic processing, 
perhaps upon angiogenic stimulus, can release the bound growth factors.  Such a role 
for Reelin has not yet been explored, although its large size could indicate potential in 
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this respect and may provide a means by which Reelin could interact with other, as yet 
unidentified, signalling pathways (reviewed in (Tissir and Goffinet, 2003)).  There is 
also interesting research suggesting that ECM proteins can directly signal through 
growth factor receptors (reviewed in (Hynes, 2009)).  One such example is that of 
Laminin-5.  Following proteolytic processing, EGF repeats in the cleavage product can 
bind to and activate the EGF receptor (Schenk et al., 2003).  
 
7.4 Cellular mechanism of Reelin action 
 
The mechanism of Reelin action is also highly complex, and in the developing nervous 
system it has been implicated in both facilitation of migration by somal translocation 
(Franco et al., 2011) and in preventing over-migration, perhaps by regulating 
detachment from the glial scaffold and stabilising the actin cytoskeleton (Sanada et al., 
2004), (Chai et al., 2009).  The reduction in SMC coverage around collecting lymphatic 
vessels of Reln-/- mice suggested that Reelin might be involved in directly promoting 
SMC migration, and consequently recruitment to the lymphatic vessels or in 
encouraging SMC attachment to the vessel once they had already migrated.  However, a 
number of in vitro assays were unable to determine a direct effect of Reelin signalling 
on SMC behaviour.  We used venous SMC in all our in vitro assays, as a method of 
obtaining a suitable number of pure lymphatic SMC, and maintaining them in culture, is 
not yet available, and our own preliminary attempts were unsuccessful (data not 
shown).  Since there are genetic and functional differences between blood vascular and 
lymphatic smooth muscle (Muthuchamy et al., 2003), it remains a possibility that 
venous SMC may not respond the same way to Reelin that lymphatic SMC would.  
Moreover, while we examined the effect of Reelin stimulation on the production of 
LEC-derived SMC recruitment factors and found that Reelin treatment increased MCP1 
expression, we have not yet examined the effect of Reelin on SMC-derived MCP1 
mRNA.  Since it is known that SMC express both MCP-1 and its receptor CCR2 
(Potula et al., 2009), (Ma et al., 2007), it is possible that Reelin secretion from LEC 
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could enhance MCP1 expression in both LEC and SMC to promote SMC recruitment to 
the vessels.   
MCP-1 has been well documented to enhance SMC migration (Jay et al., 2010), (Ma et 
al., 2007), (Lo et al., 2005) and interestingly, endothelial cell expression of MCP1 
increased upon TGFβ stimulation and mediated the effect of TGFβ1 on SMC 
proliferation and migration (Ma et al., 2007).  However, TGFβ1 was not up-regulated in 
our experiment, suggesting that Reelin induces up-regulation of MCP1 via an 
alternative pathway, which would require further investigation to elucidate.  MCP-1 
was originally identified and characterised based on its role in monocyte recruitment 
during inflammation (reviewed in (Deshmane et al., 2009)), and pro-inflammatory 
cytokines TNFα, IL-7β and IFNγ also up-regulate endothelial cell MCP-1 expression 
(Harkness et al., 2003).  Reelin-induced up-regulation of MCP1 by LEC is consistent 
with our observation of decreased SMC coverage of Reln-/- collecting lymphatic vessels, 
and suggests that Reelin may mediate SMC recruitment to the vessels via endothelial 
MCP-1 expression.  Confirmation of this hypothesis might come from examination of 
the lymphatic phenotype of Mcp1-/- mice, which have a normal lifespan and so would be 
suitable for the same phenotypic analysis we conducted on Reln-/- mice (Lu et al., 1998).  
If similar lymphatic collecting vessel defects were observed in Mcp1-/- as Reln-/- mice, it 
would provide additional confirmation that Reelin mediates SMC recruitment via MCP-
1. 
 
7.5 Concluding remarks 
 
Despite its importance in regulating tissue fluid homeostasis, absorbing dietary fat and 
assisting the immune response, understanding of lymphatic biology has been limited.  
However, great progress has been made in the last half-century in appreciation of the 
physiological and pathological functions of the lymphatic vasculature, and the 
mechanisms governing their regulation, as well as in the molecular regulation of 
lymphatic development.  Importantly, with advancing knowledge of the genes and 
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proteins involved in regulating lymphatic vessel growth and function, is coming the 
development of therapeutic strategies to combat lymphoedema (Karkkainen et al., 
2001), (Tammela et al., 2007) (reviewed in (Norrmen et al., 2011)).  Although these 
have not yet progressed to the clinic, it gives an optimistic outlook for the future.  
The 3D environment is important for regulating gene expression and cell behaviour 
both in vitro and in vivo and truly representative cellular responses can often not be 
generated in a 2D culture system (reviewed in (Griffith and Swartz, 2006)).  Yet the 
contribution of the extracellular microenvironment to lymphatic development and 
function has remained largely unexplored.  My project has begun to touch on this issue, 
with the identification of lymphatic specific extracellular matrix proteins, and in 
particular by identifying a role for Reelin in the correct development and function of 
collecting lymphatic vessels.  Congenital lymphoedema in human patients with a RELN 
mutation emphasises the importance of the extracellular matrix in lymphatic vascular 
function and may give clinical relevance to this research (Hong et al., 2000).  It is 
possible that further research into the functional importance of extracellular matrix 
proteins surrounding the lymphatic vasculature may identify other proteins whose loss 
results in lymphatic dysfunction, which could contribute to our understanding of 
lymphoedema and its causes, and potentially give rise to new therapeutic targets. 
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Figure 8.1 Reln mutation leads to collecting vessel defects: original vessel images 
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Figure 8.2 Normal lymphatic collecting vessels in Apoer2-/-;Vldlr-/- and Dab1Scm 
mice: original vessel images.   
Immunofluorescence staining of whole vessels shown in Figure 6.2; white boxes 
indicate areas magnified. Scale bars = 200µm. 
 
 
 
Figure 8.3 Collecting vessel defects following lymphatic-specific Efnb2 deletion 
resemble those of Reln-/- mice: original vessel images.   
(A-B) Immunofluorescence staining of Efnb2lx/lx;Prox1-creERT2 vessels shown in 
Figure 6.4; white boxes indicate areas magnified.  Scale bars = 200µm. 
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Figure 8.4 Phospho-array key (R&D systems).  
Details of phosphorylated proteins found at each membrane co-ordinate, together with 
phosphorylation site and cell source / treatment.  Scan from Human proteome profiler 
kit handbook. 
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